Durham E-Theses

An electrophysiological study of the interaction between fenamate NSAIDs and the GABA(A) receptor

Patten, Debra

How to cite:

Patten, Debra (1999) An electrophysiological study of the interaction between fenamate NSAIDs and the GABA(A) receptor, Durham theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/4561/

Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a link is made to the metadata record in Durham E-Theses
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the full Durham E-Theses policy for further details.
An electrophysiological study of the interaction between Fenamate NSAIDs and the GABAA receptor.

Debra Patten
Submitted for the Degree of Ph.D.

The copyright of this thesis rests with the author. No quotation from it should be published without the written consent of the author and information derived from it should be acknowledged.
Table of Contents

AN ELECTROPHYSIOLOGICAL STUDY OF THE INTERACTION BETWEEN FENAMATE NSAIDs AND THE GABA\textsubscript{A} RECEPTOR

CHAPTER ONE: GENERAL INTRODUCTION

1.1. An overview of the hypothesis addressed in this thesis .................................................. 1

1.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs) ........................................................ 3
   1.2.i. Mechanism of action of NSAIDs .................................................................................. 3
   1.2.ii. Classification of NSAIDs ......................................................................................... 5
   1.2.iii. Analgesic Effects of NSAIDs .................................................................................. 8
      1.2.iii. i. Peripheral antinociceptive effects ...................................................................... 8
      1.2.iii. ii. Central antinociceptive effects ....................................................................... 8
      1.2.iii. iii. Alternative Mechanisms for analgesic effects of NSAIDs in the CNS ............ 9
   1.2.iv. NSAIDs and neuroplasticity ...................................................................................... 10
   1.2.v. Novel Clinical Applications of NSAIDs ..................................................................... 11
      1.2.v. i. Ischaemia and Neuroprotection ......................................................................... 11
      1.2.v. ii. Alzheimer's Disease ......................................................................................... 12
   1.2.vi. The effect of prostaglandins on seizure models ....................................................... 13
   1.2.vii. NSAIDs used in seizure models ............................................................................. 14
      1.2.viii. Physiological effects of NSAIDs on ion channel function .................................. 17
         1.2.viii. i. Non-neuronal preparations ........................................................................... 17
         1.2.viii. ii. Neuronal Preparations ............................................................................... 18

1.3. Ligand-Gated Ion Channels-general features .................................................................. 20

1.4. The \textgamma-Aminobutyric Acid Type A (GABA\textsubscript{A}) Receptor ......................... 20
   1.4.i. \textgamma-Aminobutyric Acid (GABA) ........................................................................ 20
   1.4.ii. GABA Receptor Classification ................................................................................ 21
   1.4.iii. Structure of the GABA\textsubscript{A} receptor ............................................................. 22
   1.4.iv. Biophysical Properties of the GABA\textsubscript{A} receptor ........................................ 25
   1.4.v. Subunit Heterogeneity & Stoichiometry of GABA Receptors ................................. 26

1.5. GABA\textsubscript{A} Receptor Pharmacology: ................................................................. 30
   1.5.i. Agonists .................................................................................................................... 30
   1.5.ii. Partial Agonists ....................................................................................................... 31
   1.5.iii. Competitive Antagonists ....................................................................................... 33
   1.5.iv. Non-competitive antagonists ................................................................................ 36
### Section 3.2: Electrophysiological and neuropharmacological properties of cultured rat hippocampal neurones.

1. **Introduction** ........................................................................... 89
2. **Electrophysiological Characteristics of Hippocampal Neurones** .................................................................................. 89
3. **Procedures** ............................................................................ 90
4. **Results - Ligand-gated Anion Channels** ................................. 91
   4.i. **Physiological and pharmacological properties**  
       of GABA-evoked currents ($I_{\text{GABA}}$) .......... 91
       (a) $I-V$ Relationship of ($I_{\text{GABA}}$) ................ 91
       (b) Pharmacology of ($I_{\text{GABA}}$) ................. 91

4.ii. **Physiological and pharmacological properties**  
      of glycine-evoked currents ($I_{\text{glycine}}$) .......... 92
      (a) Pharmacology of the ($I_{\text{glycine}}$) .............. 93
5. Results - Ligand-gated Cation Channels .............................................. 93
5.i. Ionotropic Glutamate Receptors ..................................................... 93

5.i. Physiological and pharmacological properties of NMDA-evoked currents \(I_{\text{NMDA}}\) ................................................................. 93
(a) \(I-V\) Relationship of \(I_{\text{NMDA}}\) .............................................. 93
(b) Pharmacology of \(I_{\text{NMDA}}\) ..................................................... 93
5.ii. Physiological and pharmacological properties of AMPA-evoked currents \(I_{\text{AMPA}}\) .................................................. 94
(a) \(I-V\) Relationship of \(I_{\text{AMPA}}\) .............................................. 94
(b) Pharmacology of \(I_{\text{AMPA}}\) ..................................................... 94
5.iii. Physiological and pharmacological properties of kainic acid-evoked currents \(I_{\text{kainic acid}}\) .................................................. 94
(a) \(I-V\) Relationship of \(I_{\text{kainic acid}}\) .......................................... 94
(b) Pharmacology of \(I_{\text{kainic acid}}\) .............................................. 95

6. Discussion ...................................................................................... 95

Section 3.3: Determination on the effect, site and molecular mechanism of action of fenamates at neuronal GABA\(_A\) receptors

1. Introduction ................................................................................. 98
2. Procedures .................................................................................... 98
3. Results ......................................................................................... 99
3. i. Mefenamic acid potentiates GABA-evoked whole-cell currents ... 99
3.ii. Determination of the effects of non-fenamate NSAIDs on GABA-evoked whole-cell currents ............................................. 100
3.iii. Modulation of GABA-evoked whole cell currents by fenamate NSAIDs .......................................................... 100
3.iv. The potentiating effects of mefenamic acid are not mediated via the benzodiazepine site of the GABA\(_A\) receptor ................. 101
3.v. The potentiating effects of mefenamic acid are not due to GABA uptake inhibition ............................................................ 102
3.vi. The potentiating effects of mefenamic acid are not due to membrane perturbation ....................................................... 103
3.vii. The modulatory effects of niflumic acid and mefenamic acid are not use-dependent ....................................................... 104
3.vii. i. Procedures ............................................................................ 104
3.vii. ii. Results ................................................................................ 105
3.viii. The potentiating effects of mefenamic acid are voltage-dependent ........................................... 105
3.viii. i. Procedures .......................................................................................................................... 105
3.viii. ii. Results ............................................................................................................................. 106
3.ix. Mefenamic acid directly activates the GABA<sub>A</sub> receptor ........................................... 106
3.ix. i. Procedures .......................................................................................................................... 106
3.ix. ii. Results- Mefenamic acid alone activates an inward current ....................................... 106
3.ix. iii. Current-voltage relationship of mefenamic acid-activated currents ......................... 107
3.x. Sensitivity to the modulatory effects of mefenamic acid varies across hippocampal neurones ..... 108
3.xi. Mefenamic acid acts at or shares a recognition site with loreclezole ................................. 108
4. Summary- modulation of GABA-evoked responses in hippocampal neurones by mefenamic acid ................................................................. 109

RESULTS: Chapter 4
Determination of the effects of mefenamic acid on other neuronal ligand-gated ion channels

1. Introduction .................................................................................................................................. 111
2. Methods ...................................................................................................................................... 111
3. Results ....................................................................................................................................... 112
  3.i. Glycine ..................................................................................................................................... 112
  3.ii. NMDA ..................................................................................................................................... 113
  3.iii. AMPA ..................................................................................................................................... 113
  3.iv. Kainate .................................................................................................................................... 113
4. Summary ..................................................................................................................................... 114

CHAPTER FIVE: General Discussion

1. The selectivity of action of propofol ......................................................................................... 115
2. Mefenamic acid potentiates GABA-evoked responses in voltage-clamped rat hippocampal neurones ................................................................. 119
3. Inhibition of GABA-evoked responses by fenamates in hippocampal neurones

4. Fenamate Structure-activity relationships at native GABA<sub>A</sub> receptors

5. Possible site(s) and molecular mechanism(s) of action of mefenamic acid at native GABA<sub>A</sub> receptors

5.i. The role of the "benzodiazepine site" for the modulation of GABA currents by mefenamic acid or

5.ii. Possible mechanisms of action of mefenamic acid on neuronal GABA<sub>A</sub> receptors

5.iii. Potentiation of GABA currents by fenamates and GABA re-uptake inhibitors.

5.iv. Mefenamic acid-induced modulation of GABA currents and inhibition of prostaglandin synthesis?

5. v. Modulation of GABA currents by membrane perturbation

5.vi. Modulation of GABA currents by changes in receptor protein phosphorylation

5.vii. Use- and Voltage-dependence of the effects of mefenamic acid and niflumic acid on GABA<sub>A</sub> receptors.

5.viii. Neuronal sensitivity to mefenamic acid varies across cultured hippocampal neurones- similarities to loreclezole?

5.ix. Overlapping sites and/or transduction mechanisms for mefenamic acid and loreclezole?

5.x. Evidence for direct activation of the GABA<sub>A</sub> receptor by mefenamic acid.

6. Effects of mefenamic acid on other ligand-gated ion channels

7. Pharmacological Implications-a mefenamic acid binding site exists on the GABA<sub>A</sub> receptor?

8. Neurophysiological and clinical relevance of the action of mefenamic acid at the GABA<sub>A</sub> receptor.

REFERENCES
List of Figures

Figure 1.1: Prostaglandin synthesis pathway.

Figure 1.2: Schematic representation of the GABA_A receptor.

Figure 1.3: Examples of GABA_A receptor agonists.

Figure 1.4: Examples of GABA_A receptor antagonists.

Figure 2.1: Schematic of rat thorax showing position of vagus nerve.

Figure 2.2: A schematic of the grease-gap technique.

Figure 2.3: Photograph of rat hippocampal dissection.

Figure 2.4: Photomicrograph of primary culture of rat hippocampal neurones: method 1.

Figure 2.5: Photomicrograph of primary culture of rat hippocampal neurones: method 2.

Figure 2.6: Photomicrograph of primary culture of rat hippocampal neurones: method 3.

Figure 2.7: Photomicrograph of primary culture of rat hippocampal neurones: method 4.

Figure 2.8: Schematic of the whole-cell patch-clamp recording technique.

Figure 3.1: Chart recorder traces of GABA-, 5-HT-, α,β-MeATP- and DMPP-evoked responses in the rat isolated vagus nerve.

Figure 3.2: A graph showing that GABA, 5-HT, α,β-MeATP and DMPP-evoke concentration-dependent agonist-evoked responses in the rat isolated vagus nerve.
Figure 3.3: Chart recorder traces of GABA-, 5-HT, $\alpha,\beta$-MeATP- and DMPP-evoked responses and the effects of picrotoxin, MDL-72222, suramin and hexamethonium.

Figure 3.4: Histograms showing that GABA, 5-HT, $\alpha,\beta$-MeATP and DMPP-evoked responses of the rat vagus nerve are inhibited by drugs acting at the GABAA, 5-HT3, P2X and nACh receptors.

Figure 3.5: A graph and chart recorder traces showing that GABA and glycine evoke concentration-dependent responses of the rat isolated optic nerve.

Figure 3.6: Histograms and chart recorder traces showing that GABA- and glycine-evoked responses of the rat isolated optic nerve are inhibited by picrotoxin and strychnine, respectively.

Figure 3.7: A graph and chart recorder traces showing that GABA-evoked responses of the rat isolated vagus nerve are potentiated by propofol, sodium pentobarbitone and alphaxalone.

Figure 3.8: Chart recorder traces of GABA-, 5-HT-, $\alpha,\beta$MeATP- and DMPP-evoked responses in the presence of propofol in the rat isolated vagus nerve.

Figure 3.9: A graph showing that propofol potentiates submaximal GABA-evoked responses, but has little or no effect on 5-HT-, $\alpha,\beta$MeATP- and DMPP-evoked responses in the rat isolated vagus nerve.

Figure 3.10: A histogram and chart recorder traces showing that propofol potentiates submaximal GABA- and glycine-evoked responses in the rat isolated optic nerve.

Figure 3.11: A graph and chart recorder traces showing that mefenamic acid concentration-dependently potentiates GABA-evoked responses in the rat isolated vagus nerve.
Figure 4.1: Chart recorder traces showing that hippocampal neurones exhibit spontaneous activity which is inhibited by tetrodotoxin.

Figure 4.2: A graph and chart recorder traces showing the GABA-evoked whole-cell current-voltage relationship in voltage-clamped rat hippocampal neurones.

Figure 4.3: A graph and chart recorder traces showing that bicuculline antagonises GABA-evoked responses in voltage-clamped rat hippocampal neurones.

Figure 4.4: Chart recorder traces of GABA-evoked currents potentiated by alphaxalone, diazepam, propofol, loreclezole and pentobarbitone.

Figure 4.5: A graph showing concentration-dependent potentiation of GABA-evoked responses by diazepam, propofol, alphaxalone, pentobarbitone and loreclezole.

Figure 4.6: A graph and chart recorder traces showing that strychnine inhibits glycine-evoked responses in voltage-clamped rat hippocampal neurones.

Figure 4.7: A graph and chart recorder traces showing the NMDA-evoked whole-cell current-voltage relationship in rat hippocampal neurones.

Figure 4.8: A graph and chart recorder traces showing that (D)-APV inhibits NMDA-evoked responses in voltage-clamped rat hippocampal neurones.

Figure 4.9: A graph and chart recorder traces showing the AMPA-evoked whole-cell current-voltage relationship in rat hippocampal neurones.

Figure 4.10: A graph and chart recorder traces showing that CNQX inhibits AMPA-evoked responses in rat hippocampal neurones.
Figure 4.11: A graph and chart recorder traces showing the kainic acid-evoked whole-cell current-voltage relationship in voltage-clamped rat hippocampal neurones.

Figure 4.12: A graph and chart recorder traces showing that CNQX inhibits kainic acid-evoked responses in voltage-clamped rat hippocampal neurones.

Figure 5.1: Chart recorder traces showing GABA-evoked responses potentiated by mefenamic acid, sodium pentobarbitone and propofol.

Figure 5.2: Graphs showing concentration-dependent potentiation of GABA-evoked response amplitude and duration by mefenamic acid, sodium pentobarbitone and propofol.

Figure 5.3: A graph and chart recorder traces showing the effects of 3 non-fenamate NSAIDs on GABA-evoked whole-cell currents.

Figure 5.4: Chart recorder traces of GABA-evoked whole-cell currents concentration-dependently potentiated by tolfenamic acid and inhibited by niflumic acid.

Figure 5.5: A graph showing that mefenamic acid concentration-dependently potentiates GABA-evoked whole-cell currents.

Figure 5.6: A graph and chart recorder traces showing that mefenamic acid-induced potentiation of GABA-evoked currents is not reversed by flumazenil.

Figure 5.7: A graph and chart recorder traces showing that the mefenamic acid-induced potentiation of GABA-evoked currents is not via GABA-uptake inhibition.

Figure 5.8: A graph and chart recorder traces showing that the potentiating effects of mefenamic acid are not due to membrane perturbation.

Figure 5.9: A graph and chart recorder traces showing that inhibition of GABA-evoked currents by niflumic acid is not use-dependent.
Figure 5.10: A graph and chart recorder traces showing that potentiation of GABA-evoked currents by mefenamic acid is not use-dependent.

Figure 5.11: Chart recorder traces showing the voltage-sensitivity of the potentiating effects of mefenamic acid and propofol.

Figure 5.12: Histograms showing the voltage-sensitivity of the potentiating effects of mefenamic acid and propofol.

Figure 5.13: A histogram and chart recorder traces showing that the mefenamic acid-evoked whole cell current is potentiated by allosteric modulators of the GABA_A receptor.

Figure 5.14: A graph and chart recorder traces showing the mefenamic acid-evoked whole cell current-voltage relationship for voltage-clamped rat hippocampal neurones.

Figure 5.15: A histogram and chart recorder traces showing that hippocampal neurones displayed a differential sensitivity to potentiation by mefenamic acid and loreclezole.

Figure 5.16: Histograms and chart recorder traces showing that the maximal potentiations evoked by mefenamic acid and loreclezole are not additive.

Figure 6.1: Chart recorder traces of glycine-evoked currents in the presence of mefenamic acid.

Figure 6.2: A graph showing the effects of mefenamic acid on submaximal glycine-evoked currents.

Figure 6.3: Chart recorder traces of glycine-evoked currents in the presence of propofol.
Figure 6.4: Chart recorder traces of NMDA-evoked currents in the presence of mefenamic acid.

Figure 6.5: A graph showing the effects of mefenamic acid on submaximal NMDA-evoked currents.

Figure 6.6: Chart recorder traces of AMPA-evoked currents in the presence of mefenamic acid.

Figure 6.7: A graph showing the effects of mefenamic acid on submaximal AMPA-evoked currents.

Figure 6.8: Chart recorder traces of kainic acid-evoked currents in the presence of mefenamic acid.

Figure 6.9: A graph showing the effects of mefenamic acid on submaximal kainic acid-evoked currents.
Candidates Declaration

The work presented in this thesis was composed by me and is an accurate record of the experimental work undertaken by me. This work, under the supervision of Dr. Robert Francis Halliwell, has been carried out at the Department of Biological Sciences, at the University of Durham, and has not been previously submitted for a higher degree.

"The copyright of this thesis rests with the author. No quotation from it should be published without their prior written consent and information derived from it should be acknowledged."
Acknowledgements

I am grateful to Dr. Robert Francis Halliwell for giving me the opportunity to carry out my Ph.D. in his laboratory, for his academic supervision of this project and for his unfailing support and friendship throughout my time in his laboratory. I am also grateful to Dr. Keith Martin for his academic support and to Knoll Pharmaceuticals for financial support. Thanks must also go to Dr. Kevin Thompson, of Knoll Pharmaceuticals, for his technical assistance and to Dr. David Hyde of Durham University for his role as second supervisor.

My thanks are also due to Graham, Sarah and Niggy who have been great friends throughout my studies and who have always helped me to see the light at the end of the tunnel. Thanks are also due to Tracy and Paul for their invaluable assistance with typing and graphic design.

Finally, I am indebted to my parents, Joe and Doreen, my sister, Joanne and my brother, Martin who have supported me in everything I’ve ever achieved, helped me to keep a good perspective and have always kept me smiling.
Debra Patten
An Electrophysiological Study of the Interaction between Fenamate NSAIDs and the GABA\textsubscript{A} receptor.
Submitted for the Degree of Ph.D. 1999

Abstract
The effects of certain NSAIDs were determined on agonist-evoked responses recorded from rat neurones maintained \textit{in vitro} using electrophysiological techniques.

Initially, the rat isolated vagus and optic nerves were employed. Alphaxalone, pentobarbitone, propofol and the NSAID, mfenamic acid (MFA), potentiated GABA-evoked responses of the vagus nerve. Propofol (1-100\textmu M) selectively potentiated GABA and glycine-evoked responses of the rat vagus and optic nerves, but had little effect on nicotinic acetylcholine-, \textalpha,\beta-methylene-ATP or 5-hydroxytryptamine-mediated responses.

The interaction between MFA and ligand-gated receptors was investigated further using voltage-clamped rat hippocampal neurones maintained in culture. MFA (3-100\textmu M) selectively, concentration-dependently and reversibly potentiated GABA-evoked responses, consistent with the observations made using the vagus nerve. MFA (3-100\textmu M) however had little or no effect on glycine, AMPA, kainate or NMDA-receptor mediated responses.

A final series of experiments investigated the site and molecular mechanism of the interaction between MFA and the GABA-gated chloride ion channel. The potentiating effects of MFA (and other fenamates) were not the result of prostaglandin synthesis inhibition, since other NSAIDs did not modulate the GABA\textsubscript{A} receptor (GR). The actions of MFA were not mediated via the benzodiazepine site of the GR, nor where they due to inhibition of GABA-uptake or membrane perturbation. The modulatory effects of MFA were not use-dependent, but the potentiating effects of MFA were voltage-dependent, where the potentiation was 3-fold greater at -100mV than at +40mV, with no change in the equilibrium potential for GABA. MFA activated a current, in the absence of GABA. Hippocampal neurones varied in sensitivity to modulation by MFA and the anticonvulsant, loreclezole, which may indicate a degree of subunit selectivity.

These data are discussed in relation to the possible site and mechanism of action of fenamates at the GR, their similarities with other positive modulators of the GR and the neurophysiological implications of these findings.
CHAPTER ONE: GENERAL INTRODUCTION

1.1. An Overview of the Hypothesis Addressed in this Thesis

Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for their analgesic, anti-inflammatory and anti-pyretic properties (Orme, 1990). Due to their efficacy and relative lack of toxicity, NSAIDs are the most widely consumed drugs world-wide with over 100 million prescriptions per year and an estimated seven-fold higher consumption of non-prescription drugs in the US alone (Roth, 1996). Perhaps, not surprisingly, these drugs are also a common source of self-poisoning and although most cases of NSAID overdose do not result in serious cases of toxicity, there have been some cases of NSAID overdose resulting in severe toxicity.

Mefenamic acid (Ponstan) is the fifth most commonly prescribed NSAID in the UK (McMurray et al., 1987). It is a fenamate NSAID commonly prescribed for the relief of mild to moderate pain including that experienced during dysmenorrhoea and rheumatoid arthritis. The most common side effects observed with mefenamic acid treatment, like other NSAIDs, generally pertain to gastrointestinal disturbances. However, other adverse effects observed include headache, visual disturbances, dizziness, drowsiness and anxiety (Winder et al., 1966). In cases of mefenamic acid overdose, the severity of these adverse drug effects is increased with symptoms of coma and seizures occurring in over one third of all overdose cases (Smolinske et al., 1990). Interestingly, another NSAID, fenbufen, has been reported to dramatically increase the risk of convulsions in humans when co-prescribed with antimicrobial fluoroquinolones (Lietman, 1995).

Almost thirty years ago, Vane (1971) demonstrated that aspirin-like drugs, namely NSAIDs, inhibited prostaglandin synthesis, thus reducing inflammation and thereby symptoms of pain. Subsequently, over 40 NSAIDs used in clinical practice have been found to inhibit prostaglandin synthesis
(Cronstein and Weissman, 1995). In addition to inhibition of prostaglandin synthesis in the periphery, NSAIDs are known to penetrate the central nervous system (CNS; Bannwarth et al., 1989) and have been shown to have direct effects on various neuronal (and non-neuronal) ion channels including non-selective cation channels (Lerma and Del Rio, 1991; Shaw et al., 1995) and chloride channels (White and Alywin, 1990; McCarty et al., 1993). Indeed the fenamate NSAIDs, for example, flufenamic acid and niflumic acid, are routinely used as pharmacological tools to block Ca$^{2+}$-activated Cl$^{-}$ channels when investigating Ca$^{2+}$ permeable channels in *Xenopus* oocytes (Leonard and Kelso, 1990; White and Alywin, 1990; Vernino et al., 1992 and Séguéla et al., 1993). More recently, a number of the fenamate NSAIDs have also been shown to modulate rat brain γ-aminobutyric acid type-A (GABA$_A$) receptors expressed in *Xenopus* oocytes (Woodward et al., 1994). Moreover, a preliminary study by Halliwell et al., (1994) demonstrated a marked positive modulation of GABA-mediated currents recorded in rat hippocampal neurones by mefenamic acid.

Modulation of the GABA$_A$ receptor, which probably mediates the majority of inhibitory synaptic transmission in the mammalian brain, may have significant behavioural and psychological effects (for reviews see Matsumoto, 1989; Krogsgaard-Larsen et al., 1994). Indeed GABA$_A$ receptors have been implicated in the regulation of appetite via GABA$_A$ receptor modulation in hypothalamic satiety centres, in the mediation of analgesic effects present throughout the brain and spinal cord via pre- and post-synaptic mechanisms and in GABA$_A$ receptor-mediated decreases in heart rate and blood pressure. GABA may also play a role in many other physiological and behavioural processes such as arousal, sexual behaviour, coma, stress, anxiety, depression, memory, thermal regulation, muscle relaxation and sleep. Many anaesthetic agents have been shown to produce sedation and anaesthesia probably by enhancing GABA-mediated synaptic transmission (Franks and Leib, 1994). GABA has also been linked with a number of neurological disorders such as schizophrenia, epilepsy, and Alzheimer's disease (for review see Krogsgaard-Larsen et al., 1994).
It is well established that antagonists of the GABA\textsubscript{A} receptor, such as bicuculline and picrotoxin are proconvulsant drugs (Curtis and Johnston 1974), and positive allosteric modulators of the GABA\textsubscript{A} receptor such as alphaxalone, propofol and diazepam enhance the inhibitory actions of \(\gamma\)-aminobutyric acid (GABA) and thereby reduce neuronal excitation. It is possible, therefore, that some of the actions of NSAIDs may be mediated through direct effects on the CNS. In particular, coma and/or convulsions, which result from fenamate overdose, suggest an interaction between these drugs and neuronal ligand-gated ion channels.

The experiments reported in this thesis examined the effects of selected NSAIDs on the major inhibitory and excitatory amino acid receptors in mammalian CNS neurones. The effects of these NSAIDs were compared to the effects of other experimental and clinically important modulators of these receptors, in an attempt to elucidate, in particular, the mechanism of action of fenamate NSAIDs within the CNS.

1.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

1.2.i. Mechanism of action of NSAIDs.

In 1971, a number of investigators demonstrated that aspirin-like drugs (later known as NSAIDs) inhibited prostaglandin synthesis in a variety of cells and tissues from different species (Vane, 1971; Smith and Willis, 1971; Ferreira et al., 1971). This important discovery led to the hypothesis that aspirin-like drugs mediated their therapeutic effects through the inhibition of prostaglandin synthesis (Flower and Vane, 1974).

Prostaglandin formation occurs via a two-step process. The first step involves the oxygenation of arachidonic acid by cyclo-oxygenase (COX) enzymes to form unstable prostaglandins known as PGG\textsubscript{2}. Subsequently, these unstable PGG\textsubscript{2} are converted into stable prostaglandins, PGH\textsubscript{2}, by peroxidases, which are then converted into prostaglandins of the D-, E- and F-series by individual synthases or reductases.
Figure 1.1: Prostaglandin synthesis. The flow diagram shows the metabolic pathway of arachidonic acid which leads to the production of prostaglandins F$_2$, D$_2$ and E$_2$. Inhibition of prostaglandin synthesis can occur by inhibiting the action of cyclo-oxygenase enzymes, which catalyse the conversion of arachidonic acid to cyclic endoperoxidases. NSAIDs inhibit prostaglandin synthesis by inhibiting cyclo-oxygenase enzymes, COX-1 and COX-2 (modified from Rang *et al.*, 1998).

Initially, COX was thought to be a single enzyme, producing inflammatory prostaglandins at the inflamed site and also homeostatic prostaglandins required for normal function within other tissues, such as the kidney and stomach (Hanes, 1990). Recently, a second COX enzyme has been isolated and subsequently, these enzymes have been termed COX-1 and COX-2. COX-1 has been described as having "constitutive activity" and is
expressed in most tissues throughout the body, including the gastrointestinal mucous (Kargman et al., 1996; Ristimaki et al., 1997). COX-2 has been described as having "inducible activity" (O'Bannion et al., 1992); it is expressed in low levels throughout the body, including the gastrointestinal mucosa, but its expression can be up-regulated at sites of inflammation by cytokines and bacterial lipopolysaccharides. These enzymes are encoded by different genes and are regulated at transcriptional and post-transcriptional levels to different degrees, with the "inducible" COX-2 being regulated to a much higher degree than COX-1 (reviewed by Jouzeau et al., 1997). It is commonly thought that the analgesic, anti-pyretic and anti-inflammatory properties of NSAIDs are related to their capacity to inhibit COX-2, whereas the anti-thrombotic and some adverse effects of certain NSAIDs, such as gastrointestinal toxicity, are related to their ability to inhibit COX-1 (Vane, 1994; Battistini et al., 1994).

1.2.ii. Classification of NSAIDs

Most clinically useful NSAIDs are weak organic acids which vary in their ability to inhibit prostaglandin synthesis. Most acidic NSAIDs bind extensively to plasma albumin, but differ in their binding capacity to other proteins and tissues (for review, see McCormack, 1994). Traditionally, NSAIDs were classified in accordance with their chemical grouping, namely: the carboxylic acids (which are sub-divided into salicylates, heteroarylacetic acids, propionic acids and fenamates), the pyrazoles and oxicams (Weissmann, 1991; Rang et al., 1998, see Table 1.1).

Recently NSAIDs have been classified according to their relative inhibition of cyclo-oxygenase isoenzymes 1 and 2 (Jouzeau et al., 1997; Frölich, 1997); this classification system may be more representative of the different therapeutic properties of NSAIDs. However, confusion arises from the diversity of biological systems used to assay COX selectivity such that their selectivity ratios are not directly comparable when obtained from different sources and under different experimental conditions (Vane et al., 1997). For example, Young et al., (1996) and others report that COX-1 and -2 sequence homology and mechanisms of inhibition (e.g. competitive, non-competitive,
reversible, irreversible) are strongly species-dependant, such that selectivity of rat enzymes did not correlate with human selectivity. Other studies, using assays of whole human blood have shown, for example, mefenamic acid to be COX-1 selective (Gierse et al., 1995; Young et al., 1996) whereas others indicate it is COX-2 selective (Cryer and Feldman, 1998). Indeed, Young et al., (1996) using purified human recombinant cell-free COX enzymes, suggest mefenamic acid is COX-2 selective. In fact, from the available data, the primary mechanism of action of mefenamic acid in humans, for example, still remains unclear.
NONSTERoidal ANTI-INFLAMMATory DRUGS.

<table>
<thead>
<tr>
<th>SALICYLATES</th>
<th>ACETIC ACIDS</th>
<th>PROPIONIC ACIDS</th>
<th>FENAMATES</th>
<th>PYRAZoLES</th>
<th>OXICAMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylsalicylic acid (aspirin)</td>
<td>Indomethacin</td>
<td>Ibuprofen</td>
<td>Mefenamic acid</td>
<td>Phenylbutazone</td>
<td>Piroxicam</td>
</tr>
<tr>
<td>Salsalate</td>
<td>Acemetacin</td>
<td>Flurbiprofen</td>
<td>Meclofenamic Acid</td>
<td>Feprazone</td>
<td>Isoxicam</td>
</tr>
<tr>
<td>Diflusal</td>
<td>Cinmetacin</td>
<td>Naproxen</td>
<td>Flufenamic Acid</td>
<td>Apazone</td>
<td>Tenoxicam</td>
</tr>
<tr>
<td>Fendosan</td>
<td>Sulindac</td>
<td>Ketoprofen</td>
<td>Niflumic Acid</td>
<td>Trimethazone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tolmetin</td>
<td>Fenoprofen</td>
<td>Tolfanic</td>
<td>Mofebutazone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zomepirac</td>
<td>Benoxaprofen</td>
<td></td>
<td>Kebutazone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diclofenac</td>
<td>Indoprofen</td>
<td></td>
<td>Suxibutazone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fenclofenac</td>
<td>Pirprofen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Isolexapac</td>
<td>Carprofen</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FENAMATES**

Structure of Fenamates

![Fenamate Structure](image)

<table>
<thead>
<tr>
<th>Fenamate</th>
<th>R1</th>
<th>R2</th>
<th>R3</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mefenamic Acid</td>
<td>CH₃</td>
<td>CH₃</td>
<td>H</td>
<td>C</td>
</tr>
<tr>
<td>Meclofenamic acid</td>
<td>Cl</td>
<td>CH₃</td>
<td>Cl</td>
<td>C</td>
</tr>
<tr>
<td>Flufenamic Acid</td>
<td>H</td>
<td>CF₃</td>
<td>H</td>
<td>C</td>
</tr>
<tr>
<td>Tolfenamic Acid</td>
<td>Cl</td>
<td>CH₃</td>
<td>H</td>
<td>C</td>
</tr>
<tr>
<td>Niflumic Acid</td>
<td>H</td>
<td>CH₃</td>
<td>H</td>
<td>N</td>
</tr>
</tbody>
</table>

Table 1. showing (top) traditional NSAID classification system, based upon chemical structure and (bottom left) general structural representation of fenamates. Bottom right, shows table of group substitutions for a series of fenamates.
1.2.iii. Analgesic Effects of NSAIDs

1.2.iii. i. Peripheral antinociceptive effects of NSAIDs

Prostaglandin production in the periphery causes vasodilation and increased vascular permeability resulting in inflammatory symptoms. In addition, prostaglandins serve to potentiate pain caused by other mediators of inflammation such as histamine and bradykinin (Lim et al., 1964, Handwerker, 1976, Chahl and Iggo, 1977). Thus, NSAIDs inhibit the hyperalgesic state of peripheral afferent fibres caused by the concerted action of prostaglandins and other mediators of pain.

An early study using an animal model of pain elicited by bradykinin (Lim et al., 1964) led to the development of a classification scheme for analgesic agents acting either centrally or peripherally. This study and others (for example Horton, 1964; Guzman, 1964; Juhlin and Michaelson, 1969; Crunkhorn and Willis, 1971 and Karim, 1971) indicated that, for analgesia, the inhibitory action of NSAIDs on prostaglandin synthesis is predominant in the periphery. However, in addition to their effects in the peripheral nervous system, it is clear that NSAIDs, depending on their lipophilicity, can readily cross the blood-brain-barrier and enter the CNS (Bannwarth et al., 1989, 1990) where they can also inhibit prostaglandin synthesis and exert antinociceptive effects.

1.2.iii. ii. Central antinociceptive effects of NSAIDs

A number of studies have clearly shown that NSAIDs exert analgesic effects even when placed directly into the CNS, but the mechanisms behind this action are currently undefined. For example, early studies by Dubas and Parker (1971) demonstrated that sodium salicylate, injected subcutaneously, increased the nociceptive threshold to electrical stimulation of the lateral hypothalamus in rats and concluded that this structure is involved in a primary level of integration of behavioural responses to pain in the CNS and that aspirin exerts actions centrally. Later experiments demonstrated that acetylsalicylate inhibited electrically stimulated nociceptive responses in monkeys when micro-injected into the pre-optic region of the hypothalamus (Shyu et al., 1984).
A number of investigators have demonstrated that NSAIDs administered intrathecally also exert antinociceptive effects. Using this method of administration in rats, acetylsalicylic acid, has been shown to attenuate acetic acid-induced writhing responses (Yaksh, 1982). Intrathecal administration of acetylsalicylic acid, ibuprofen and ketorolac trimethamline have also been shown to inhibit pain behaviour and thermal hyperalgesia evoked by intrathecal injection of NMDA (N-methy-D-aspartate), AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and substance P (Malmberg and Yaksh, 1992). Jurna et al., (1992) demonstrated that intrathecal injection of acetylsalicylic acid, salicylic acid and indomethacin depressed the activity of rat thalamic and spinal neurones observed following electrical stimulation of afferent C-fibres in the sural nerve. In human studies, high doses of acetylsalicylic, administered orally, reduced the amplitude of brain electrical potentials evoked by electrical stimulation of the tooth (Chen and Chapman, 1980) and intrathecal administration of lysine acetylsalicylic acid, an injectable acetylsalicylic acid derivative, produced pain relief in cancer patients (Devoghel, 1983).

In addition, increased prostaglandin synthesis in the brain has temperature-raising effects and actions of NSAIDs on brain prostaglandin levels may contribute to their antipyretic properties. Cooper et al., (1982) have suggested that the antipyretic effects of NSAIDs are mediated through inhibition of prostaglandin synthesis in the hypothalamus, particularly in the preoptic region.

These studies suggest that spinally released prostaglandins are involved in the transmission of nociceptive stimuli and that NSAIDs may be effective in spinal antinociception. Importantly, these studies suggest that there may be a central component to the actions of NSAIDs.

1.2.iii. Alternative mechanisms for the analgesic effects of NSAIDs in the CNS

A review in 1991 by McCormack and Brune concluded that there was little correlation between the analgesic effects of NSAIDs and their ability to inhibit prostaglandin synthesis in vitro, prompting the notion that other, or
mechanisms additional to prostaglandin synthesis inhibition, may contribute to the clinical effects of NSAIDs. Thus, NSAIDs have been shown to affect the synthesis and activity of other neuroactive substances involved in nociceptive responses in the dorsal horn. For example, an in vivo study by Durbourdieu and Dray (1989) reported that ketoprofen reduced substance P levels in the hypothalamus and spinal cord of rats. These actions may contribute to the effects of NSAIDs on spinal nociceptive processing (reviewed by McCormack, 1994). In addition, NSAIDs have also been shown to exert changes in membrane fluidity (Weissmann, 1991) and to enhance descending serotonergic inhibitory nociceptive pathways (McCormack 1994). Indeed, Shyu et al., (1984), in an in vivo study, report a direct relationship between the analgesic effects of aspirin and increased central serotonergic activity in the control of dental pain in primates. Recently, NSAIDs have also been shown to modulate opioid peptide release (Herrero and Headley, 1996) and to potentiate the analgesic actions of μ-opioid receptor agonists in the periaqueductal gray (PAG; Vaughan et al., 1998). These additional pharmacological effects may contribute to the actions of NSAIDs in the CNS.

1.2.iv. NSAIDs and neuroplasticity

Arachidonic acid has been implicated in neuronal excitation and synaptic plasticity. It has been suggested that inhibition of COX enzymes by NSAIDs would lead to an accumulation of arachidonic acid, which may subsequently be diverted along lipoxygenase and epoxygenase metabolic pathways (Vaughan, 1998). Arachidonic acid has been shown to enhance synaptic transmission in the hippocampus (Williams et al., 1989). It is released following glutamate receptor (particularly NMDA) activation (Dumuis et al., 1988,1990; Lazarewicz et al., 1988, 1990; Sanfeliu et al., 1990), during long term potentiation (Lynch et al., 1989) and has been proposed to rapidly inhibit glutamate uptake during long-term potentiation (Barbour et al., 1989; Volterra et al., 1992). Binding studies have also suggested that arachidonic acid and its metabolites may play a role in neuronal excitation, partly by inhibition of GABA-mediated neuronal
inhibition (Schwartz et al., 1988; Schwartz and Yu, 1992; Koenig and Martin, 1992). Recently, Bezzi et al., (1998) have shown that prostaglandins stimulate calcium-dependent glutamate release in astrocytes and that inhibition of prostaglandin synthesis by NSAIDs prevents this release of glutamate; these authors have suggested that NSAIDs may play a role in synaptic plasticity.

1.2.v. Novel Clinical Applications of NSAIDs

1.2.v. i. Ischaemia and Neuroprotection

Post-ischaemic inflammation has been implicated in playing an important role in the delayed progression of damage to brain tissue (Kochanek and Hallenbeck, 1992; Feuerstein et al., 1997). Following cerebral ischaemia, local expression of a cascade of inflammatory proteins is induced (for review see Feuerstein et al., 1997) which includes COX-2, a mediator of the cytotoxic effects of inflammation (Seibert et al., 1995; Smith and DeWitt, 1995). Nogawa et al., (1997) have demonstrated in rats that cerebral ischaemia leads to the up-regulation of COX-2, (but not COX-1) expression, protein and reaction products (PGE$_2$) within the injured site. The selective COX-2 inhibitor, NS-398, attenuated the ischaemic damage, suggesting that selective COX-2 inhibitors may be protective during the post-ischaemic period.

Chen et al., (1998) have recently reported that fenamate NSAIDs (and the NMDA receptor antagonist MK-801) protect embryonic chick retinal neurones against glutamate-induced damage and ischaemia-induced injury. In particular, fenamates were protective against NMDA- and kainate-induced excitotoxicity. However, in the same study, voltage-clamp experiments using salamander retinal neurones, demonstrated that fenamates inhibited NMDA-evoked currents, but not kainic acid-evoked currents. The authors suggest that this neuroprotection by fenamates may be due to inhibition of chloride influx rather than AMPA/kainate receptor blockade (Chen, op. cit.).

These data suggest that although inhibition of prostaglandin synthesis by NSAIDs undoubtedly plays a role in their neuroprotective effects during post-ischaemic inflammation, other mechanisms may contribute to these effects. The
neuroprotective properties of NSAIDs have also been implicated in other neurodegenerative disorders, such as Alzheimer's disease.

1.2.v. ii. Alzheimer's Disease

Recent data also suggests that the neurodegeneration associated with Alzheimer's disease involves COX enzymes. Alzheimer's disease lesions are characterised not only by the presence of amyloid plaques and neurofibrillary tangles, but also by the accumulation of many inflammatory proteins, such as inflammatory cytokines, complement proteins and their regulators, which may promote neuronal death (McGeer et al., 1994, 1995). These pro-inflammatory cytokines cause a marked induction of COX-2 enzyme levels (Hampel and Müller, 1995; Cochran and Vitek, 1996). These data have led to the hypothesis that patients taking NSAIDs to control other anti-inflammatory diseases, such as arthritis, may also have a reduced chance of developing Alzheimer's disease. Although there is no direct evidence to-date, a number of epidemiological studies have indicated that NSAIDs (and other anti-inflammatory treatments) may indeed delay the onset and slow the progression of neurodegenerative disorders such as Alzheimer's disease (McGeer et al., 1996, Breitner, 1995, 1996). In addition, Breitner et al., (1995) have reported a delayed onset of Alzheimer's Disease with NSAIDs and histamine H2 blocking drugs and suggest that the actions of these very different drugs may be linked to the actions of COX on the NMDA pathway to reduce NMDA-mediated glutamatergic excitotoxicity.

Together, the data above strongly indicate that NSAIDs exert analgesic and anti-inflammatory effects, not only in the periphery, but also within the CNS. The mechanisms underlying these actions may involve targets additional to COX enzyme inhibition.

A number of studies have demonstrated that NSAIDs modify the behavioural effects of chemically- and electrically-induced seizures in rodents. These data will now be reviewed.
1.2.vi. The effect of Prostaglandins on Seizure-models

Prostaglandin presence in the CNS has been well-documented *in vivo* and *in vitro* (Eliasson, 1959; Samuelsen, 1964; Wolfe, 1978; Galli et al., 1980). Prostaglandin release appears to be stimulated by increased neuronal activity, for example, during chemically- or electrically-induced seizures (Bosisio et al., 1976; Berchtold-Krantz et al., 1981; Förstermann et al., 1982; Baran et al., 1987) and decreased by certain anti-convulsant drugs such as benzodiazepines and barbiturates (Wolfe, 1978; Steinhauer et al., 1979). Interestingly, Förstermann et al., (1984) found that spontaneously convulsing gerbils had unusually low prostaglandin levels and suggested that prostanoid deficiency, either due to reduced availability of arachidonic acid, impairment of cyclo-oxygenase activity or increased prostanoid metabolism, could be a contributing factor to seizure susceptibility.

Early studies demonstrated that administration of prostaglandins of the E series intracerebrally in unanaesthetized cats, intravenously in chicks (Horton, 1964) or intraperitoneally in rats (Haubrich et al., 1973) produced sedative effects. Later, it was shown that intracerebral administration of these prostaglandins also inhibited pentylenetetrazole (PTZ)- (Bhattacharya and Sanyal, 1978; Rosenkranz and Killam, 1979) and also picrotoxin-, strychnine- and isoniazid-induced seizures in rats (Rosenkranz and Killam, 1979).

Several studies have shown that certain NSAIDs increase the susceptibility of experimental animals to seizures, possibly due to inhibition of prostaglandin synthesis. Indeed, clinical evidence shows that certain NSAIDs, such as mefenamic acid, administered in high doses in humans, can themselves be epileptogenic. However, some reports indicate an anti-convulsant effect of NSAIDs. These issues will now be discussed in detail below.

Chapter One: General Introduction 13
1.2.vii. NSAIDs used in seizure models

Following a report that maternal indomethacin induced convulsions in a breast-fed infant (Eeg-Olofsson, 1978), Steinhauer et al., (1979) and later Steinhauer and Hertting, (1981), investigated the effects of NSAIDs on chemically-induced seizures in mice. The authors demonstrated that ibuprofen, indomethacin, diclofenac and flurbiprofen lowered the convulsive threshold and LD$_{50}$ of PTZ-induced seizures and, also inhibited the increase of prostaglandins and thromboxane B$_2$ normally observed following chemically- and electrically-induced seizures in rodents. However aspirin did not affect either of these parameters. Moreover, the authors demonstrated that indomethacin also accelerated seizure onset.

Wallenstein (1985a) demonstrated that mefenamic acid, meclofenamic acid and ibuprofen (and paracetamol which is not an NSAID) delayed the onset of PTZ-induced seizures in rats and that, in addition, mefenamic acid and meclofenamic acid potentiated the excitatory effects of subconvulsive and convulsive doses of PTZ. In a study examining the effect of NSAIDs on the electrocorticogram recorded in rats, Wallenstein (1985b) found that mefenamic acid and meclofenamic acid produced dose-dependent increases in excitation (including seizure) whereas the non-fenamate NSAIDs, ibuprofen and indomethacin (and paracetamol) produced dose-dependent increases in sedation. Wallenstein (1987) later examined the effects of NSAIDs on penicillin-induced "primary generalised seizures" and "focal seizures" and demonstrated that ibuprofen (and paracetamol) inhibited the number and delayed the onset of penicillin-induced "primary generalised seizures" in rats, whereas mefenamic acid inhibited the incidence, but did not affect the onset of these seizures. In the penicillin-induced "focal seizure" model, mefenamic acid (and paracetamol) delayed the number and onset of seizures, whilst ibuprofen only delayed the onset and indomethacin only reduced the number of penicillin-induced seizures.

Ikonomidou-Turski et al., (1988) demonstrated that a range of NSAIDs differentially modulated the threshold for pilocarpine-induced seizures in rats. Some NSAIDs, for example, sodium salicylate and phenylbutazone, were pro-convulsant, others (e.g. indomethacin and ibuprofen) had no effect, and one in

Chapter One: General Introduction 14
particular, mefenamic acid, was anti-convulsant. Interestingly, in this study, mefenamic acid not only prevented pilocarpine-induced seizures, but was also neuroprotective against the ensuing seizure-related brain damage. Wallenstein (1991) using behavioural and electrocorticogram studies, later demonstrated that mefenamic acid, but not ibuprofen, attenuated PTZ-induced seizures in kindled rats without effects on latency to onset, but that high doses of mefenamic acid also produced excitatory effects. More recently, Baran et al., (1994) reported that indomethacin potentiated kainic-acid induced seizure activity in rats, whilst ibuprofen and the lipoxygenase inhibitor, ebselen, had no affect. However, the combined cyclo-oxygenase and lipoxygenase inhibitor, BW755C (3-amino-1-, m-(trifluoromethyl-phenyl)-2-pyrazoline) was neuroprotective and reduced the severity of PTZ-induced seizures. Most recently, Kaminski et al., (1998) demonstrated, using an electrically-induced seizure model in mice, that a number of NSAIDs differentially increased the protective effects of two antiepileptic drugs (diphenylhydantoin and valproate magnesium), whilst having no effect on the threshold of electrically-induced seizures themselves: acetylsalicylic acid, ibuprofen, indomethacin, metamizole and piroxicam all potentiated the protective effects of valproate magnesium, whilst only ibuprofen and piroxicam increased the protective effects of diphenylhydantoin.

These data demonstrate that certain NSAIDs modify seizure activity. However, the evidence regarding their effects is conflicting, with some NSAIDs potentiating and others inhibiting seizure activity, depending on the seizure model employed. Intriguingly, mefenamic acid overdose in humans has been reported to result in convulsive seizures. In fact, Prescott et al., (1981) reported that over one third of all overdose cases of mefenamic acid resulted in grand mal convulsions. Typical symptoms of such overdose cases include generalised seizures, clonic-tonic limb movements and lack of response to painful stimuli (Young et al., 1979, Balali-Mood et al., 1981, Shipton and Müller, 1985, Turnbull et al., 1988). Interestingly, Shipton and Müller (1985) describe a case of mefenamic acid overdose resulting in a generalised convulsion where the patient was remarkably resistant to diazepam treatment, but did respond to

Chapter One: General Introduction 15
etomidate. However, other clinicians have reported successful treatment of mefenamic acid-induced generalised convulsions with diazepam (Gossinger et al., 1982). In addition to seizures, other reported symptoms of mefenamic acid overdose include coma (Gossinger et al., 1982, Hendrikse, 1988), which in one case was followed by a grand mal convulsion (Gossinger et al., 1982).

In the main, it has been proposed that NSAIDs could produce their complex effects on seizure threshold and latency by their concurrent inhibition of cyclo-oxygenase activity. However, this hypothesis does not explain the range of effects exhibited by different NSAIDs, all of which have the ability, albeit to different degrees, to inhibit cyclo-oxygenase activity. For example, indomethacin and ibuprofen, which have no effect on pilocarpine-induced seizures, are more potent inhibitors of cyclo-oxygenase activity than sodium salicylate and phenylbutazone, both of which exacerbate pilocarpine-induced seizures (Ikonomidou-Turski et al., 1988). In addition, this hypothesis does not explain the complex biphasic effects of mefenamic acid on chemically induced seizures. Recently, Wong (1993) demonstrated that relatively high doses of indomethacin (200-400mg/Kg), but not acetylsalicylic acid, afforded protection against chemically- and electrically induced seizures in mice. Wong suggested that this protection could be due to GABA-uptake inhibition rather than inhibition of cyclo-oxygenase activity and also suggested that the high dosages required are due to the "relative insensitivity of mice to CNS depression compared to humans."

In addition to inhibition of cyclo-oxygenase activity, a number of alternative explanations have been proposed. Bhattacharya and Sanyal (1978), for example, suggest a serotonergic, but not catecholamine-mediated component to the convulsive effects induced by PTZ. These authors demonstrated that the anti-convulsant effect of PGE-1 on PTZ-induced seizures was inhibited by p-chlorophenylalanine (PCPA; a selective serotonin synthesis inhibitor), methysergide (a mixed 5-HT1/2 receptor antagonist) and 5,6-dihydroxytryptamine (DHT; an inductor of selective degeneration of serotonergic neurones), but not by the catecholamine synthesis inhibitor, α-methyl-p-tyrosine (MPT), or the adrenoreceptor antagonists phenoxybenzamine (PBZ), propanolol or haloperidol.
Despite the clinical evidence, a paucity of studies investigating the mechanisms underlying the complex effects of NSAIDs on seizure activity has precluded a convincing explanation for these observations. Some electrophysiological studies, in a number of non-neuronal and a limited number of neuronal preparations, have revealed that NSAIDs may dramatically influence the behaviour of a variety of ion channels. These experiments, which may provide a valuable insight into the effects of NSAIDs on the CNS, will now be discussed in detail.

1.2.viii. Physiological effects of NSAIDs on Ion Channel function

1.2.viii. i. Non-neuronal Preparations

A number of studies have demonstrated that NSAIDs modulate ion channel function in non-neuronal preparations.

Several studies have shown that certain fenamates induce intracellular Ca\(^{2+}\) release. McDougall, et al., (1988) demonstrated that flufenamic acid and mefenamic acid uncoupled oxidative phosphorylation causing an inhibition of calcium uptake (with an IC\(_{50}\)s of 7\(\mu\)M and 68\(\mu\)M, respectively), and thereby increased cytosolic Ca\(^{2+}\) levels in mitochondria isolated from rat liver. Later, Northover et al., (1990) showed that flufenamate (5\(\mu\)M) induced intracellular Ca\(^{2+}\) release in isolated myocardial cells and Poronnik et al., (1992), showed that flufenamic (with an EC\(_{50}\) of 100\(\mu\)M), mefenamic and niflumic acid (in descending order of potency) induced intracellular Ca\(^{2+}\) release in a mouse mandibular cell line. In addition, flufenamic acid (between 37-500\(\mu\)M) and mefenamic acid (with less potency) have been shown to directly activate potassium channels in human jejunum (Farrugia et al., 1993a); similar results were obtained in canine jejunum (Farrugia et al., 1993b). Niflumic acid (with a \(K_d\) of 261\(\mu\)M), flufenamic acid and mefenamic acid (although less potently than flufenamic acid) also potentiated calcium-activated K\(^+\) channels in plasma membranes vesicles from pig coronary smooth muscle (reconstituted into lipid bilayers) by increasing open channel probability (Ottolia and Toro, 1994).
Fenamates have also been shown to inhibit non-selective cation channels in non-neuronal preparations. For example, flufenamic, mefenamic (both with IC\textsubscript{50} values of 10\textmu M), and niflumic acid (with an IC\textsubscript{50} of 50\textmu M) inhibited non-selective cation channels in rat exocrine pancreas; indomethacin, ibuprofen or aspirin did not modulate these channels (Gögelein \textit{et al.}, 1990). Fenamates have also been shown to block non-selective cation channels in rat distal colon cells (Siemer and Gögelein, 1992), in murine L cells (Jung \textit{et al.}, 1992), rat capillary endothelial cells (Popp and Gögelein, 1992) and in a mouse mandibular cell line (Poronnik \textit{et al.}, 1992).

An early study by Cousin and Motais, (1979) demonstrated that niflumic and meclofenamic acid (with IC\textsubscript{50} values of 0.63\textmu M and 0.75\textmu M, respectively), non-competitively inhibited anion transport in human erythrocytes. More recently, it has been shown that fenamates inhibit Ca\textsuperscript{2+}-activated chloride channels in certain epithelial cell types (Chao and Mochizuki, 1992). For example, niflumic and flufenamic acid inhibit chloride conductance in the basolateral membrane lining the ascending Loop of Henle in rabbit kidney (Wangemann, \textit{et al.}, 1986). In addition, flufenamic and niflumic acid have been shown to inhibit Ca\textsuperscript{2+}-activated chloride conductance in \textit{Xenopus} oocytes (White and Aylwin, 1990, Séguëla \textit{et al.}, 1993; Woodward \textit{et al.}, 1994). McCarty \textit{et al.}, (1993) report that flufenamic acid (200\textmu M) inhibits the cystic fibrosis transmembrane conductance regulator chloride channel expressed in \textit{Xenopus} oocytes by a voltage-dependent mechanism, suggesting open-channel blockade.

1.2.viii. i. Neuronal Preparations.

There have been few studies investigating the actions of NSAIDs on ion channel function in neuronal preparations. However, early studies demonstrated that salicylic acid, albeit at millimolar (1-30mM) concentrations, inhibited chloride ion permeability and increased potassium ion permeability in buccal ganglion neurones of the marine mollusc, \textit{Navanax inermis} (Barker and Levitan, 1971). Neto (1980) later demonstrated that salicylic acid (2-5mM) reduced the spike amplitude, and at higher concentrations (10-20mM), blocked
conduction of the compound action potentials recorded extracellularly in rabbit vagus and frog sciatic nerves.

Interestingly, Shaw et al., (1995) demonstrate non-selective cation channel block with flufenamic acid (300-500\(\mu\)M), but not mefenamic acid in molluscan neurones, and also showed that at these concentrations flufenamic, but not mefenamic acid, also induced intracellular \(Ca^{2+}\) release in these molluscan neurones. Lerma and Martin del Rio, (1991) reported that niflumic and flufenamic inhibited NMDA-gated cation channel in mouse spinal cord neurones, with \(IC_{50}\) values of \(\approx 350\mu\)M. More recently, Chen et al., (1998) report an inhibition of NMDA, but not kainate-mediated responses, by mefenamic acid, meclofenamic acid and flufenamic acid (all at 1mM), recorded in salamander retinal ganglion neurones.

The studies reviewed above clearly reveal that NSAIDs influence the behaviour of a variety of ion channels. However of particular interest are three studies which demonstrate that fenamates modulate neuronal GABA\(_A\) receptors. A radio-ligand binding study by Evonuik and Skolnick (1988) demonstrated that niflumic acid inhibited Cl\(^{-}\)-modulated [35\(\text{S}\)]-t-butylibicyclophosphorothionate (TBPS) binding to rat neuronal GABA\(_A\) receptors and suggested that niflumic acid acts at or near a binding site within the GABA-gated Cl\(^{-}\) channel. More recently, Woodward et al., (1994) demonstrated that fenamates modulated rat cortical GABA\(_A\) receptors expressed in Xenopus oocytes. Furthermore, a preliminary study by Halliwell et al., (1994) demonstrated that mefenamic acid was a potent modulator of native GABA\(_A\) receptors in rat hippocampal neurones; these studies will be discussed in detail below.

In light of the observations reviewed above, the effects of NSAIDs upon neuronal ligand-gated ion channels have been investigated, with particular focus on the GABA\(_A\) receptor. For this reason, the general properties of ligand-gated ion channels and, in particular, the GABA\(_A\) receptor, will now be discussed.
1.3. Ligand-Gated Ion Channels-general characteristics

Ligand-gated ion channels probably mediate the majority of fast inhibitory and excitatory synaptic transmission in the mammalian CNS. These channels comprise a multi-subunit assembly forming a central ion selective channel and associated ligand binding sites. Neuronal excitation is usually associated with the opening of cation channels and subsequent membrane depolarisation. Neuronal inhibition, by contrast, is often associated with an increase in anion/chloride ion permeability and subsequent membrane hyperpolarisation. The GABA$_A$ receptor, like the nicotinic acetylcholine (nACh), strychnine-sensitive glycine, 5-hydroxytryptamine$_3$ (5-HT$_3$), ionotropic glutamate and recently, the purinoceptor P$_{2X}$ receptor, is part of the ligand-gated ion channel super-family (Unwin et al., 1993; Schofield et al., 1987). The structure of the nACh receptor is the best characterised of this receptor super-family. However, since the GABA$_A$ receptor is a major focus of this thesis, the properties of GABA$_A$ receptors will be reviewed in detail below.

1.4. The γ-Aminobutyric Acid Type A (GABA$_A$) Receptor

1.4.1. γ-Aminobutyric Acid (GABA)

GABA has been known to act as a neurotransmitter in mammals for over thirty years. Early studies demonstrated that GABA had marked depressant effects on mammalian cerebral cortical neurones (Hayashi, 1956), and that GABA could inhibit chemically-induced seizure activity in the motor cortex of the dog (Hayashi, 1959). Later, seminal electrophysiological studies performed by Krnjevic and Schwartz, (1966, 1967) compared the properties of inhibitory postsynaptic potentials (IPSPs) and GABA-induced membrane hyperpolarization in cat neocortical neurones and found that in both cases these events were chloride-dependent and had similar reversal potentials. GABA is now thought to be the major inhibitory amino acid neurotransmitter in the vertebrate CNS with between 20 to 50% of all central synapses using
GABA as their neurotransmitter, depending on brain region (Bloom and Iverson, 1971; Bormann, 1988; Young & Chu, 1990). GABA is found predominantly within the CNS with only small amounts being located in the periphery. It is a neutral amino acid which is synthesised in GABAergic nerve terminals by the action of the decarboxylating enzyme, glutamic acid decarboxylase (GAD) on L-glutamic acid (Roberts And Frankel, 1950). It is released from nerve terminals in response to a stimulus in a calcium-dependent manner (Bradford, 1970) and following release; it is removed from the synaptic cleft by high affinity sodium-dependent uptake systems (Iverson and Neal, 1968). GABA is the endogenous ligand for a diversity of GABA receptors.

1.4.ii. GABA Receptor Classification

Three different receptor classes for GABA have been defined in terms of physiology and pharmacology namely, GABA_A, GABA_B and GABA_C receptors. Of these the GABA_A receptor has been the most extensively characterised.

The first GABA receptor subtype to be described was later defined as the GABA_A receptor. GABA_A receptors have been shown to be directly associated with a Cl- channel (Bormann, 1988; Silvilotti and Nistri, 1991) and are located pre- and post-synaptically throughout the CNS. GABA influences neuronal excitability and affects glial cells at GABA_A receptors by increasing permeability to chloride ions (Curtis et al., 1968; Krnjevic, 1974; Olsen, 1982) usually causing membrane hyperpolarization in neurones and depolarisation in glial cells. GABA_A receptors are activated by GABA, muscimol and isoguvacine, inhibited competitively by bicuculline and, non-competitively, by picrotoxin, and are subject to allosteric modulation by a number of chemically diverse allosteric modulators which will be discussed in detail below.

GABA_B receptors have been shown to be coupled to Ca^{2+} or K^{+} ionophores via G-proteins (Bormann 1988; Bowery 1993); they are located pre- and post-synaptically throughout the CNS and are composed of heterogeneous subtypes (Bonnanno et al., 1993). Recently, Kaupmann et al., (1997) have
cloned a GABA\textsubscript{B} receptor, which is a 7-transmembrane domain protein, bearing similarities to metabotropic glutamate receptors. GABA\textsubscript{B} receptors are bicuculline-insensitive, stimulated by GABA and baclofen (Bowery \textit{et al.}, 1980; Hill and Bowery, 1981) and inhibited by phaclofen (Kerr \textit{et al.}, 1987) and CGP 54626 \((\text{[S-(R*,R*)]-[3-[(1-(3,4-dichlorophenyl) ethyl] amino-2-hydroxypropyl] (cyclohexylmethyl) phosphinic acid; Froestl \textit{et al.}, 1996).}

GABA\textsubscript{C} receptors (Drew \textit{et al.}, 1984; Cutting \textit{et al.}, 1991; Polenzani \textit{et al.}, 1991) may represent a simpler homo-oligomeric type of ligand-gated ion channel, having simpler pharmacology than GABA\textsubscript{A} receptors. They are stimulated by GABA, muscimol, cis-4-aminocrotonic acid (CACA; a conformationally restricted analogue of GABA) and its trans-isomer (trans-4-aminocrotonic acid; TACA) (Sivilotti and Nistri, 1989, 1991; Feigenspan \textit{et al.}, 1993; Lukasiewicz \textit{et al.}, 1994; Dong \textit{et al.}, 1994), but are insensitive to baclofen and bicuculline (Quian and Dowling, 1993; Feigenspan \textit{et al.}, 1993; Dong \textit{et al.}, 1994). Unlike GABA\textsubscript{A} receptors, GABA\textsubscript{C} receptors are not modulated by benzodiazepines, barbiturates (Sivilotti and Nistri, 1991; Bormann and Feigenspan, 1995) or neurosteroids (Feigenspan \textit{et al.}, 1993). GABA\textsubscript{C} receptors have recently been localised to sub-populations of vertebrate retinal neurones (Cutting \textit{et al.}, 1991, Feigenspan \textit{et al.}, 1993; Quian and Dowling, 1993; Lukasiewicz \textit{et al.}, 1994; Dong \textit{et al.}, 1994) and are thought to contain the recently discovered \(\rho\)-subunit (Cutting \textit{et al.}, 1991, 1992).

Thus, a diversity of receptor classes exists for which GABA is the endogenous ligand. This diversity is further increased by the existence of a number of subtypes of the GABA receptor which differ in terms of physiology and pharmacology.
1.4.iii. Structure of the GABA<sub>A</sub> receptor

Determination of the molecular structure of the GABA receptor was aided by the discovery that the receptor protein could be photo-affinity labelled by [³H]-flunitrazepam (Möhler <i>et al.</i>, 1980). A single polypeptide was labelled in crude brain homogenates with a molecular weight of 51kD. Subsequently, the existence of additional benzodiazepine binding polypeptides was demonstrated (Sieghart and Drexler, 1983). On the basis of these and similar biochemical studies (e.g. Sigel <i>et al.</i>, 1983), the GABA<sub>A</sub> receptor was proposed to form a hetero-oligomeric complex of about 200-300kD composed of 2 or more different polypeptides (α and β). Later, five different GABA<sub>A</sub> receptor subunit subtypes (each between 48-56kDa.) were identified on the basis of sequence analysis (Schofield <i>et al.</i>, 1987; Olsen and Tobin, 1990; Levitan <i>et al.</i>, 1988; Pritchett <i>et al.</i>, 1989; Burt & Kamatchi 1991). Electron microscope and image analysis studies have revealed that the GABA<sub>A</sub> receptor probably comprises a pentameric subunit organisation surrounding a central pore (Nayeem <i>et al.</i>, 1994). Hydropathy analysis of the sequences of GABA<sub>A</sub> receptor subunits predicts an extracellular N-terminal of about 200 amino acids containing three glycosylation sites, and four putative α-helical hydrophobic transmembrane (TM) spanning regions (TM1-4; Schofield <i>et al.</i>, 1987; Olsen and Tobin, 1990; Burt and Kamatchi, 1991; Wisden and Seeburg, 1992). A large intracellular loop exists between TM3 and TM4, which contains phosphorylation sites thought to be responsible for receptor assembly and regulation (for review see Moss and Smart, 1996). The N-terminus is thought to be involved in ligand recognition. As in the nicotinic acetylcholine (nACh) receptor (Leonard <i>et al.</i>, 1988; Sakmann, 1992; Lester, 1992; Akabas, 1992, 1994; Unwin, 1993), the TM2 region of the GABA<sub>A</sub> receptor is thought to be involved in the formation of the channel wall (Xu and Akabas, 1993,1996).
**Figure 1.2**: Schematic representation of the GABA<sub>A</sub> receptor: showing a pentameric subunit organisation surrounding a central pore. Known binding sites on specific subunits for GABA and some positive allosteric modulators of the GABA<sub>A</sub> receptor are shown (see key). α- and γ- subunits are shown adjacent to each other comprising the benzodiazepine binding site. The β-subunit, carrying binding sites for loreclezole (etomidate) and propofol is shown between two other unknown subunits, which may also be involved in ligand binding. Binding sites for barbiturates and steroids may be present on all subunits. (Schematic modified from McKernan and Whiting, 1996).
1.4.1'v. Biophysical Properties of the GABAergic receptor

The GABAergic receptor is an anion-selective channel. Electrophysiological studies by Bormann \textit{et al.}, (1987) using cultured mouse spinal neurones revealed the following permeability sequence (relative to chloride ions) for the GABAergic receptor: SCN$^-$ > I$^-$ > NO$_3^-$ > Br$^-$ > NO$_2^-$ > Cl$^-$ > HCO$_3^-$ and an ionic conductance sequence which was reversed in order. These authors estimated an effective pore diameter of 5.6nm for the GABAergic receptor. In mammalian neurones a gradient of chloride ions exists across the membrane. Activation of GABAergic receptors results in movement of chloride ions in or out of cells, depending on the electrochemical driving force present.

Development of the single-channel recording technique (Hamill \textit{et al.}, 1981) has enabled the characterisation of GABAergic receptors at the single-channel level. Using this technique, Bormann \textit{et al.}, (1987) described multiple conductance levels of the GABAergic receptor in outside-out patches of cultured mouse spinal neurones and found a predominant conducting state of 30pS with three less frequently occurring states of 44, 19 and 12 pS. Similar experiments conducted by Macdonald \textit{et al.}, (1989a), again in cultured mouse spinal neurones, also revealed main conductance states of 27-30pS and two less frequently occurring states of 17-19pS and 11-12pS for GABAergic receptors.

The single-channel gating properties of the main conductance level of GABAergic receptors in cultured mouse spinal neurones has been well characterised (Sakmann \textit{et al.}, 1983; Macdonald \textit{et al.}, 1989a; Twyman \textit{et al.}, 1990; Twyman and Macdonald, 1992). These investigators have shown that the GABAergic receptor has three different open states. For example, low concentrations (0.5$\mu$M) of GABA open channels with a mean open duration of 0.5ms whereas higher concentrations (up to 5$\mu$M) open channels with mean durations of 2.6 and 7.6ms (Macdonald \textit{et al.}, 1989a; Macdonald and Olsen, 1994). Multiple closed states, with different mean closed durations, also exist for the GABAergic receptor, namely two brief closed states with mean durations of 0.2 and 1.4ms states with time constants which are concentration independent, and at least three longer closed states with time constants which decrease with increasing agonist concentration. Perhaps, not surprisingly, several investigators have shown that the gating properties of recombinant GABAergic...
receptor single channels vary according to subunit subtype (reviewed by Macdonald & Olsen, 1994).

1.4.v. Subunit Heterogeneity & Stoichiometry of GABA Receptors

The GABA$_A$ receptor is formed by the assembly of five subunits to produce a ligand-gated ion channel complex (Macdonald & Olsen, 1994; Nayeem et al., 1994). To date, molecular cloning and expression studies have revealed the presence of at least nineteen different, but structurally similar, gene products encoding for GABA$_A$ receptor subunit isoforms. Subsequently, six distinct glycoprotein classes have been identified on the basis of predicted amino acid sequences. These contain the following isoforms: $\alpha_1$-$\alpha_6$, $\beta_1$-$\beta_4$, $\gamma_1$-$\gamma_3$, $\delta$, $\varepsilon$ (Davies et al., 1997a; Whiting et al., 1997) and $\pi$ (Heblom and Kirkness, 1997). These polypeptides are all approximately 50 kD in size, with four putative transmembrane spanning regions. In addition, some of the GABA$_A$ receptor genes undergo alternative splicing and splice variants exist for the genes encoding $\alpha_6$, $\beta_2$, $\beta_4$ and for $\gamma_2$-subunits. For example, the rat cerebellar $\alpha_6$ splice variant has a short sequence of amino acids missing from the N-terminus which renders the receptor non-functional when in combination with other subunits (Korpi et al., 1994). In the chick, two splice variants have been identified for $\beta_2$ and $\beta_4$ subunits (Bateson et al., 1991; Harvey et al., 1994). In addition, two splice variants have been identified for $\gamma_2$-subunits, $\gamma_2S$ and $\gamma_2L$, in human, rat and bovine tissue, with the $\gamma_2L$ splice variants containing an 8-amino acid insert with a consensus substrate sequence for phosphorylation (Whiting et al., 1990; Kofuji et al., 1991). In the CNS, GABA$_A$ receptors comprise combinations of $\alpha$- and $\beta$-subunits, together with one or more of the $\gamma$-, $\delta$- or $\varepsilon$-subunits (McKernan and Whiting, 1996; Davies et al., 1997a; Barnard et al., 1998). To date, in humans, the $\pi$-subunit has been located mostly in peripheral tissues, particularly in the uterus, but it has also been identified in small amounts in the hippocampus and temporal cortex (Heblom and Kirkness, 1997). In addition, $\rho$-subunits have been found to make up GABA$_A$ receptors only in the retina (Cutting et al., 1991, 1992 and Ogurusu and Shingai, 1996).
The amino acid sequence homology between subunit classes is about 30-40%, but within a subunit class, it is 60-80%. A separate gene encodes for each subunit and these genes have been shown to cluster together on different chromosomes. For example, in the human genome, genes encoding α1, α6, β2 and γ2 subunits are clustered onto chromosome 5 (Wilcox et al., 1992; Hicks et al., 1994; Buckle et al., 1989), genes encoding α2, β1 and γ1 are clustered onto chromosome 4 (Wilcox et al., 1992; Buckle et al., 1989) and genes encoding α5, β3 and γ3 are clustered onto chromosome 15 (Wagstaff et al., 1991; Knoll et al., 1993; Greger et al., 1995).

Immunoprecipitation and in situ hybridization studies have revealed the existence of a large diversity of GABA_A receptor isoforms in native cells which differ in terms of their subunit combination. These different receptor isoforms are known to predominate in different brain regions (Wisden et al., 1992; Rabow et al., 1995). In fact, in situ hybridisation studies have indicated that an overlapping regional distribution of the various subunits exists throughout the brain. In a comprehensive in situ hybridization study, Wisden et al., (1992) mapped the mRNA distribution of 13 GABA_A receptor subunit-encoding genes in adult rat brain and demonstrated that the mRNAs of the rat GABA_A receptor subunits were present in a complex, overlapping pattern. For example the mRNA distribution of the α1 subunit was ubiquitous throughout the brain, whereas the mRNA of the α6 subunit was confined to cerebellar granule cells (Wisden et al., 1992, Laurie et al., 1992). A number of studies have shown that most GABA_A receptor subunits are expressed in the hippocampus (reviewed by McKernan and Whiting, 1996). Wisden et al., (1992) demonstrated that in the hippocampus, α1-5 mRNA were expressed throughout, with the α2-subunit mRNA being the most prevalent, particularly in dentate gyrus cell layers and in the CA1 and CA3 regions. α3 mRNA expression was highest in the dentate granule cells, but was also present, to a lesser degree, in pyramidal cells. α5 mRNA expression levels, virtually absent from all other areas of the brain in this study, was highest in CA1 and CA3 regions, but was also present in the dentate gyrus (see also Thompson et al., 1992). β1, β2 and β3 mRNAs were
found throughout the hippocampus with β1 and β3 being predominant and β1 being rarely expressed elsewhere in rat brain. All γ-subunit mRNAs were expressed in the hippocampus, with the γ2-subunit being the most common and γ3 being relatively uncommon. Finally, the δ-subunit mRNA distribution was found to be confined to dentate granule cells.

Although the number of possible combinations of these native isoforms is vast, only twelve to twenty-four combinations are thought to exist in the native form (e.g. Smith and Olsen, 1995). Studies involving the expression of GABAₐ receptor subunits in *Xenopus* oocytes and mammalian cells suggest the occurrence of an ordered assembly of GABAₐ receptor subunits into a preferred complex of functional GABAₐ receptors, rather than a random assembly of subunits (Macdonald & Olsen, 1994).

A number of possible subunit stoichiometries has been shown to exist in mammalian brain. For example, immunoprecipitation studies (Khan *et al.*, 1994,1996; Pollard *et al.*, 1995) have indicated that two different α-subunits, α1 and α6, can co-occur in cerebellar receptors. In similar studies, other investigators have demonstrated the co-occurrence of different β-subunits and that this co-occurrence varies with brain region. For example, Li and De Blas, (1997) have indicated that 33% of rat cerebral cortex GABAₐ receptors contain both β1 and β2 subunits and that 19% contain both β1 and β3 subunits; also β subunit co-occurrence was seen predominantly in the hippocampus with the least occurring in the cerebellum. Additionally, using immunoprecipitation techniques in whole rat brain, Benke *et al.*, (1996) demonstrated that γ2 and γ3 subunits co-assembled in native GABAₐ receptors. Immunoprecipitation studies in α6-containing cerebellar granule cells indicated that 10%, 51% or 21% of these cells contained homogeneous β1, β2 or β3 subunits, respectively and that two different β-subunits were present in 18% of these cells (Jechlinger *et al.*, 1998).

Kirsch *et al.*, (1995), for example, have demonstrated that any ternary combination of α, β and γ subunits expressed recombinantly in oocytes or cultured cells can form functional membrane-bound receptors. In fact, the triple combination of α1β2γ2 has been suggested to constitute the majority of GABAₐ
receptor mRNAs in many neurone populations in the brain (McKernan et al., 1991; McKernan and Whiting, 1996). In the case of the native receptor, however, it has been suggested that the combination of specific subunit subtypes may be genetically predetermined for given cell populations (McKernan and Whiting, 1996).

It is now increasingly recognised that the precise subunit composition of the receptor confers distinct pharmacological and physiological properties to GABA\textsubscript{A} receptors (Mihic et al., 1995; McKernan and Whiting, 1996). These properties will be discussed in detail where appropriate.

Additionally, GABA\textsubscript{A} receptor function may be modified by agents that increase protein phosphorylation. Phosphorylation is a process whereby receptor structure is covalently modified and it is catalysed by enzymes known as protein kinases, for example, cyclic adenosine monophosphate-dependent protein kinase (PKA), protein kinase C (PKC) and protein kinase G (PKG) calmodulin dependent protein-kinase II and tyrosine kinases. In vitro recombinant studies (reviewed by Moss and Smart, 1996) suggest that the $\beta$ and $\gamma_2$ subunits are the primary sites of GABA\textsubscript{A} receptor phosphorylation.

Phosphorylation of GABA\textsubscript{A} receptors in different neuronal preparations may cause enhancement or inhibition of GABA\textsubscript{A} receptor function. For example, in mouse spinal neurones, phosphorylation by PKA decreases GABA\textsubscript{A} receptor activation (Porter et al., 1990), whereas in rat retinal cells PKA phosphorylation may increase receptor function (Veruki and Yeh, 1992, 1994) and may also be involved in receptor assembly (Angelotti et al., 1993). PKC-mediated phosphorylation usually results in inhibition of GABA\textsubscript{A} receptor function. For example, early studies using rat or chick brain mRNA injected into Xenopus oocytes, demonstrated, for the first time, that activation of PKC by phorbol esters caused inhibition of GABA-evoked whole-cell currents (Sigel and Baur, 1988; Moran and Dascal, 1989). Several other investigators have also demonstrated inhibition of GABA\textsubscript{A} receptor function by PKC-mediated phosphorylation (for review see Moss and Smart, 1996). In contrast, tyrosine phosphorylation has been reported to enhance GABA\textsubscript{A} receptor function in
superior cervical ganglion neurones by increasing mean open time and open channel probability (Moss et al., 1995).

1.5. GABA<sub>A</sub> Receptor Pharmacology: Agonists and Antagonists

The GABA<sub>A</sub> receptor possesses binding sites for many chemically diverse compounds. Included amongst these are sites for agonists, partial agonists, competitive-antagonists and positive and negative allosteric modulators. A description of some of the important agonist and antagonists which have contributed to the characterisation of the GABA<sub>A</sub> receptor is presented below, followed by a description of the allosteric modulators of the GABA<sub>A</sub> receptor which are central to this thesis.

1.5.i. Agonists

GABA is the primary endogenous ligand for the GABA<sub>A</sub> receptor. It is a flexible molecule which can adopt a number of low energy conformations allowing it to interact with different GABA receptors, enzymes and transporters (Johnston et al., 1978). Another GABA<sub>A</sub> agonist, which is more potent than GABA itself is muscimol, the naturally occurring isoxazole analogue obtained from the hallucinogenic mushroom Amanita muscaria. Curtis et al., (1971) demonstrated that GABA (0.5M) and imidazole acetic (0.5M) acid were approximately equipotent as depressants of cat spinal interneurones when applied iontophoretically, whereas muscimol (0.5M) was much more potent. The potency ratio was reflected by the currents required to produce equal diminution of neuronal firing (20nA for GABA compared to 1nA for muscimol in one cell; firing (2nA for GABA compared to 3nA for imidazole acetic in a second cell). Similar experiments by Krogsgaard-Larsen et al., (1977) have shown that THIP (4,5,6,7-tetrahydroisoxazolo-[4,5-c]pyridin-3-ol), a conformationally restricted, bicyclic synthetic analogue of muscimol, is more selective for GABA<sub>A</sub> receptors than muscimol or GABA, but is equipotent with GABA and less potent than muscimol in terms of its ability to inhibit neuronal activity in the cat spinal cord, in vivo (Krogsgaard-Larsen et al., 1977). Isoguvacine (1,2,3,4-
tetrahydropyridine-4-carboxylic acid), a compound where the isoxazole of THIP has been substituted by a carboxyl group, however, is equipotent with muscimol in its ability to inhibit neuronal activity in the cat spinal cord, in vivo (Krogsgaard-Larsen et al., 1977) and demonstrates some selectivity for β subunits (Bureau and Olsen, 1990). Studies in rat cerebral cortex slices demonstrate that neither THIP nor isoguvacine (0.5-1mM) affect GABA transaminase activity or GABA uptake (Krogsgaard-Larsen et al., 1977). ZAPA (Z-3-[(aminoiminomethyl)thio]prop-2-enoic acid) is a conformationally restricted isothiouronium analogue of GABA and it is selective for low affinity GABAA receptors, which are modulated by benzodiazepines. ZAPA facilitates the binding of diazepam (EC50 0.19µM for ZAPA and 0.46µM for GABA; Allan et al., 1986) and displaces the low affinity binding of GABA to rat brain membranes (IC50 in washed synaptosomal membranes for inhibition of [3H] GABA binding – GABA 70µM and ZAPA 46µM; Allan et al., 1991). (+)-TACP ((+)-trans-(1S,3S)-3-aminocyclopentane-1-carboxylic acid) is a stereoisomer of a cyclopentane analogue of GABA (Allan et al., 1979). (+)-TACP is a potent GABAA agonist, which does not interact with GABA enzymes or transport systems.

1.5.ii. Partial Agonists

A number of partial agonists also exist, for example, 4-PIOL (5-(4-piperidyl) isoxazol-3-ol), thio-THIP, (Krogsgaard-Larsen et al., 1994), piperidine-4-sulphonic acid and other related compounds (Falch et al., 1985). 4-PIOL is a "non-fused" THIP analogue which is approximately 200 times less potent than isoguvacine as an agonist, with an EC50 of 91µM in whole-cell voltage-clamped hippocampal neurones, and 30 times less potent than bicuculline methochloride as an antagonist (Kristiansen et al., 1991). Thio-THIP appears to be a low-efficacy partial agonist in human brain recombinant receptors expressed in oocytes (Krogsgaard-Larsen et al., 1994), but a full agonist in cat spinal dorsal horn interneurones where it has half the potency of THIP or GABA when these agonists are applied electrophoretically at concentrations of 0.2M (Krogsgaard-Larsen et al., 1983).
Figure 1.3: Shows the GABA\textsubscript{A} receptor agonists, GABA, muscimol, THIP, isoguvacine, (+)-TACP and ZAPA.
Competitive antagonists of the GABAA receptor are thought to act at GABA recognition sites. In 1970, bicuculline, a convulsant compound from the plant Dicentra cucullaria, was found to antagonise the inhibitory actions of GABA in cat spinal Renshaw cells, whereby bicuculline (10mM) was found to considerably reduce the depressant action of electrophoretically-applied GABA on neuronal excitability (Curtis et al., 1970). Bicuculline is a phthalide isoquinoline alkaloid and is structurally similar to the GABAA receptor agonist, muscimol (Andrews and Johnston, 1979). In addition, other convulsant isoquinoline alkaloids, such as (+) hydrastine and corlumine have been associated with GABA antagonism (Curtis and Johnston, 1974). Securinine, from the plant Securinega suffructicosa, is a convulsant indolizidine alkaloid which is a selective GABAA receptor antagonist. Securinine induced tonic seizures in mice with a CD$_{50}$ dose four times less potent than that of bicuculline (28±3mg/kg versus 8±4mg/kg), but was approximately 7 times less potent than bicuculline in inhibiting $[^{3}H]$GABA binding to rat brain membranes (Beutler et al., 1985). In the same study, electrophysiological experiments conducted in cat spinal cord neurones revealed that securinine blocked the inhibitory action of GABA, but not glycine. Electrophysiological studies conducted in the cat spinal cord in vivo revealed that SR95531 (5mM), ("gabazine" or 2-(3-carboxypropyl)-3-amino-6-p-methoxyphenylpiridazinium bromide), was a selective GABAA receptor antagonist (Gynther and Curtis, 1986). In addition, Michaud et al., (1986) demonstrated in a microiontophoretic in vivo study that SR95531 (5mM) and bicuculline methochloride (5mM), with equal potency, inhibited GABA-elicited responses recorded extracellularly in the rat cuneate nucleus in a dose-dependent, competitive and reversible manner for ejection currents up to 100nA.

RU5135 (3-$\alpha$-hydroxy-16-imino-5$\beta$-17-aza-androstan-11-one) is an aminidine steroidal compound which is the most potent GABAA receptor antagonist known, being about 214 times more potent than bicuculline in the rat cuneate nucleus slice with a pA$_2$ value of 8.31(Simmonds and Turner, 1985). RU5135, however, also acts as a glycine antagonist in the rat optic nerve (pA$_2$...
Pitrazepin (3-(piperazinyl-1)-9H-dibenz(c,f)triazolo(4,5-a)azepine) (and a number of other N-aryl piperazines) is known to be a potent, but not selective, GABA<sub>A</sub> receptor antagonist. In binding studies, pitrazepin reversed the inhibitory effect of 1\textmu M GABA on 35S-TBPS binding with an EC50 of 0.36\mu M and was found to be 4 to 5 times more potent than bicuculline (Squires and Saederup, 1987). In electrophysiological studies in the cat spinal cord in vivo, pitrazepin hydrochloride (5mM) blocked GABA- and glycine-mediated neuronal inhibition (Curtis and Gynther, 1986). Other competitive GABAA receptor antagonists include (+)-tubocurarine (5mM), which apart from being an acetylcholine nicotinic antagonist, also weakly antagonised cortical GABA<sub>A</sub> and glycine receptors (Hill et al., 1972) and cuneate nucleus glycine receptors (Hill et al., 1973).
Figure 1.4: Showing chemical structures of competitive antagonists of the GABA<sub>A</sub> receptor in order of potency: RU5135 > pitrazepine > SR95531 = (+) hydrastine > bicuculline > securinine.
1.5.iv. Non-competitive antagonists

Picrotoxin, obtained from the poisonous plant *Anamirta cocculus*, is an equimolar mixture of a potent convulsant, picrotoxinin, and a less potent convulsant, picrotin (Curtis and Johnston, 1974). Picrotoxin is a non-competitive antagonist of the GABA_A receptor, which is thought to directly block the chloride channel, rather than binding to the GABA recognition site. In contrast to bicuculline (10μM), picrotoxin (10μM) can act as an antagonist whether applied intra- or extracellularly to voltage-clamped bullfrog dorsal root ganglion cells (Akaike et al., 1985). Also, in the rat cuneate nucleus, synergistic antagonism of GABA-evoked currents by a combination of picrotoxin and bicuculline suggested different sites of action for these compounds (Simmonds, 1980). Indeed, picrotoxinin binding sites, identified with [35S]-TBPS, are known to be closely associated with the chloride channel of the GABA_A receptor. Apart from antagonising GABA-mediated responses, at higher concentrations, picrotoxin has also been reported to antagonise the neuronal effects of glycine in neurones (Davidoff and Aprison, 1969) and in spinal neurones (Curtis et al., 1969). In addition, iontophoretic application of picrotoxin, albeit at higher concentrations (a saturated solution) than those required for GABA antagonism, antagonized the inhibitory effect of 5-HT on visual cortex neurones of the rat in vivo (Mayer and Straughan, 1981).

Furosemide is a chloride transport blocker which has been shown to antagonise the action of GABA in a number of preparations, for example in rat cuneate nucleus slices (Simmonds, 1982), guinea pig ileum (Taniyama et al., 1988) and frog sensory neurones (Inomata et al., 1988). Simmonds, (1982) demonstrated that furosemide (0.1-1mM) antagonised muscimol-evoked responses in rat cuneate nucleus slices in a non-competitive manner. In addition, furosemide antagonises recombinant GABA_A receptors expressed in oocytes in a subunit-selective manner. Electrophysiological experiments by Korpi et al., (1995) have shown that furosemide potently antagonizes α6β2γ2s- (IC50=10μM), but not α1β2γ2s-containing receptors (IC50>3mM). Binding studies by the same authors also indicated that furosemide was selective for
\(\beta 2/3\gamma 2\)-containing receptors and was ineffective at \(\alpha 1/6\beta 1\gamma 2s\)-containing receptors.

\(Zn^{2+}\) (50-300\(\mu\)M) has also been shown to inhibit GABA-evoked responses in rat neurones (Smart and Constanti, 1990; Smart, 1992). Patch-clamp studies of embryonic and adult sympathetic neurones performed by Smart, (1992) revealed that antagonism of GABA-evoked currents by \(Zn^{2+}\) was subject to a developmental influence, whereby embryonic neurones were much more sensitive to inhibition than adult neurones. This study demonstrated that \(Zn^{2+}\) did not affect the main single-channel conductance and mean open and shut times, but rather reduced the opening frequency of the GABA-gated Cl\(^-\) channel. Moreover, recombinant studies have shown that only hetero-oligomeric recombinant GABA\(_A\) receptors, devoid of a \(\gamma\)-subunit are sensitive to \(Zn^{2+}\) inhibition (Draguhn et al., 1990; Smart et al., 1991).

Penicillin is approximately 100 times less potent than bicuculline (Curtis and Johnston, 1974). Penicillin (100-5000\(\mu\)M) has been shown to concentration-dependently antagonise GABA\(_A\) receptor-mediated events recorded in voltage-clamped mouse spinal cord neurones by shortening the duration of channel openings and producing simple open channel blockade of the GABA\(_A\) receptor (Twyman et al., 1992).

Other non-competitive GABA\(_A\) receptor antagonists or more correctly, negative allosteric modulators (for review see Johnston, 1996), include convulsant \(\beta\)-carbolines and quinolone antibiotics together with NSAIDs, these will be discussed below.

1.6. Positive Allosteric Modulators of the GABA\(_A\) Receptor

A variety of compounds do not interact directly with the GABA binding site but, instead, bind to additional allosteric modulatory sites present on GABA\(_A\) receptors. This allosteric binding elicits a conformational change in the GABA\(_A\) receptor which subsequently influences the properties of other binding sites present on the receptor, thus modulating GABA-induced chloride ion flux.
Johnston (1996) has reviewed over 100 compounds which act at the GABA<sub>A</sub> receptor. An overview of the clinical effects, electrophysiology and pharmacology of the major classes of positive allosteric modulators of the GABA<sub>A</sub> receptor, together with a review of the recent evidence of novel modulators including fenamates will be presented below. These data form the background to the experimental work described later in this thesis.

### 1.6.i. Benzodiazepine Modulation of the GABA<sub>A</sub> Receptor

The first benzodiazepines were introduced into the clinic in the early 1960s, but it was not until some years later that it was recognised that benzodiazepines exerted their therapeutic effects by facilitating GABA-mediated neurotransmission. For example, experiments by Costa et al., (1975) revealed the extraordinary potency (<1 μM) with which diazepam antagonised convulsions elicited by blockade of GABA synthesis in mice. Subsequently, benzodiazepines have become amongst the most widely used drugs, employed for their anticonvulsant, sedative-hypnotic, anxiolytic and muscle relaxant properties.

On the basis upon early radio-ligand binding studies using rat brain membranes, it was thought there was a single class of benzodiazepine receptors. These studies first revealed the existence of benzodiazepine-specific high-affinity binding sites, in close association with GABA<sub>A</sub> receptors (Braestrup and Squires, 1977; Mohler and Okada, 1977). Initially, benzodiazepine receptors were classified according to their regional distribution, i.e. "central" and "peripheral" type benzodiazepine receptors, which appeared to be pharmacologically distinct (Braestrup and Squires, 1977). Peripheral benzodiazepine receptors have since been shown to be largely associated with the outer mitochondrial membrane (Verma and Synder, 1989) and to be involved in controlling steroidogenesis. However, these receptor types have also been identified within the CNS and thus benzodiazepine receptor subtypes may be re-defined as a "neuronal and non-neuronal benzodiazepine receptors" (Gardner et al., 1992).

*Chapter One: General Introduction* 38
“Central” or “neuronal” benzodiazepine receptors associated with GABA receptors have subsequently been classified into subtypes according to their pharmacology. Benzodiazepines, such as diazepam or flunitrazepam, increase the potency of GABAergic ligands at GABA receptors (Study and Barker, 1981), whereas, other benzodiazepines, for example, methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate (DMCM), decrease the potency of GABAergic ligands. Both of these effects are blocked by benzodiazepine antagonists, such as flumazenil (Nutt et al., 1982; Polc et al., 1982). The availability of compounds such as the triazolopyridazine, CL 218872, the imidazopyridine, zolpidem and certain β-carbolines, such as DMCM have indicated the existence of other classes of benzodiazepine receptors (Braestrup et al., 1982; Braestrup et al., 1984). These compounds displaced [3H]-benzodiazepine binding in a biphasic manner and had different affinities for benzodiazepine receptors in the cerebellum, compared to other brain regions (e.g. Seighart, 1989; Arbilla and Langer, 1986).

Subsequently, these benzodiazepine subtypes have been termed BDZ1 types, BDZ2 types and BDZ3 types. BDZ1 type receptors have greater affinity for the C1 218,872, zolpidem and certain β-carbolines than BDZ2 type receptors. BDZ2 type receptors, in contrast, have low affinity for these compounds, but high affinity for flunitrazepam. BDZ3 type receptors are selective for the negative allosteric modulator, Ro15-4513, and insensitive to diazepam.

Recombinant studies have shown that benzodiazepine modulation has been shown to be absolutely dependent upon the presence of the γ-subunit in recombinant GABA receptors, with α-subunits modulating benzodiazepine sensitivity. Electrophysiological studies by Pritchett et al., (1989) demonstrated that co-expression of the human γ2 subunit, together with α1 and β1 in HEK 293 cells, mediated GABA receptor responses which were potentiated by flunitrazepam and that this potentiation was abolished by the benzodiazepine antagonist, Ro15-1788. To date, recombinant BDZ1, BDZ2 and BDZ3 type receptors may be distinguished not only by their pharmacology but also by the presence of different α-subunits. The pharmacological and electrophysiological properties of BDZ1 type receptors appear to depend on the presence of the α1
together with another β and the γ2 subunit. BDZ₁ type receptors constitute the predominant GABAₐ receptor subtype throughout the CNS. Autoradiographic studies of human brain by Faull et al., (1987) and Faull and Villinger, (1988) demonstrated that BDZ₁ receptors were concentrated in the cerebellum but were scarce in the hippocampus, whereas BDZ₂ type receptors were concentrated in the hippocampus, striatum and spinal cord. BDZ₂ type receptor pharmacological and electrophysiological properties appear to depend on the presence of the α₂, 3 or 5 together with another β and the γ2 subunit. The BDZ₃ type receptor is the least common subtype, being restricted to cerebellar granule cells (Lüddens et al., 1990) which contain the α6 subunit together with β2 and γ subunits.

Electrophysiological studies in a variety of neuronal preparations have indicated that benzodiazepines enhance the actions of GABA at the GABAₐ receptor but are unable to directly activate the GABAₐ receptor in the absence of GABA (e.g. Study and Barker, 1981). Fluctuation analysis studies on mouse spinal neurones demonstrated that diazepam increased GABAₐ receptor open channel frequency, without effects on channel conductance or open time (Study and Barker, 1981). Subsequently, single channel studies have shown that this increase in opening frequency is due to increased occurrence of bursting activity, rather than increases in burst duration or single-channel events (Macdonald and Twyman, 1992; Macdonald and Olsen, 1994).

1.6.ii. Steroidal Modulation of the GABAₐ Receptor

Almost 60 years ago, Hans Selye (1941) described the potent sedative-anaesthetic properties of the ring A-reduced metabolites of progesterone and deoxycorticosterone. Subsequently, these "neuroactive steroids" have been shown to rapidly alter CNS excitability and also give rise to rapid behavioural changes via non-genomic mechanisms. Binding studies using synaptosomal membrane preparations from rat forebrain demonstrated that certain synthetic and endogenous steroids at physiologically relevant concentrations, were
potent allosteric modulators of the GABA$_A$ receptor (Harrison and Simmonds, 1984, Majewska et al., 1986).

To date, the 3α-hydroxy ring A-reduced pregnane steroids are the most widely studied "neuroactive steroids." Allopregnanolone (5α-pregnan-3α-ol-one; 3α-OH-DHP) and allotetrahydrodeoxycorticosterone (5α-pregnan-3α,21-diol-20-one; 5αTHDOC), at physiologically relevant concentrations, have been shown to be amongst the most potent of the known ligands for the GABA$_A$ receptor (Callachan et al., 1987; Peters et al., 1988). It has been suggested that these steroids may be endogenous GABA$_A$ receptor ligands, producing sedative and/or anxiolytic effects. Early electrophysiological studies conducted in voltage-clamped bovine chromaffin cells and rat hippocampal neurones demonstrated that alphaxalone (Cottrell et al., 1987) and 5β-pregnan-3α-ol-20-one and 5β-pregnan-3,20-dione (Callachan et al., 1987; Harrison et al., 1987) reversibly and dose-dependently potentiated GABA-evoked chloride currents in these cells. Conversely, steroids such as RU5135, pregnenolone sulphate and dehydroepiandrosterone sulphate (DHEAS; for review see Lambert et al, 1995) have been shown to antagonise GABA$_A$ mediated chloride currents.

Like a number of other positive allosteric modulators of the GABA$_A$ receptor, steroids have been shown, at concentrations higher than those required for potentiation of the GABA response, to directly activate the GABA$_A$ receptor in the absence of GABA. For example, using voltage-clamped bovine chromaffin cells, Cottrell et al., (1987) demonstrated that alphaxalone (>1µM) and Callachan et al., (1987) demonstrated that 5β-pregnan-3α-ol-20-one and 5β-pregnan-3,20-dione, directly elicited a membrane current in the absence of GABA, which was potentiated by diazepam and phenobarbitone and inhibited by bicuculline and also had a reversal potential similar to currents elicited by GABA.

Although a number of studies have shown that GABA$_A$ receptor subunit composition may exert some influence the action of steroids at this receptor.
site, generally steroidal effects at the GABA<sub>A</sub> receptor are considered to be relatively subunit-independent (Lambert et al., 1995). For example, two-point voltage-clamp studies conducted by Belelli et al., (1996), using human (α<sub>1, 3β1γ2L</sub>) recombinant GABA<sub>A</sub> receptors expressed in Xenopus oocytes, demonstrated that the maximal potentiation of GABA-evoked responses by pregnanediols was not influenced by α-subtype. However, this study also demonstrated that in α2-containing receptors such pregnanediols were less potent than in α1- or α3-containing receptors.

Due to the relative potency and selectivity of action of steroids it is thought that they interact at a specific binding site on the GABA<sub>A</sub> receptor. The notion that these steroids, which are highly lipophilic, could exert their short-term effects by perturbation of cell membranes has been questioned by the fact that intracellularly applied steroids are inert on GABA<sub>A</sub> receptors (Lambert et al., 1990). Single-channel studies conducted in voltage-clamped mouse spinal neurones and bovine chromaffin cells have revealed that steroids, like barbiturates, increase average channel open time duration by increasing the probability of the channel being in long duration open states and, like benzodiazepines, increase the frequency of single channel openings (Callachan et al., 1987; Lambert et al., 1987; Barker et al., 1987; Twyman and Macdonald, 1992).

1.6.iii. Barbiturate Modulation of the GABA<sub>A</sub> Receptor

Barbiturates have been long been used since as sedative-hypnotics, anticonvulsants and anaesthetics and have been shown to potentiate GABA<sub>A</sub>-mediated inhibition in a manner distinct to benzodiazepines.

The potentiating effects of barbiturates do not appear to be subunit dependent; recombinant studies have shown that GABA- induced chloride flux in homomeric channels consisting of either α-, β-, γ2 or δ subunits could be stimulated by barbiturates, indicating that a barbiturate binding site could be
present on each of these subunits, in either homo- or hetero-oligomeric formations (Seighart, 1995). However, Thompson et al., (1996) have demonstrated in *Xenopus* oocytes expressing human recombinant GABA<sub>A</sub> receptors that the degree of maximum potentiation evoked by barbiturates on submaximal GABA-evoked responses is dependent on the presence of the \( \alpha \)-subunit, \( \alpha 6 \) conferring the greatest and \( \alpha 1 \) conferring the lowest maximal potentiation.

In contrast, high concentrations of barbiturates have been shown to directly activate GABA<sub>A</sub> receptors in the absence of GABA (Macdonald and Barker, 1979; Bormann, 1988). Recombinant studies indicate that different domains on the \( \beta \) subunits may be required for channel activation by barbiturates (Amin and Weiss, 1993), in particular the \( \beta 1 \) subunit (Pritchett et al., 1989; Mohler et al., 1990; Sanna et al., 1994) and also the \( \beta 3 \) subunit (Cestari et al., 1994) have been implicated. Murine \( \beta 1 \) homomeric channels expressed in *Xenopus* oocytes are activated by pentobarbitone, but not by GABA, muscimol or isoguvacine (Krishek et al., 1995) thus, reinforcing the notion that the dual action of barbiturates indicates at least two distinct sites of interaction for barbiturates on the GABA<sub>A</sub> receptor: one for direct activation and another for potentiation. However, it has been reported in *Xenopus* oocytes expressing recombinant GABA<sub>A</sub> receptors that the degree of direct activation of the GABA<sub>A</sub> receptor by pentobarbitone was also influenced by the presence of the \( \alpha \)-subunit. \( \alpha 6 \)-containing receptors expressed in *Xenopus* oocytes mediated a maximal response to pentobarbitone which was larger than that obtainable with a maximal concentration of GABA (Thompson et al., 1996). These authors also report that in \( \alpha 6 \)-containing receptors, the type of \( \beta \)-subunit present did not markedly influence the direct action of pentobarbitone, whereas in \( \alpha 1 \)-containing receptors, pentobarbitone was more potent and efficacious in \( \beta 3 \)-containing receptors, compared to \( \beta 2 \)- and \( \beta 1 \)-containing receptors. Wafford et al., (1996) report that pentobarbitone potentiated, but did not directly activate \( \alpha 4 \beta 1 \gamma 2 \) subunits expressed in *Xenopus* oocytes.
In addition, binding studies conducted in rat cerebral cortex membrane preparations revealed that barbiturates increased the rate of \( \text{GABA}_A \) receptor desensitisation (Cash and Subbarao, 1988). Thus, additional barbiturate binding sites on the \( \text{GABA}_A \) receptor may contribute to the modulation of \( \text{GABA}_A \) receptor desensitisation.

A number of single channel studies in voltage-clamped mouse spinal neurones have revealed that barbiturates enhance \( \text{GABA}_A \)-receptor mediated events by increasing mean channel open duration time, but have no effect on opening frequency or receptor conductance (Study and Barker, 1981, Macdonald and Twyman, 1992; Macdonald and Olsen, 1994).

1.6.iv. Modulation of the \( \text{GABA}_A \) Receptor & Other Neuronal Ligand-gated Ion Channels by propofol.

Propofol (2,6 di-isopropylphenol) is a chemically novel, intravenous general anaesthetic agent (James & Glen, 1980, Smith et al, 1994) which has also been reported to have mood-altering properties (Zacny et al., 1992), anti-emetic effects (Borgeat et al., 1992, Borgeat et al, 1994a, Scher et al., 1992) and neuroprotective effects during neurological insults (Kochs et al., 1992; Weir et al., 1989; Hans et al., 1994). Propofol has also been used successfully in the treatment of status epilepticus (Wood et al., 1988, MacKenzie et al, 1990, Borgeat et al., 1994b). Although there have been no reports of propofol causing epileptiform activity in non-epileptic patients to date (Mahla et al., 1991), the effects of propofol on the electroencephalogram (EEG) activity of epileptic patients appears to be variable, with some patients experiencing increased and others reduced neuronal excitation (Samra et al., 1993).

Pharmacological evidence suggests that the sedative, hypnotic and anaesthetic actions of propofol might be, in part, explained by their action at the \( \text{GABA}_A \) receptor-gated chloride channel. Initial electrophysiological studies reported that propofol enhanced synaptic inhibition in the cat spinal cord (Lodge
and Anis, 1984). Whole-cell voltage-clamp studies later demonstrated that propofol concentration-dependently potentiated GABA-evoked membrane currents, which desensitised with high concentrations of propofol, and directly activated GABA_{A} receptors in bovine adrenomedullary chromaffin cells, native rodent cortical neurones and in murine hypothalamic GT1-7 neurones (Hales and Lambert, 1991; Hara et al., 1994; Orser et al., 1994; Adodra and Hales, 1995). These experiments revealed that propofol caused an increase in the probability of the GABA_{A}-gated chloride channel being in the conducting state, without a significant effect on the single channel conductance (Hales and Lambert, 1991; Orser et al., 1994) or on the reversal potential of GABA (Hales and Lambert, 1991; Hara et al., 1993). In addition, propofol increased the frequency, but not duration of GABA-activated single channel events (Orser et al., 1994). Electrophysiological studies (Hales and Lambert, 1991; Hara et al., 1993) and radio-ligand binding studies (Concas et al., 1991 and 1994) have indicated the existence of separate binding sites for propofol, steroids and barbiturates.

At clinically relevant concentrations (up to 22μM in plasma; Vyuck et al., 1992), in the absence of GABA, propofol has also been shown to directly activate the GABA_{A} receptor, in a bicuculline-sensitive manner (Hales and Lambert, 1991; Hara et al, 1993). Recently, studies using different human brain GABA_{A} receptor subunit isoforms and mRNAs from mouse brain expressed in Xenopus oocytes have demonstrated that this direct activation requires the presence of the β subunit (e.g. Sanna et al., 1995ab; Hill-Venning et al., 1997). In Xenopus oocytes expressing human recombinant GABA_{A} receptors, the presence of the β_{2}-subunit conferred a slightly greater sensitivity for direct activation than β_{1}-subunit (Hill-Venning et al., 1997).

Potentiation of GABA-evoked responses was thought to be subunit-independent (Sanna et al., 1995b; Davies et al., 1997b). However, more recent studies demonstrate that expression of α and γ_{2L}-subunits influences the direct and modulatory effects of propofol on the GABA_{A} receptor. Lam and Reynolds, (1998) have shown using human recombinant GABA_{A} receptors in Xenopus...
oocytes, that the efficacy of propofol potentiation was greater in $\alpha_1\beta_2$ than in $\alpha_1\beta_2\gamma_{2L}$ receptor isoforms and that potentiation of the $\alpha_2\beta_2\gamma_{2L}$ receptor isoform by propofol occurred with higher affinity and lower efficacy than in the $\alpha_1\beta_2\gamma_{2L}$ receptor isoform. These authors also demonstrated that the presence of the $\gamma_{2L}$ subunit decreased the sensitivity of the $\alpha_1\beta_2$ receptor isoform to the direct effects of propofol and that replacement of the $\alpha_1$- with the $\alpha_2$-subunit subtype increased the receptor sensitivity to the direct effects of propofol. Additionally, human recombinant GABA$_A$ receptors in *Xenopus* oocytes containing $\alpha_4$-subunit subtypes were subject to allosteric modulation, but not direct activation by propofol (Wafford et al., 1996). Kradowski et al., (1998) have reported that a point-mutation in the TM3 region of the $\beta_1$-subunit (M286W) of human recombinant GABA$_A$ receptors expressed in HEK cells, abolished the potentiation of GABA by propofol without affecting the ability of propofol to directly activate the GABA$_A$ receptor. Conversely, a mutation in the TM2 region of the $\beta_1$ subunit $\alpha_2\beta_1$(S265I) did not greatly affect potentiation, but reduced direct activation by propofol. Kradowski et al., (1997) have also demonstrated that the efficacy of propofol for modulation, but not its potency, was influenced by the presence of the $\alpha$-subunit: presence of $\alpha_1$ enabled a greater maximal potentiation than $\alpha_6$; in contrast, the direct activation evoked by propofol was greater in $\alpha_6$- than in $\alpha_1$-containing receptors. In addition, Jones et al., (1995) and Kradowski et al., (1997) have reported that modulation by propofol is independent of the $\gamma$-subunit.

A number of behavioural studies have attributed the CNS excitation observed following propofol-mediated general anaesthesia in mice to glycine antagonism (Al Muhandis et al., 1991; Dolin et al.,1992; Bansinath et al., 1995). However, voltage-clamp studies have shown that propofol potentiated native strychnine-sensitive glycine receptor-mediated currents in murine spinal neurones (Hales and Lambert 1991), but neither potentiated nor directly activated these receptors in hippocampal neurones (Hara et al., 1994).
Barann et al., (1993) initially reported that propofol non-competitively inhibited the 5-HT-induced influx of $^{14}$C-guanidinium through 5-HT$_3$ receptors of N1E-115 neuroblastoma cells and concluded that the 5-HT$_3$ receptor could be a target for general anaesthetic agents like propofol. However, a later binding study by Appadu and Lambert, (1996) using the same preparation, concluded that propofol exerts little direct effects on 5-HT$_3$ receptors at clinically relevant concentrations (<22μM in plasma, Vyuk et al., 1992). Voltage-clamp studies performed in homomeric 5-HT$_3$ receptors expressed in *Xenopus* oocytes by Machu and Harris (1994) examined the effects of propofol on 5-HT$_3$ receptors expressed in *Xenopus laevis* oocytes and found that over the therapeutic concentration range (1-22μM, Vuyk et al., 1992), propofol did not enhance or inhibit 5-HT$_3$ receptor-mediated responses.

A number of electrophysiological investigations have examined the effects of propofol on nicotinic acetylcholine receptors (nAChR). Voltage-clamp studies on clonal BC3H-1 cell (an embryonic muscle type nAChR with a subunit stoichiometry of α2βγδ) by Watchtel and Wegrzynowicz (1992) and Dilger et al., (1994) have demonstrated, that propofol (81μM; Watchtel and Wegrzynowicz, 1992 and 25-250μM; Dilger et al., 1994) decreased channel open time. Dilger et al., (1994) observed that propofol decreased the channel open time, but did not cause flickering or decreased amplitude of the channel. The authors suggest that the anaesthetic effects of propofol on nAChRs may be in part the result of propofol binding to the nAChR, though not necessarily in the channel pore, and an ensuing "interruption of the flow of ions through the pore of the channel" (Dilger et al., 1994, 1995).

Early studies revealed that propofol inhibits NMDA-receptor mediated polysynaptic reflexes in cat spinal cord (Lodge & Amis, 1984). Yamakura et al., (1995) in a voltage-clamp study, demonstrated that propofol (50-1000μM) only slightly inhibited current responses to AMPA-, kainate- and NMDA-selective glutamate receptor channels expressed in *Xenopus* oocytes and concluded that NMDA receptor activity is only slightly suppressed throughout propofol-
maintained anaesthesia. Voltage-clamp studies in cultured mouse hippocampal neurones have also demonstrated that propofol, at concentrations outside the therapeutic range, inhibited the NMDA receptor subtype of the glutamate receptor family with an IC$_{50}$ of 160|aM (Orser et al., 1995). These authors suggest that this inhibition occurs through an allosteric modulation of the channel rather than a blocking action on the ion channel.

1.6.v. Loreclezole & its Action at the GABA$_A$ Receptor

The triazole derivative loreclezole (Z)-1-[2-chloro-2-(2,4-dichlorophenyl) ethenyl]-1,2,4-triazole or R 72 063) is a broad-spectrum antiepileptic agent which reduces seizure activity and increases seizure threshold in animal models based on chemical or electrical stimulation (Waqueier et al., 1990; Ashton et al., 1992, Green et al., 1996) but, unlike many other anticonvulsants, does not induce sedative-hypnotic effects (Waqueier et al., 1990, Ashton et al., 1992). These effects are thought to be, at least in part, due to positive allosteric modulation of the GABA$_A$ receptor.

A number of electrophysiological studies have demonstrated the potentiating effects of loreclezole at human recombinant GABA$_A$ receptors expressed in Xenopus oocytes. Convincing data from recombinant studies has demonstrated that loreclezole acts at a novel allosteric site located on $\beta$2- or $\beta$3 GABA$_A$ receptor subtypes (Wafford et al., 1994). Point-mutation analysis has identified a single amino acid in the TM2 region of $\beta$2 (asparagine 289) and $\beta$3 (asparagine 290) subunits which confers sensitivity to loreclezole-induced channel modulation; this sensitivity was some 300-fold higher in $\beta$2- or $\beta$3-containing receptors than $\beta$1-containing receptors where the amino acid at this corresponding position is serine (Wafford et al., 1994; Wingrove et al., 1994; Donnelly and Macdonald, 1996).

Recently, Kapur and Macdonald (1996) have demonstrated that only 50% of whole-cell voltage-clamped dentate granule cells were sensitive to modulation by loreclezole and suggested that these were not $\beta$1—containing
receptors. Additionally, Xue et al., (1996) in a binding study, have demonstrated a greater potency of loreclezole and a higher GABA sensitivity in the cerebellum and thalamus where there is a relatively higher expression of β2 and β3 subunits compared to other areas of the CNS. Stevenson et al., (1995) have shown that potentiation of GABA-evoked currents by methyl-6,7-dimethoxy-4-ethyl-β-carboline (DMCM) is dependent on the presence of the same amino acid residue which confers loreclezole sensitivity in β2 or β3 subunits, providing evidence that the low affinity site for β-carboline potentiation is indeed the loreclezole site. Further evidence supporting the importance of the β-subunit in loreclezole-induced modulation of the GABA_A receptor was given by Whittemore et al., (1996) who report that loreclezole induced a strong modulation of β2γ2L receptors expressed in Xenopus oocytes, but that there was little difference between modulation of α1β2γ2L and α4β2γ2L receptors, suggesting that the modulation induced by loreclezole is not greatly influenced by the presence of the α-subunit. Interestingly, Donnelly and Macdonald (1996) have described a second, subunit independent, voltage-independent and non-competitive inhibitory action of loreclezole on GABA_A receptors. These investigators have shown that loreclezole enhances the degree and rate of desensitisation of GABA-mediated currents recorded from recombinant GABA_A receptor containing α1, α5, or α6 together with γ2L and β1, 2 or 3 subunits, expressed in fibroblasts, and also in native GABA_A receptors from mouse cortex.

Several binding studies (Vaught and Waquier, 1991, Van Rijn and Willems van Bree, 1993, Xue et al., 1996; Sanna et al., 1995; Ghiani et al., 1996; Green et al., 1996) have demonstrated that the actions of loreclezole at the GABA_A receptor do not appear to be mediated through the benzodiazepine, barbiturate, steroid or propofol site. However, Green et al., (1996) also report, using rat cerebral cortex membrane preparation, that although loreclezole interacts specifically with an allosteric site on the β-subunit of the GABA_A receptor, it also alters the binding characteristics of other modulatory sites for chlormethiazole and pentobarbitone.

Chapter One: General Introduction 49
In addition, several binding studies (Sanna et al., 1995c; Ghiani et al., 1996; Sanna et al., 1996) and electrophysiological studies (Sanna et al., 1996) have indicated that loreclezole (at concentrations higher than those required for potentiation), like propofol, can directly activate the GABA$_A$ receptor in the absence of GABA. To date, however, no study has determined the effects of loreclezole at the single channel level.

1.6.vi. Negative Allosteric Modulators of the GABA$_A$ Receptor

A number of negative allosteric modulators also exist for the GABA$_A$ receptor (reviewed by Johnston, 1996) including the $\beta$-carboline, DMCM, diazepam-binding inhibitor (DBI) and the $\beta$-substituted $\gamma$-butyrolactone, $\beta$-ethyl-$\beta$-ethyl-$\gamma$-butyrolactone ($\beta$-EMGBL). A novel negative allosteric modulation occurring at the GABA$_A$ receptor involves an interaction between certain quinolone antimicrobial agents and NSAIDs.

1.6.vii. NSAIDs, Quinolones & the GABA$_A$ Receptor

Quinolones are widely prescribed as antimicrobial agents with a relatively low incidence of side effects, such as headaches, insomnia and convulsive seizures. However, certain quinolones when taken in combination with the NSAID, fenbufen, cause a marked increase in the incidence and/or severity of these adverse side effects which can lead to convulsive seizures in humans (Simpson and Brodie, 1985; Anastasio et al., 1988) and in animals (Murayama et al., 1987; Akahane et al., 1989; Hirai et al., 1989).

Subsequently, it has been shown that certain quinolones act as antagonists at the GABA$_A$ receptor (Akaike et al., 1991; Halliwell et al., 1991; Shirasaki et al., 1991) and that this antagonism is greatly increased in the
presence of biphenyl acetic acid (BPAA), the active metabolite of the NSAID, fenbufen (Akaike et al., 1991; Halliwell et al., 1991; 1995; Shirasaki et al., 1991; Green and Halliwell 1997). In agreement with these electrophysiological studies, several binding experiments have demonstrated the inhibition of [³H]muscimol and [³H]GABA binding and modulation of [³⁵S]-TBPS binding by certain quinolones and BPAA at neuronal GABA_A receptors (Hori et al., 1987; Yamamoto et al., 1988; Akahane et al., 1989; Squires and Saederup, 1993; Domagala, 1994). Moreover, Akahane et al., (1989) have demonstrated a close correlation between the epileptogenic activity of quinolones and BPAA and their inhibitory potencies for [³H] muscimol binding to GABA_A receptors. Recently, it has been shown that a hybrid molecule of norfloxacin and BPAA is also a potent antagonist at native GABA_A receptors (Imanish et al., 1996; Ito et al., 1996).

The antagonism induced by quinolones and BPAA has been shown to be selective for the GABA_A receptor since this combination of drugs have little or no effect at neuronal 5-HT_3, P_2x and nACh receptors of the vagus nerve (Green and Halliwell, 1997), ionotrophic glutamate receptors in hippocampal neurones (Akaike et al., 1991; Halliwell et al., 1995) or recombinant glutamate and 5-HT_3 receptors expressed in Xenopus oocytes (Kawakami et al., 1997). In addition, Green and Halliwell, (1997) have shown a marked decrease in the synergy of antagonism evoked by the action of certain quinolones and BPAA on GABA_A receptors of the optic nerve suggesting that regional differences exist across the CNS to quinolones and NSAIDs, perhaps reflecting differences in GABA_A receptor subunit composition.

1.7. Fenamate Modulation of GABA_A-gated-chloride channels

Woodward et al., (1994) were the first to demonstrate that fenamate NSAIDs both potentiated and inhibited GABA-activated currents recorded from rat brain GABA_A receptors, expressed in Xenopus oocytes. In descending order of potency, flufenamic, meclofenamic, mefenamic and niflumic acid, (10μM)
reversibly potentiated currents evoked by low concentrations of GABA. In contrast, currents evoked by high concentrations of GABA were non-competitively inhibited by these fenamates, with a reverse order of potency. Woodward et al., (1994) also reported that MFA had the highest efficacy in terms of its facilitatory effects, but was the weakest inhibitor, and that the opposite was the case for niflumic acid. The agonist concentration was shown to be the critical determinant between facilitatory and inhibitory effects of fenamates.

In rat cortex GABA<sub>A</sub> receptors expressed in Xenopus oocytes, the only other (non-fenamate) NSAIDs which produced facilitatory effects at similar concentrations were sulindac (an acetic acid with effects similar to niflumic acid) and diflusinal (salicylic acid with effects similar to flufenamic and meclofenamic acid). At ten-fold higher concentrations, fenoprofen, indomethacin, ibuprofen, naproxen and piroxicam evoked modest potentiations (<120%), whereas flurbiprofen and phenylbutazone caused modest inhibitions in GABA-evoked currents (Woodward et al., 1994). As a positive modulator of GABA-evoked responses, MFA was shown to be 10 000 times more potent than ethanol, equipotent with α- and δ-hexachlorohexane, twice as potent as pentobarbitone and 100 times less potent than allopregnanolone. In this study it was also shown that the modulatory effects of MFA, together with pentobarbitone or δ-hexachlorohexane, were additive (Woodward et al., 1994).

The potentiating effects of mefenamic acid on rat brain GABA<sub>A</sub> receptors expressed in Xenopus oocytes were insensitive to the benzodiazepine antagonist, flumazenil. In the presence of the weak steroid antagonist, 5β-pregnan-3βol-20-one (3β-OH-DHP) the MFA-potentiated GABA response amplitude was not appreciably decreased, but instead, a synergistic increase on response decay rate was observed (Woodward et al., 1994). In addition, Woodward et al., (1994) have demonstrated that only extracellular application of mefenamic acid resulted in appreciable modulation of GABA-mediated responses, arguing strongly for a membrane-bound recognition site for fenamates, rather than a non-specific membrane perturbation effect.
A preliminary study by Halliwell et al., (1994) demonstrated that mefenamic acid concentration-dependently potentiated submaximal GABA-evoked currents in voltage-clamped rat hippocampal neurones in terms of amplitude and duration. In contrast, Shirasaki et al., (1991) demonstrated a suppression of GABA-evoked (EC_{60-70}) responses by mefenamic acid recorded in dissociated rat hippocampal neurones.

The data reviewed above suggest that fenamates may modulate neuronal GABA_A receptor function. However, no study to date has investigated this interaction on neuronal (or recombinant) GABA_A receptors.

1.8. Aims of This Study

The main focus of this study was to investigate the actions of fenamate NSAIDs on a series of neuronal ligand-gated ion channels. The initial studies examined the action of a range of allosteric modulators, and the NSAID, mefenamic acid, on GABA_A receptor-mediated responses recorded from the rat vagus nerve employing a grease-gap recording technique (Marsh, 1989). The grease-gap recording technique is a relatively simple, but robust recording system which allows long-term and stable recordings to be made from a variety of neuronal preparations, including the rat vagus and optic nerves. The rat vagus nerves express a number of extra-synaptic receptors, such as the GABA_A, 5-HT_3-, nicotinic acetylcholine, P_2x receptors and the optic nerve expresses strychnine-sensitive glycine receptors and GABA_A receptors, which allow the collection of quantitative pharmacological data on a number of drug-receptor interactions to be obtained (e.g. Marsh, 1989; Ireland and Tyres, 1987; Trezise et al., 1993). Thus, the effects of mefenamic acid were compared with other allosteric modulators of the GABA_A receptor, and in particular, propofol. Additional experiments investigated the action of propofol on 5-HT_3-, nicotinic acetylcholine- and P_2x receptor-mediated responses of the rat vagus nerve and strychnine-sensitive glycine receptor-mediated responses of the rat optic nerve.
To further elucidate the mechanism of action and selectivity of fenamates on neuronal ligand-gated ion channels, investigations were carried out using the patch-clamp technique (Hamill et al., 1981) to make recordings from cultured single hippocampal neurones. This technique allows the experimenter to control the internal and external ionic environments of the membrane in order to make high fidelity recordings of agonist-gated channel activity. Primary cultures of hippocampal neurones possess morphological and neurophysiological characteristics similar to those found in vivo and are easily accessible under patch-clamp recording conditions. These cells also express a number of ligand-gated ion channels, again with characteristics similar to those seen in vivo. Further experiments also investigated the actions of other fenamates at the GABA_A receptor in order to gain some insight into the structure-activity relationship of fenamates.
CHAPTER TWO: GENERAL METHODS

2.1. Extracellular Recording Methods

Electrophysiological recordings were made from freshly excised rat vagus and optic nerves. Agonist-evoked changes in membrane potential were recorded across a high resistance grease-gap using extracellular electrodes. The method employed is an adaptation of that described by Marsh (1989). A description of this method together with the dissection procedures employed is described below.

2.1.i. Vagus Nerve Dissection

Male Sprague-Dawley rats (100-250g) were killed by a rising concentration of CO₂ (a Schedule 1 method of euthanasia). The skin overlying the throat area was removed to expose the thyroid gland, the sternomastoideus, posterior digastricus and sternohyoideous muscles; these were carefully removed (see figure 2.1). Using a binocular dissecting microscope (Nikon SMZ-2B) the vagus nerves could then be seen adjacent to the common carotid arteries (which run bilateral to the trachea). The vagus nerves were carefully separated from the carotid arteries and cut away at the point at which they entered the thorax. The freed vagus nerves (15-25mm) were then transferred to a 35mm dish of cold, oxygenated, physiologically balanced salt solution (PBS) and the connective tissue sheaths surrounding the nerves were removed using watchmakers forceps. The removal of the sheath was essential to facilitate drug penetration.

2.1.ii. Optic Nerve Dissection

Male Sprague-Dawley rats (100-250g) were killed by a rising concentration of CO₂ (a Schedule 1 method of euthanasia) and were then decapitated. Skin overlying the back of the neck to the snout area was removed to expose the skull. The dorsal surface of the skull was bisected using bone scissors and the bone was gently broken away using artery forceps to reveal the frontal cortex. The bone of the orbits above the zygomatic arch was also broken away. The ocularmotor muscles were teased away using watchmaker's forceps.
to expose the optic nerves. The brain was gently lifted from the cavity of the skull using a spatula and the optic nerves were severed at the optic chiasma. The optic nerves were removed from the back of the eyeballs using small dissecting scissors. The freed optic nerves were then transferred to a 35mm dish of cold, oxygenated PBS.
Figure 2.1: shows a schematic of the rat thorax showing the position of the vagus nerve (highlighted in yellow) in relation to major blood vessels and muscles. This schematic was modified from Marsh (1989).
2.2. Extracellular Recording From The Excised Rat Vagus and Optic Nerves

A thin seam of grease, (approximately 2mm deep x 2mm wide) (BDH High Vacuum Silicone Grease) was placed midway across the width of a microscope slide. A piece of nappy liner (Boots one-way nappy liner) was placed on each side of the grease seam, as shown in figure 2.2. The nappy liner served to facilitate superfusion of recording PBS and drugs onto and off the nerve. The vagus or optic nerve was placed on top of the microscope slide and onto the nappy liner, so that half of it lay on either side of the grease barrier. A second layer of grease was then placed on top of the first layer, thus, forming a high resistance seal around the nerve trunk. The grease seam also served to hold the nerve in position on the slide. The slide was secured onto a Perspex frame and housed inside a Faraday cage.

Silver-silver chloride electrodes (RC1 electrodes, Clark Electromedical) were positioned on either side of the grease seam, adjacent to the free ends of the nerves; these electrodes were held in position by brackets clamped onto the Perspex frame.

Agonist-evoked changes in DC-potential across the silver-silver chloride electrodes were relayed through miniature coaxial cable to a Neurolog Amplifier (Digitimer, NL106) and a Neurolog Filter (Digitimer, NL125). Signals were low-pass filtered at DC-50Hz. and the recordings were displayed on a Kipp-Zonen flatbed pen chart recorder. Agonist-evoked changes in DC-potential were recorded between 0.03mV and 5mV, under these conditions. Baseline noise levels were approximately ≤0.02mV in amplitude and were mainly attributable to perfusion drip; improvement in these baseline noise levels could often be achieved by re-positioning the electrodes and/or the perfusion pipes.
Figure 2.2: A simple schematic of the grease-gap technique. A vagus or optic nerve was placed across a grease-gap barrier onto a microscope slide, which was mounted onto a perspex holder and housed inside a Faraday cage (not shown). The nerve was perfused with a physiologically balanced solution (PBS). Agonist-evoked responses were recorded, extracellularly, amplified, filtered and displayed on a flatbed pen chart recorder. Drugs were dissolved in PBS and delivered to the nerve via the perfusion system.

2.2.1. Drugs and Solutions

PBS was made up in ultra pure water (Milli-QPLUS) with the following salts (all B.D.H. Ltd., Poole, U.K. except where stated otherwise; concentrations in mM): NaCl (118.0), KH$_2$PO$_4$ (1.18), KCl (4.7), MgSO$_4$ (1.18), CaCl$_2$ (2.5), Glucose (11.0), HEPES (Sigma; 10.0). The PBS was then titrated to pH 7.2 using concentrated (2.5M) hydrochloric acid.

γ-amino butyric acid (GABA) and glycine (both Sigma, Poole, U.K.) were dissolved in PBS as 10mM stock solutions and serially diluted in PBS as required. α,β methylene adenosine tri-phosphate (α,β-MeATP), 5-hydroxytryptamine (5-HT) and dimethyl-phenylpiperazinium (DMPP; all from Sigma) were dissolved in PBS as 1mM stock solutions and serially diluted as required in PBS. Sodium pentobarbitone (Sigma) and alphaxalone (a gift from Dr. David Gemmel, Akzo Nobel, Organon Laboratories, Newhouse, Scotland) were also made up as 1mM stock solutions in PBS. Propofol (also a gift from Dr. David Gemmel) was dissolved in absolute ethanol as a 10mM stock solution.
and then serially diluted in PBS. The maximal concentration of ethanol used was 20\(\mu\)M. In selectivity studies, the final concentration of ethanol was 2\(\mu\)M. Picrotoxin (Sigma), suramin (R.B.I., Minnesota, U.S.A.), hexamethonium and strychnine (both Sigma) were all made up as 1mM stocks in PBS and diluted in PBS as required. MDL72222 (1\(\alpha\)H,3\(\alpha\),5\(\alpha\)H-tropan-3-yl-3,5-di-chlorobenzoate; R.B.I.) was dissolved in 50% ethanol, as a 1mM stock, and diluted as required in PBS. All solutions and drugs were made up as fresh stocks at the beginning of each experiment.

2.2.ii. Experimental Protocol

All experiments were conducted at room temperature. PBS and drugs were dripped onto the free ends of the nerves at a rate of 2ml/min using a variable speed peristaltic pump (Gilson Minipuls3), via 21G hypodermic needles connected to flexible polythene tubing (internal diameter=0.76mm, Portex, U.K.). Concentration-response curves to each agonist were determined by perfusing different concentrations of agonist, in a quasi random order, onto one end of the preparation only. Pilot experiments indicated that an agonist contact time of approximately 1.5-2 minutes was sufficient to evoke a response in which an equilibrium peak was clearly discernible. Thus, in all experiments, agonists were perfused onto the nerves for 1.5-2 minutes. Application of agonist to the preparation once every 10±1 minutes for GABA and once every 15±1 minutes for 5-HT, \(\alpha,\beta\)MeATP and DMPP was sufficient to minimise any sensitisation/desensitisation of the preparation to the agonist.

In experiments investigating drug effects, three control sub-maximal agonist-evoked responses were obtained, followed by three agonist-evoked responses in the presence of each modulator or antagonist concentration. Pilot experiments demonstrated that all compounds produced their maximal effect after 15 minutes pre-incubation; thus, in most cases (except where specified), a 15-20 minute drug pre-incubation period was employed. At the end of such a
protocol the preparation was washed with PBS and control agonist-evoked responses re-established to determine the reversibility of the drug action.

2.2.iii. Data analysis

Agonist-evoked responses were measured at their peak amplitude and are expressed as the arithmetic mean (±s.e.mean of n experiments) of the responses before addition of any drugs. Agonist-evoked responses in the presence of drugs are expressed as the percentage of the response in their absence (control). Data were pooled and mean log [agonist]-response plots and log[modulator] response plots were fitted with a sigmoidal function using a four-parameter logistic equation (sigmoidal concentration-response curve with a variable slope; Graphpad Prism™ v2.0) to determine EC$_{20}$ and EC$_{50}$ (±95% confidence intervals; C.I.) values. Control concentration-response curves to agonists were normalised by expressing all responses relative to the concentration that evoked a maximum response for each agonist. The equation used to fit the concentration-response relationship was:

\[
Y = \text{Bottom} + \frac{(\text{Top} - \text{Bottom})}{(1 + 10^{(\log\text{EC}_{50} - X) \times \text{Hill Slope}})}
\]

where X is the logarithm of concentration of drug. Y is the response, which starts at Bottom and goes to Top with a sigmoid shape. "Pseudo" Hill slopes were calculated from the curve. Care must be taken in interpreting these data since the final concentration of agonist which reaches the receptor may differ from the concentration exogenously applied. For example, the degree of agonist uptake/degradation within the nerve is unknown and may reduce agonist concentrations at receptor sites.

2.3. WHOLE-CELL VOLTAGE-CLAMP RECORDING METHODS

Hippocampal Cell Culture

In agreement with Bottenstein (1986), neuronal survival in serum-supplemented media has been found to be variable and varied with different batches of serum. Thus, a variety of experimental procedures and culture media
conditions were employed to improve neuronal viability. All cell culture solutions and media types were filter sterile (0.22μm GS filters, Millipore).

2.3.i. Hippocampal Dissection

Embryonic (E17-19 days gestation) rat hippocampal neurones were isolated and cultured using the method described by Halliwell et al., (1989). Time-mated Wistar rats were killed by cervical dislocation and the embryos (usually around 10-12) were removed and placed into a beaker containing chilled Hanks’ balanced salt solution (HBSS; GIBCO). Embryonic brains were removed rapidly and aseptically, using small dissection scissors and a scapula, and placed into petri dish of chilled HBSS. Hippocampi were dissected out under a dissecting microscope (Nikon SMZ-2B) into a 35mm dish containing HBSS as follows: following excision of the embryonic brain, the cerebellum was removed using a small scalpel and discarded. The cerebral hemispheres were separated along the midline fissure, using the blunt edge of the scalpel, and the underlying midbrain was removed. Hippocampi were dissected free from each cerebral hemisphere along the length of the blood vessel as indicated in figure 2.3 and subsequently then chopped into small fragments (2mm³).

The tissue was incubated at 37°C, for 60 minutes, in 10mls of filtered enzyme solution (0.22μm GS filters, Millipore) containing the following (all BDH, except where indicated; in mM): NaCl (116.0), KCl (5.4), NaHCO₃ (26.0), NaH₂PO₄ (1.0), CaCl₂ (1.5), MgSO₄ (1.0), EDTA (Sigma; 0.5), glucose (25.0), DL cysteine (Sigma;1.0) and papain (Sigma; 20units/ml). Dissociation of the tissue was facilitated by gently shaking the flask periodically. The tissue fragments were then washed in 5mls of filtered HBSS containing bovine serum albumin (BSA) and ovomucoid (both Sigma, at 1mg/ml each) and were transferred to another sterile test tube containing 3-4mls of the same solution. The tissue was dissociated mechanically by gentle trituration using a fire polished Pasteur pipette. The upper layer of dissociated cells was layered onto 5mls of HBSS containing BSA and ovomucoid (at 10mg/ml each); this process was repeated until all of the tissue was dissociated. The cell suspension was centrifuged at 100g for 10 minutes. After discarding the supernatant, the cells were re-suspended in 4mls of media 1 or media 2 (described later).
plated out at a density of approximately $1-2 \times 10^5/35\text{mm}$ Primaria culture dishes (Falcon, Becton Dickinson) and incubated in 1.5mls of culture media 1 or 2, at $37^\circ\text{C}$, 95% air/5%/CO$_2$ and 100% relative humidity. Subsequently, every 5-7 days, approximately two-thirds of the media was replaced with fresh media.
Figure 2.3: photograph (x3 magnification) shows the left hemisphere of an embryonic rat brain (19 days gestation) with a scalpel blade underlying the hippocampus. The arrows indicate marker blood vessels around boundaries of hippocampus.
2.3.11. Methods for cell culture maintenance

Four different methods were employed for the maintenance of rat hippocampal neuronal primary cultures. These are now described below.

Method 1: Hippocampal neurones were plated into culture media 1, containing 88% (v/v) minimal essential medium, 5% (v/v) heat-inactivated fetal calf serum, 5% (v/v) heat-inactivated horse serum, penicillin/streptomycin (5000i.u./ml-5000ug/ml), glutamine (2mM) (all supplied by GIBCO) and glucose (20mM). When background glial cells reached confluence (usually within 5-7 days), the media was replaced with fresh media containing the mitotic inhibitor cytosine furano-arabinoside (10\mu M; Sigma) for 48 hours. This method was employed for a period of two years from the commencement of this study until Summer 1996, when the serum batch was identified as a critical factor for neuronal survival. Until this time neuronal cell cultures were reliably maintained for up to 40 days (figure 2.4-main image). After Summer 1996, neuronal viability deteriorated after a period of 5 days in culture, critically depending on serum batch, (figure 2.4-insert).

Figure 2.4: Main image: shows a phase-contrast photomicrograph (x500 magnification) of a primary culture of embryonic rat hippocampal neurones 20 days in culture maintained using method 1, bottom right : insert shows a phase-contrast photomicrograph (using a green filter) of a primary culture of embryonic rat hippocampal neurones 20 days in culture (x 500 magnification) using a different batch of serum. Both primary cultures were derived from the same embryos.
Method 2: cells were grown in a serum-free media (media 2) containing 97.5% (v/v) "Neurobasal" media supplemented with 1% B-27 supplement (v/v), 1% penicillin-streptomycin (v/v) and 0.5% glutamax (v/v) (all GIBCO). Neurobasal media does not support rapid glial development, subsequently neurones survived in clusters or clumps and were unevenly distributed in the culture dishes, (see figure 2.5). This method maintained phase-bright, pyramidal-shaped hippocampal neurones which survived in culture for up to 35 days. Many of these neurones grew larger (≈25μm in diameter) when compared to those maintained in serum-based media (15μm in diameter). Neuronal survival was best in areas of the culture dish where cell density was low, thus plating density was lowered using this method. Following difficulty experienced in whole-cell patch-clamp recording from cells grown in serum-free media 2 and the observation that hippocampal neurones appeared unusually large in size compared to those grown in serum-based media 1, the osmolarity of media 2 was measured and found to be hypo-osmotic at 199±1 mosmol (n=3) relative to the recording solution (264±2, n=3). Thus, to optimise recording conditions, the osmolarity of media 2 was adjusted from 199 mosmol to 265 mosmol by the addition of glucose. This markedly improved recording success with some cells allowing stable recordings which lasted up to 2.5 hours.

Figure 2.6: shows a phase-contrast photomicrograph (x500 magnification) of a primary culture of embryonic rat hippocampal neurones 7 days in culture, maintained using method 2. Using this method, large neurones (c.f. method 1), which had a “clumped” distribution, were frequently observed and glial development was reduced.
**Method 3**: cells were grown in the serum-supplemented *media 1* for between 3-4 days and then transferred into glucose-supplemented *media 2*, as previously described. Undefined media supplements, such as serum, contribute variable amounts of hormones, growth factors, vitamins, substratum modifying proteins, and glycoproteins (for example, fibronectin) which may promote rapid glial and neuronal development (Bottenstein, 1986). Initial plating in serum-supplemented media facilitated the development of a confluent glial layer for neuronal attachment. This method sustained phase-bright, pyramidal-shaped hippocampal neurones in culture for up to 30 days. Although cells were dispersed evenly without obvious clumping using this method, cell death was considerably higher in these cultures, see figure 2.6 (top left). Those surviving cells, however, did enable stable recordings, which lasted over 2 hours in duration.

**Figure 2.6**: shows a phase-contrast photomicrograph (x500 magnification) of a primary culture of embryonic rat hippocampal neurones 21 days in culture (x 500 magnification) maintained using method 3. Figure shows evenly distributed neurones on bed of glial cells. **Bottom left arrow** indicates granulated cells which are undergoing cell death, **top right hand arrow** indicates phase-bright cells.
METHOD 4: cells were over-layered onto a previous culture (at least 7 days old in serum-based media) and grown in media 2 or in the serum-supplemented media 1 for 3-4 days and then transferred into media 2. Both of these methods sustained phase-bright, pyramidal-shaped hippocampal neurones in culture for up to 30 days, (see figure 2.7). Again, these cells enabled stable recordings, some of which lasted over 2 hours in duration.

Figure 2.7: shows a phase-contrast photomicrograph (x500 magnification) of a primary culture of embryonic rat hippocampal neurones 21 days in culture maintained in culture using method 4. Phase-bright cells are evenly distributed on glial feeder layer.
2.4. Whole-Cell Voltage Clamp Recording

Whole-cell currents were recorded from voltage-clamped hippocampal neurones using the patch clamp technique (Hamill et al., 1981). Agonists were pressure applied at 1.4kPa and between 0.02-0.033Hz. Cells were superfused with a physiologically balanced solution (PBS) containing 0.3μM tetrodotoxin (TTX, except where stated) at a rate of approximately 2ml/min. All drugs were dissolved in PBS containing 0.3μM TTX. All experiments were carried out at ambient room temperature (20-23°C). All responses were measured at their peak amplitude. Responses in the presence of drugs are expressed as the mean± s.e.m of control.

Whole-cell voltage-clamp recordings were made from hippocampal neurones maintained in culture between 10 to 35 days. The culture media for hippocampal neurones was replaced by the external recording solution (bath solution, see below) containing tetrodotoxin (TTX; 0.3μM) and cells were viewed under a phase-contrast inverted microscope (Nikon TMS) at a magnification of x200. The microscope and micromanipulators used to position the microelectrodes were mounted on a vibration-free air table (Wentworth, U.K.) and housed in a copper Faraday cage (built in house).

Thin glass pipettes (Kimble, soda-lime non-heparinized microhaematocrit tubes) of approximate tip diameter 1-5μm and tip resistance of between 1-3MΩ were manufactured using a Narishige PB-7 (Tokyo, Japan) two-stage electrode puller. These pipettes were coated at the tip with Sylgard (Dow Corning, Belgium) and fire-polished just prior to use using a fire-polisher built in-house. The pipettes were filled with a conducting salt solution (internal solution; detailed below) containing 2mM Mg-ATP which served to maintain intracellular ATP stores and thus reduce rundown of GABA currents as previously described by Stelzer et al., (1988). A silver chloride coated silver wire, together with the electrolyte-containing pipette formed the recording electrode which was connected to a low-noise, high gain current amplifier (Axopatch 200A, California, U.S.A.). Another silver/silver-chloride RC1-type bath electrode (Clark Electromedical, U.K.) was connected to the virtual ground of the amplifier's headstage.

Chapter Two: General Methods 69
Figure 2.8: A schematic of the patch-clamp recording technique. Schematic shows a hippocampal neuron adhered to the base of a culture dish. Recordings were made using the patch electrode, (shown on the far left) which is continuous with cell membrane. A spritzer pipette delivering agonist to the cell is shown on the far right. Drugs and PBS were delivered to the cell using a directional perfusion system (not shown to scale); the gray arrow indicates the direction of flow solutions over the cell.
Once a suitable cell was selected on the basis of cell morphology (phase-bright, pyramidal shaped neurons), the pipette electrode was advanced towards the cell using a piezo-driven micromanipulator (Burleigh Patch Clamp Driver, PCS-250, New York, U.S.A.) and, simultaneously, a low voltage square wave pulse (0.2-0.6mV, 4.5ms duration, 5Hz, Grass S48 Stimulator, Warwick, U.S.A.) was delivered to the pipette electrode tip to enable the monitoring of seal resistance using the Axon 200A amplifier. As the pipette electrode tip touched the cell, the current recorded was reduced, thus indicating an increase in seal resistance. Application of negative pressure (via a 5ml syringe attached to the amplifier headstage with Nalgene tubing) then allowed the formation of a "gigaseal"; this was indicated by a sharp increase in seal resistance with almost zero current recorded. Once a "gigaseal" was obtained (>20GΩ), capacitance transients due to the patch pipette and cell membrane were electronically cancelled and the cell was voltage clamped at -60mV unless otherwise stated. Further application of negative pressure caused the patch of membrane below the pipette tip to rupture, allowing the internal milieu of the cell to be accessed and subsequently dialysed with internal solution. At this point the whole cell membrane capacitance and series resistance transient currents were electronically and iteratively cancelled using the amplifier's whole-cell capacitance and series resistance circuitry. Currents were recorded and low pass filtered at 2kHz with an eight-pole Bessel filter before digitisation, storage and display.

Agonists were applied to cells under voltage-clamp by pressure ejection (0.02-0.03Hz, 1.4kPa, 10-100ms duration) from the tip of a "spritzer" microelectrode (tip diameter ≤20μm) using a picospritzer device (General Valve Corporation, New Jersey, U.S.A.). The spritzer pipette was positioned in close proximity to the neurone (80-100μm laterally from cell and ≈50μm above cell) using a Narishige Joystick micromanipulator (Narishige, Tokyo, Japan). Drugs were perfused onto cells from the tip of a plastic cannula (tip diameter, 2mm) positioned in close proximity to the cell (~300μm laterally from cell and~200μm above cell) using a Prior micromanipulator. This directional, gravity-feed perfusion system was manufactured in-house by the experimenter.
Where drugs were applied to the cell interior, the time constant for the diffusional exchange of the drug between the recording pipette and the cell interior was calculated according to methods described by Pusch and Neher (1988). The diffusional exchange rate between the patch pipette solution and the cell depends on a number of factors: the molecular weight of the drug, the cell-pipette access resistance and the cell volume (which may be estimated from the cell capacitance, assuming a specific membrane capacitance of 1μF/cm²; Pusch and Neher, 1988). Under the present recording conditions, (using the equation \( \tau = (0.6 \pm 0.17) R_A M^{1/3} \) and a correction factor for hippocampal cells; Pusch and Neher, 1988) the time constant (\( \tau \)) for diffusional exchange of mefenamic acid between the pipette recording solution and the cell interior was calculated to be approximately 71 secs. Drugs were allowed to dialyse the cell interior for a duration four times in excess of the calculated time constant. Whole-cell currents were monitored on a storage oscilloscope (Tectronix 2212, Holland) and recorded onto a two-channel chart recorder (Lectromed, Jersey, U.K.) and on a Digital Audio Tape Recorder (DAT; Biologic DTR-1202, France). The DAT recorder single was sampled at a frequency of 48KHz and was low-pass filtered using "Digital Comb and FIR filters."

### 2.4.1. Drugs and Solutions

Bath solution was made up in ultra pure water (Milli-QPLUS) with the following salts (all BDH, except where stated; concentrations in mM): NaCl (140.0), KCl (2.8), MgCl₂ (2.0), CaCl₂ (1.0), HEPES (Sigma; 10.0). Tetrodotoxin (Sigma, 0.3μM) was also added to the bath solution to block spontaneous voltage-dependent sodium channel activity. NMDA-evoked currents were recorded in the nominal absence of Mg²⁺ and in the presence of glycine (1μM). Internal solution was made up in ultra pure water (Milli-QPLUS) with the following salts (all BDH; concentrations in mM): KCl (140.0) or CaCl₂ (140.0), MgCl₂ (2.0), CaCl₂ (0.1), EGTA (Sigma; 1.1), HEPES (Sigma; 10.0) MgATP (Sigma; 2). These solutions were then titrated to pH 7.2 using concentrated hydrochloric acid and were filtered before use (0.22μm GV filters, Millipore, U.K.).
GABA, glycine, sodium pentobarbitone and strychnine (Sigma) were dissolved in bath solution as 10mM and 1mM stock solutions, respectively. AMPA, kainate and NMDA (Sigma) were dissolved in 0.1NaOH as 1mM stocks. D(-)-2-amino-5-phosphonopentanoic acid (D-AP5), and 6-cyano-7-nitroquinoxaline-2,3-dione disodium (CNQX; both Tocris-Cookson, Bristol, U.K.) were dissolved in water as 1mM stocks. Propofol, alphaxalone (both gifts from Dr. David Gemmel, Akzo Nobel, Organon Laboratories, Newhouse, Scotland), diazepam and flumazenil (SIGMA) were dissolved in absolute ethanol as a 1mM stock solutions (the final concentration of ethanol used was always less than 0.1%). Bicuculline was dissolved in 0.1ml of hydrochloric acid (1M) and further diluted with water to form to a 10mM stock. The fenamate NSAIDs: mefenamic acid, flufenamic acid, meclofenamic acid, tolfenamic acid and niflumic acid, were made up as 10mM stock solutions in 0.1M NaOH. The NSAIDs, indomethacin, ibuprofen, diflusinal and biphenylacetic acid (BPAA; all Sigma) were made up as 10mM stock solutions in ethanol. Loreclezole (Janssen Research Foundation) was made up as a 1mM stock in DMSO. All drugs were serially diluted in bath solution as required.

2.4.ii. Experimental Protocol.

GABA (10μM) and other agonists were delivered to the cell via pressure ejection as previously described until a series of submaximal control agonist-evoked responses, consistent in amplitude and duration, were obtained prior to drug application using the directional perfusion system. Drugs were washed off once a clear asymptotic drug effect was observed. Control responses were re-established before further drug applications.

2.4.iii. Data Analysis

Submaximal agonist-evoked responses were measured at their peak amplitude, and in some cases duration of charge, and are expressed as the
arithmetic mean (±s.e.mean of n experiments) of the response before addition of any drugs. Such experiments from different neurones were pooled and log[modulator]-response plots were constructed. Log[modulator]-response plots were fitted to a sigmoidal function as described above (page 56) to determine EC$_{50}$ (±95% C.I.) values. The equation used to fit the concentration-response relationship was:

\[ Y = Bottom + \frac{(Top - Bottom)}{1 + 10^{(\log EC_{50} - X)HillSlope}} \]

where X is the logarithm of concentration, Y is the response which starts at Bottom and goes to Top with a sigmoid shape. Log[inhibitor]-response plots were fitted point to point and IC$_{50}$ (±95% C.I.) values were interpolated. “Pseudo” Hill slopes (see page 58) are calculated from the curve.
CHAPTER THREE: RESULTS

Section 3.1: Modulation of agonist-evoked responses of the rat vagus by mefenamic acid

1. Introduction

Woodward et al., (1994) have reported that fenamate NSAIDs modulated rat brain GABA_A receptors expressed in *Xenopus* oocytes and a preliminary study by Halliwell et al., (1994) reported modulation of GABA-evoked currents in voltage-clamped rat hippocampal neurones by mefenamic acid. It was of interest, therefore, to further examine the effects of mefenamic acid on neuronal GABA_A receptors and other ligand-gated ion channels.

The rat isolated vagus and optic nerves have proved useful preparations to examine the mechanism, site and selectivity of compounds acting on neuronal receptors, since a number of ligand-gated ion channels are present on these nerves (e.g. Marsh, 1989). In the first instance, experiments were undertaken to establish the action of known modulators of the GABA_A receptor and other ligand-gated ion channels present on the vagus and optic nerves, in order to ascertain the integrity of these preparations.

2. Procedures

Superfusion of submaximal concentrations of agonist onto either side of the vagus or optic nerves evoked a change in membrane polarisation in most preparations. Agonist contact time was standardised at 2±0.5min, a time which produced a clearly discernible peak agonist-evoked response. Since response amplitude varied between different sides of the nerve, most experiments were carried out on the side of the nerve which produced the largest agonist-evoked response. Agonists were applied to the nerve at regular intervals. To avoid receptor desensitisation, the intervals between agonist application were 10±0.5min, 15±0.5min, 15±0.5min and 15±0.5min for GABA-, 5-HT-, α,β-MeATP- and DMPP- evoked responses, respectively. Control agonist-evoked responses were found to remain stable for up to 14 hours. Whenever possible,
Vagus nerves were obtained from small rats (~150g) since such nerves produced larger responses to known concentrations of GABA than those from larger rats. However, optic nerves (12-15mm in length) were generally obtained from larger rats (~250g) since in smaller rats, dissection only produced very short lengths of optic nerve (~10mm) and these were more difficult to set up for extracellular recording.

The experimental protocol and data analysis were carried out as described in Methods.

3. Pharmacological characterisation of agonist-evoked responses in the vagus and optic nerves

The experiments reported here have investigated the pharmacology of GABA-, 5-HT-, α,β-MeATP- and DMPP- evoked responses of the vagus nerve and GABA- and glycine-evoked responses of the optic nerve. Further studies examined the action of certain known allosteric modulators of the GABA_A receptor. Sodium pentobarbitone, alphaxalone and the intravenous anaesthetic agent, propofol, were the compounds investigated since their modulation of the GABA_A receptor in other neuronal preparations has been well characterised (for review see: Seighart, 1995; Johnston, 1996).

4. Results
4.i. Pharmacological characterisation of agonist-evoked responses in the rat isolated vagus nerve.

Using the extracellular recording technique, concentration response curves to GABA (3-3000μM), 5-HT (100nM-10μM), α,β-MeATP (3-500μM) and DMPP (3-1000μM) were determined in the isolated vagus nerve. The EC_{50} values (geometric mean and 95% confidence intervals) for GABA, 5-HT, α,β-MeATP and DMPP-evoked responses were found to be 34μM (25-43μM, n=5), 0.8μM (0.6-1.0μM, n=4), 48μM (34-62μM, n=5) and 33μM (6-61μM, n=12), respectively. From these data, concentrations approximating these EC_{50} values were obtained from small rats (~150g) since such nerves produced larger responses to known concentrations of GABA than those from larger rats. However, optic nerves (12-15mm in length) were generally obtained from larger rats (~250g) since in smaller rats, dissection only produced very short lengths of optic nerve (~10mm) and these were more difficult to set up for extracellular recording.

The experimental protocol and data analysis were carried out as described in Methods.

3. Pharmacological characterisation of agonist-evoked responses in the vagus and optic nerves

The experiments reported here have investigated the pharmacology of GABA-, 5-HT-, α,β-MeATP- and DMPP- evoked responses of the vagus nerve and GABA- and glycine-evoked responses of the optic nerve. Further studies examined the action of certain known allosteric modulators of the GABA_A receptor. Sodium pentobarbitone, alphaxalone and the intravenous anaesthetic agent, propofol, were the compounds investigated since their modulation of the GABA_A receptor in other neuronal preparations has been well characterised (for review see: Seighart, 1995; Johnston, 1996).

4. Results
4.i. Pharmacological characterisation of agonist-evoked responses in the rat isolated vagus nerve.

Using the extracellular recording technique, concentration response curves to GABA (3-3000μM), 5-HT (100nM-10μM), α,β-MeATP (3-500μM) and DMPP (3-1000μM) were determined in the isolated vagus nerve. The EC_{50} values (geometric mean and 95% confidence intervals) for GABA, 5-HT, α,β-MeATP and DMPP-evoked responses were found to be 34μM (25-43μM, n=5), 0.8μM (0.6-1.0μM, n=4), 48μM (34-62μM, n=5) and 33μM (6-61μM, n=12), respectively. From these data, concentrations approximating these EC_{50} values were obtained from small rats (~150g) since such nerves produced larger responses to known concentrations of GABA than those from larger rats. However, optic nerves (12-15mm in length) were generally obtained from larger rats (~250g) since in smaller rats, dissection only produced very short lengths of optic nerve (~10mm) and these were more difficult to set up for extracellular recording.

The experimental protocol and data analysis were carried out as described in Methods.
values of 50μM, 0.5μM, 30μM and 30μM for GABA, 5-HT, α,β-MeATP and DMPP, respectively, were employed in further experiments. The EC20 value for GABA-evoked responses was found to be 13μM, however, for convenience a value of 10μM was employed in further experiments. The mean amplitude of responses evoked by 10μM GABA was found to be 0.1±0.01mV (n=101). The mean amplitude of responses evoked by 5-HT (0.5μM), α,β-MeATP (30μM) and DMPP (30μM) were found to be 0.36±0.03mV (n=41), 0.62±0.06mV (n=41) and 1.98±0.55mV (n=16) respectively. In experiments where the modulatory effects of drugs were investigated against control agonist-evoked responses, the drug-induced effect on the agonist-evoked response is represented as a percentage change of the control agonist-evoked response. The results of these experiments are summarised in figures 3.1 and 3.2.

In the isolated rat vagus nerve, concentrations approximating EC50 concentrations of agonist-evoked responses, were recorded in the presence of their respective antagonists. Submaximal (50μM) GABA-evoked responses were inhibited by 1μM picrotoxin to 55±8% (n=5, p<0.02) of control. Submaximal (0.5μM) 5-HT-evoked responses were inhibited by 0.1μM MDL-72222 (3-tropanyl-3,5-dichlorobenzoate) to 17±5% (n=7, p<0.0001) of control. Submaximal (30μM) α,β-MeATP-evoked responses were inhibited by 30μM suramin to 37±4% (n=5, p<0.0003) of control and submaximal (30μM) DMPP-evoked responses were inhibited by hexamethonium (300μM) to 29±13 (n=6, p<0.003) of control. These data are consistent with the activation of neuronal GABA_A, 5-HT_3, P_2x and nicotinic ACh receptors, respectively. All drug effects were reversible upon wash. The results of these experiments are summarised in a histogram (figure 3.4); chart recorder traces of these results are shown in figure 3.3.


Using the extracellular recording technique the concentration response relationships for GABA and glycine (both 0.1-10mM) were determined in the rat
Figure 3.1: GABA, 5-HT, $\alpha,\beta$-MeATP and DMPP evoked concentration-dependent responses in the rat isolated vagus nerve. The figure shows chart recorder traces of GABA-, 5-HT-, $\alpha,\beta$-MeATP- and DMPP- evoked responses. The agonist applied is indicated to the left of the appropriate traces. The concentration of agonist applied to the nerve is shown below the corresponding response and the agonist contact time is represented by the solid bar beneath each trace.
Figure 3.2: GABA, 5-HT, α,β-MeATP and DMPP evoke concentration-dependent agonist-evoked responses in the rat isolated vagus nerve. The figure shows mean log concentration-response curves for GABA-, 5-HT-, α,β-MeATP- and DMPP- evoked responses. The log_{10} of the agonist concentration is shown on the abscissa and the response amplitude is shown on the ordinate. Each agonist-evoked response has been normalized to its respective maximum response. Each data point is the mean ± s.e.m (represented by vertical lines) of 5, 6, 2-5 and 3-12 experiments for GABA, 5-HT, α,β-MeATP and DMPP, respectively. The "pseudo Hill slopes" calculated for GABA, 5-HT, α,β-MeATP and DMPP, were 0.3, 1.3, 0.4 and 0.6, respectively.
Figure 3.3: GABA-, 5-HT-, αβMeATP- and DMPP-evoked responses of the rat isolated vagus nerve are inhibited by drugs acting at the GABA_A receptor, 5-HT_3, P_2x and nACh receptors, respectively. The figure shows actual chart recorder traces of submaximal (EC_{50}) GABA-evoked responses in the absence and presence of picrotoxin (1μM); 5-HT-evoked responses in the absence and presence of MDL-72222 (0.1μM); αβMeATP-evoked responses in the absence and presence of suramin (30μM) and DMPP-evoked responses in the absence and presence of hexamethonium (300μM). The agonist concentration applied to the nerve is indicated below its corresponding response and agonist contact time is represented by the solid bar beneath each response.
Figure 3.4: GABA<sub>a</sub>, 5-HT<sub>1</sub>, α,βMeATP- and DMPP-evoked responses of the rat vagus nerve are inhibited by drugs acting at the GABA<sub>a</sub>, 5-HT<sub>1</sub>, P<sub>X</sub> and nACh receptors, respectively. Histograms summarize the inhibitory effects of (a): picrotoxin (1μM) on submaximal (50μM) GABA-evoked responses, (b): MDL-72222 (0.1μM) on submaximal (0.5μM) 5-HT-evoked responses, (c): suramin (30μM) on submaximal (30μM) α,βMeATP-evoked responses and (d): hexamethonium (300μM) on submaximal (30μM) DMPP-evoked responses. Each data bar is the mean±s.e.m (represented by the vertical lines) of 5, 7, 5 and 6 experiments for GABA<sub>a</sub>, 5-HT<sub>1</sub>, α,βMeATP- and DMPP-evoked responses, respectively.
isolated optic nerve. The EC_{50} values (geometric mean and 95% confidence intervals) for GABA and glycine-evoked responses were found to be 1.6mM (0.9-2.5mM, n=9) and 2.6mM (2.0-3.5mM, n=8), respectively. From these data concentrations approximating the EC_{20} values of 0.3mM and 1mM for GABA and glycine, respectively, were interpolated and used in further experiments. The mean amplitude of responses evoked by 300μM GABA and 1mM glycine were found to be 0.22±0.02mV (n=15) and 0.27±0.03mV (n=20), respectively. In experiments where the modulatory effects of drugs were investigated against control agonist-evoked responses, the drug-induced effect on the agonist-evoked response is represented as a percentage change of the control agonist-evoked response. These data are summarised in figure 3.5.

In the rat isolated optic nerve, submaximal GABA-evoked responses (0.3mM) were inhibited by 3μM picrotoxin to 50±9 % (n=3, p<0.02) of control. Submaximal glycine-evoked responses (1mM) were abolished by 1μM strychnine and inhibited by 0.5μM strychnine to 41±12% (n=4, p<0.02) of control. These data are consistent with activation of neuronal GABA and strychnine-sensitive glycine receptors, respectively. These data are summarised in a histogram (figure 3.6).

4.iii. Allosteric modulation of the GABA-mediated response in the rat isolated vagus nerve.

Submaximal GABA-evoked responses of the vagus nerve were concentration-dependently and reversibly potentiated by three chemically diverse drugs acting at the GABA_A receptor: submaximal (10μM) GABA-evoked responses were potentiated by sodium pentobarbitone (10-100μM), alphaxalone (1-10μM) and propofol (1-30μM). The maximum potentiation evoked by sodium pentobarbitone (10μM), alphaxalone (10μM) and propofol (10μM) was found to be to 170% (n=2), 312±18% (n=4, p<0.002) and 361±47% (n=15, p<0.0001) and of control, respectively. The results of these experiments are summarised in figure 3.7.
Figure 3.5: GABA and glycine evoke concentration-dependent responses of the rat isolated optic nerve. Left: chart recorder traces of GABA- and glycine-evoked responses. The agonist and concentration applied to the nerve is given below the response and the agonist contact time is represented by the solid line beneath the trace. Right: shows mean log concentration-response curves for GABA and glycine. The log_{10} of the agonist concentration applied to the nerves is shown on the abscissa and the peak response amplitude is shown on the ordinate. For each nerve, agonist-evoked responses have been normalized to their respective maximum response. Each data point is the mean ± s.e.m (represented by the vertical lines) of 6-9 and 1-9 experiments for GABA and glycine, respectively.
Figure 3.6: GABA- and glycine-evoked responses are antagonised by picROTOxin and strychnine, respectively in the rat isolated optic nerve. Top: shows chart recorder traces of GABA- and glycine-evoked responses in the absence and presence of their respective antagonists. The drug concentration applied to the nerve is indicated below the GABA (0.3mM)- or glycine (0.3mM)-evoked response and the agonist contact time is represented by the solid bar beneath each response. The calibration bars (shown on the right) apply to both GABA- and glycine-evoked responses. GABA- and glycine-evoked responses are taken from the same optic nerve. Bottom: shows histograms summarizing the inhibitory effects of (left) picROTOxin (3μM) on the GABA-evoked response and the inhibitory effects of (right) strychnine (0.5μM) on glycine-evoked responses. Each data point is the mean±s.e.m (represented by the vertical bars) of 3 and 4 experiments for GABA and glycine, respectively.
**Figure 3.7:** GABA-evoked responses of the rat isolated vagus nerve are potentiated by propofol, sodium pentobarbitone and alphaxalone. **Left:** Chart recorder traces of submaximal (EC$_{20}$) GABA-evoked responses potentiated by a. propofol, b. alphaxalone and c. sodium pentobarbitone (all at 10µM). The drug concentration applied to the nerve is indicated below its corresponding response and agonist contact time is represented by the solid bar beneath each response. Traces are taken from different vagus nerves. **Right:** mean log concentration-effect curves for potentiation of submaximal GABA (10µM)-evoked responses by propofol (1-30µM), alphaxalone (1-10µM) and sodium pentobarbitone (10-100µM). The log$_{10}$ concentration of modulator is plotted on the abscissa and the response, as a percentage of the control GABA response is plotted on the ordinate. Each data point represents the mean of 7-15, 2-4 and 2-13 experiments for propofol, alphaxalone and sodium pentobarbitone, respectively.
These modulatory effects of propofol, alphaxalone and pentobarbitone are consistent with those of other investigators (e.g. electrophysiological studies by Peters et al., 1988 and Hales and Lambert, 1991) and taken together are indicative of activation of a neuronal GABA<sub>A</sub> receptor. Collectively, the above data validated the use of the vagus and optic nerves as suitable preparations to examine modulation of neuronal GABA<sub>A</sub>, 5-HT<sub>3</sub>, nACh, P<sub>2x</sub> receptors and the strychnine-sensitive glycine receptors.

However, also noteworthy in these studies, was the marked and consistent modulation of the GABA-evoked response in the rat vagus nerve by propofol. Since the selectivity of this agent was unknown, the vagus and optic nerves were employed to determine the action of propofol at the 5-HT<sub>3</sub>, nicotinic acetylcholinergic (nACh) and P<sub>2x</sub> receptors of the rat isolated vagus nerve and at the GABA<sub>A</sub> and the strychnine-sensitive glycine receptor of the rat isolated optic nerve.

4.iv. Selectivity of action of propofol on vagus and optic nerves.

The effects of propofol (1-100μM) were examined on neuronal GABA<sub>A</sub>, 5-HT<sub>3</sub>, P<sub>2x</sub> and nACh receptors on the rat isolated vagus nerve. Propofol concentration-dependently potentiated submaximal (10μM) GABA-evoked responses to a maximum of 360±45% (n=15; p<0.0001) of control in the presence of 10μM propofol. In contrast, 5-HT (0.5μM), α,β-MeATP (30μM) and DMPP (30μM)-evoked responses were little or unaffected by propofol (1-10μM). In the presence of 10μM propofol, the 5-HT, α,β-MeATP and DMPP-evoked responses were reduced to 86±7% (n=6, p<0.1), 88±5% (n=5, p<0.07) and 85±7% (n=5, p<0.1) of control, respectively. In the presence of 100μM propofol the 5-HT, α,β-MeATP and DMPP-evoked responses were reduced to 60±8% (n=6), 40±9% (n=5) and 57±16% (n=5) of control, respectively. 100μM propofol only transiently potentiated the GABA response, therefore, its effects are presented at t=15 mins. The results of these experiments are summarised in figures 3.8 and 3.9.
Figure 3.8: Propofol potentiates submaximal GABA-evoked responses, but has little or no effect on 5-HT-, α,βMeATP- and DMPP-evoked responses in the rat isolated vagus nerve. Chart recorder traces of agonist-evoked responses (all approximating their EC$_{50}$, except for GABA which $\approx$ EC$_{20}$) in the absence and presence of propofol (10μM) are shown. Top calibration bars apply to traces a and b. The agonist concentration applied to the nerve is indicated below the response and the agonist contact time is represented by the solid bar beneath each response. Agonist-evoked responses are taken from different nerves.
Figure 3.9: Propofol potentiates submaximal GABA-evoked responses, but has little or no effect on 5-HT-, \(\alpha,\beta\text{MeATP-}\) or DMPP-evoked responses in the rat isolated vagus nerve. Mean log concentration-effect curves for agonist-evoked responses (all EC\(_{50}\), except GABA which \(\approx EC_{20}\)) in the presence of propofol (1-100 \(\mu\text{M}\)). The \(\log_{10}\) propofol concentration is shown on the abscissa and the response, as a percentage of the control agonist response, is shown on the ordinate. Each data point represents the mean±s.e.m (represented by the vertical bars) of 5-15 experiments.
The effect of propofol (10μM) on submaximal GABA- and glycine-evoked responses of the optic nerve was examined. Propofol (10μM) potentiated submaximal (EC\textsubscript{20}) GABA (0.3mM) and glycine (1mM)-evoked responses to \(307\pm12\%\ (n=3, \ p<0.009)\) and \(124\pm6\%\ (n=7, \ p<0.03)\) of control, respectively. These data are summarised in figure 3.10.

Thus, having validated the vagus nerve as a simple neuropharmacological assay, the effects of mefenamic acid on GABA-evoked responses of the vagus nerve were determined.

4.v. **Mefenamic acid potentiates the GABA-mediated response in the rat isolated vagus nerve.**

Submaximal (10μM) GABA-evoked responses of the vagus nerve were concentration-dependently and reversibly potentiated by mefenamic acid (10-100μM). The maximum potentiation evoked mefenamic acid (10μM) was found to be to \(164 \pm 14\%\ (n=3, \ p<0.02)\) of control. The results of these experiments are summarised in figure 3.11.

5. **Discussion**

5.i. **Characterisation of agonist-evoked responses in the vagus and optic nerves**

GABA, 5-HT, α,β-MeATP and DMPP evoked concentration-dependent depolarisation's of the rat isolated vagus nerve. The \(EC_{50}\) calculated for GABA-evoked responses was found to be 34μM; this is consistent with the \(EC_{50}\) values of 28μM and 69μM for GABA-evoked depolarisation's of the rat vagus nerve reported by Ireland and Tyers (1987) and Green and Halliwell (1997), respectively. The \(EC_{50}\) calculated for the 5-HT-evoked responses was found to be 0.8μM; this is in agreement with the work of Trezise (1993) who found that 5-HT evoked concentration-dependent depolarisation's of the vagus nerve with an \(EC_{50}\) of 0.48μM and Green and Halliwell (1997), who report a value of 0.8μM. Ireland and Tyres (1987) and Green and Halliwell (1997) also report
Figure 3.10: Propofol potentiates submaximal GABA- and glycine-evoked responses in the rat isolated optic nerve. Top: shows chart recorder traces of submaximal GABA and glycine-evoked responses in the absence and presence of propofol (10 μM); calibration bars shown apply to both sets of traces. The agonist concentration applied to the nerve is shown below the response and the agonist contact time is represented by the solid bar beneath each trace. Traces are taken from different nerves. Bottom: histograms summarizing the potentiating effect of propofol (10 μM) on submaximal GABA (0.3 mM; on the left) and glycine (1 mM; on the right) evoked responses. Each data bar is the mean ± s.e.m (represented by the vertical lines) of 3 and 7 experiments for GABA and glycine, respectively.
Figure 3.11: Mefenamic acid concentration-dependently potentiates submaximal GABA-evoked responses in the rat isolated vagus nerve. **Left:** shows chart recorder traces of submaximal GABA-evoked responses in the absence and presence of 10μM mefenamic acid (left), 30μM mefenamic acid (middle) and 100μM mefenamic acid (right); calibration bars apply to each set of traces. The agonist contact time is represented by the solid bar beneath each trace. Responses were taken from different vagus nerves. **Right:** Mean log concentration-effect plot for GABA-evoked responses in the presence of mefenamic acid (10-100μM). The log_{10} mefenamic acid concentration is shown on the abscissa and the GABA response, as a percentage on control, is shown on the ordinate. Each data point represents the mean of 3 experiments.
DMPP-evoked depolarisations of the vagus nerve with $EC_{50}$ values of 35$\mu$M and 13$\mu$M, respectively; an $EC_{50}$ value of 33$\mu$M was determined in this study. Trezise et al., (1993) and Green and Halliwell (1997) have reported that $\alpha,\beta$-MeATP concentration-dependently depolarises the rat vagus nerve with $EC_{50}$ values of 25$\mu$M and 26$\mu$M, respectively; these data are in accordance with the $EC_{50}$ value of 48$\mu$M reported in this study.

Trezise et al., (1993) and Green and Halliwell (1997) have reported that $\alpha,\beta$-MeATP concentration-dependently depolarises the rat vagus nerve with $EC_{50}$ values of 25$\mu$M and 26$\mu$M, respectively; these data are in accordance with the $EC_{50}$ value of 48$\mu$M reported in this study.

GABA and glycine evoked concentration-dependent depolarisation's of the rat optic nerve with $EC_{50}$ values of 1.6mM and 2.6mM, for GABA and glycine, respectively. These data are in agreement with those of Green and Halliwell, (1997) who report $EC_{50}$ values of 1.1mM and 1.7mM, for GABA and glycine, respectively. Also, Simmonds (1983) reports concentration-dependent depolarizations of the isolated optic nerve by the GABA analogue, muscimol, and glycine with interpolated $EC_{50}$ values of $\approx$10$\mu$M and $\approx$1.4mM, respectively.

Agonist-evoked responses had characteristic profiles: 5-HT-evoked responses were observed to develop relatively slowly when compared to GABA-evoked responses and, occasionally, a small "after-hyperpolarising" response was observed on washout of higher concentrations of 5-HT; similar observations have been reported by Azami and colleagues, (1985).

Responses evoked by $\alpha,\beta$-MeATP typically reached peak more rapidly than GABA-evoked responses and an after-hyperpolarising response was frequently observed, especially on washout of higher concentrations (>100$\mu$M) of $\alpha,\beta$-MeATP. In addition, $\alpha,\beta$-MeATP-evoked responses were observed to fade rapidly, particularly with higher concentrations and in the continued presence of the drug; this phenomena has been previously reported to occur in other preparations such as guinea-pig bladder (Kasakov and Burnstock, 1983). These observations are also in good agreement with those outlined by Trezise et al., (1993).

DMPP-evoked responses were also slower in onset than GABA-evoked responses and no after-hyperpolarising responses were observed. In addition, higher concentrations of DMPP evoked the largest depolarization's of the vagus nerve, (up to 5mV in some cases). The concentration of DMPP which evoked a maximal response appeared to be variable (10-1000$\mu$M); for this reason,
DMPP-evoked responses were normalised to the response evoked by 300μM DMPP. A possible explanation for this phenomenon could be that at concentrations of DMPP greater than 300μM other receptor types may be recruited (e.g. DMPP may promote the pre-synaptic release of acetylcholine from post-ganglionic nerve terminals, Wingard et al., 1991). Other investigators have also limited their DMPP concentration range to 3-300μM for nicotinic receptor activation of the vagus nerve (e.g. Green and Halliwell, 1997).

GABA-, 5-HT-, α,β-MeATP- and DMPP-evoked responses were inhibited by picrotoxin, MDL 72222, suramin and hexamethonium, respectively. It is well established that picrotoxin non-competitively inhibits GABA_A-mediated responses (Akaike, 1985). In this study, GABA-evoked responses were inhibited to 55% of control by picrotoxin (1μM); Green and Halliwell (1997) report similar inhibition by picrotoxin in the vagus nerve with an IC_{50} value of 3.6μM. Bowery and Brown (1974) demonstrated antagonism of extracellularly recorded GABA-evoked responses recorded in the rat superior cervical ganglion by somewhat higher concentrations of picrotoxin; in this study the IC_{50} for picrotoxin was 37μM.

MDL 72222 has been shown to act as a potent and selective antagonist of 5-HT-mediated depolarisation's of nodose and superior cervical ganglion cells (Azami et al., 1985) and has also been shown to lack affinity for 5-HT_1 and 5-HT_2 recognition sites in rat brain membranes (Fozard, 1984). In this study MDL 72222 (0.1μM) virtually abolished 5-HT_3-mediated responses of the vagus nerve. Similar observations were made in the vagus nerve by Green and Halliwell (1997) and Azami et al., (1985) in rabbit nodose ganglia and superior cervical ganglia.

Suramin has been reported to antagonise ATP-activated channels (Nakazawa et al., 1990; Evans et al., 1992). However, it lacks selectivity for P_2x subtypes (Evans, 1992). Consistent with data published by Trezise et al., (1993), suramin inhibited α,β-MeATP-evoked depolarizations of the rat vagus nerve supporting the proposal that these responses are predominantly mediated through P_2x receptors.

Chapter Three: Results, section 1, 82
In this study, DMPP-evoked responses of the rat vagus nerve were inhibited to 71% of control by hexamethonium (300|µM). Ireland and Tyres (1987) and Green and Halliwell (1997) also report similar levels of inhibition of DMPP-evoked responses of the rat vagus by hexamethonium. These pharmacological data are in accordance with nACh receptor activation.

In the optic nerve, GABA and glycine-evoked responses were inhibited by picrotoxin and strychnine, respectively. These data are consistent with those previously reported by Green and Halliwell (1997) who report antagonism of glycine-evoked responses in the optic nerve by strychnine (3|µM) and Simmonds (1983) who reported antagonism by strychnine between 0.1 and 10|µM in the optic nerve.

5.ii. Allosteric modulation of the GABA-mediated response in the rat isolated vagus nerve.

The positive allosteric modulation of the GABA\textsubscript{A} receptor by several CNS-depressant drugs, such as sodium pentobarbitone, alphaxalone and propofol, is well documented (for review see Seighart, 1995). In the vagus nerve, propofol was the most potent of the modulators examined and the relative order of potency, in descending order, was as follows propofol> alphaxalone> sodium pentobarbitone. These effects of propofol, alphaxalone and pentobarbitone are consistent with those of other investigators using single cell preparations (e.g. Peter \textit{et al.}, 1988 and Hales and Lambert, 1991) and taken together, are consistent with activation of a neuronal GABA\textsubscript{A} receptor. In binding studies (e.g. Concas \textit{et al.}, 1990), alphaxalone is usually reported to be a more potent modulator of the GABA\textsubscript{A} receptor than propofol. However in the vagus nerve, propofol is almost equipotent with alphaxalone.

The pharmacology of the GABA, 5-HT, \(\alpha,\beta\)-MeATP and DMPP-evoked responses in the rat isolated vagus nerve is consistent with the activation of GABA\textsubscript{A}, 5-HT\(_3\), P\(_{2x}\) and nACh receptors, respectively. Similarly, the pharmacology of the GABA and glycine-evoked responses in the rat isolated optic nerve is consistent with the activation of GABA\textsubscript{A} and strychnine-sensitive
glycine receptors, respectively. These data, therefore, support the use of the vagus and optic nerves as appropriate preparations with which to examine modulation of neuronal ligand-gated ion channel function.

5.iii. Selectivity of action of propofol on vagus and optic nerves

The vehicle for experiments investigating the action of propofol was ethanol. A number of studies have demonstrated that millimolar concentrations of ethanol interact with ligand-gated ion channels such as the GABA_A, 5-HT_3, nACh, P_2x and strychnine-sensitive glycine receptors.

For example, Aguayo and Pancetti (1994) have demonstrated that ethanol (0.5-850mM) potentiated GABA-evoked responses in ethanol-sensitive voltage-clamped mouse hippocampal neurones between 110 and 430% of control, respectively (EC_{50}=502mM). These authors have also demonstrated that ethanol (1-425mM) concentration-dependently potentiated ethanol-sensitive voltage-clamped mouse hippocampal neurones; a potentiation of 150% of control being achieved with 100mM ethanol. In voltage-clamped mouse spinal neurones, ethanol (1-400mM) potentiated glycine-evoked currents between approximately 102 and 190% of control, respectively. Additionally, Machu and Harris (1994) have demonstrated using 5-HT_3 receptors expressed in voltage-clamped Xenopus oocytes that ethanol (25-200mM) potentiated 5-HT evoked currents (EC_{50}=100mM) where the maximal potentiation obtainable was 50% of control.

More recently, Li, et al., (1998) have demonstrated using ATP-evoked currents recorded from voltage-clamped bull frog dorsal root ganglion cells that ethanol (50-100mM) inhibited neuronal P_2x purinoceptors by shifting the ATP-evoked dose-response curve to the right, possibly via an allosteric mechanism rather than competitive inhibition. Cardoso et al., (1999) have also shown using human nicotinic acetylcholine receptor subunits expressed in Xenopus oocytes that ethanol (75mM) potentiated acetylcholine-induced currents in α2β4, α4β4, α2β2 and α4β2 receptor constructs, where the potentiation was due to an increase in E_{max}, rather than a change in EC_{50} or the Hill coefficient. The same
study also demonstrated that $\alpha_3\beta_2$ and $\alpha_3\beta_4$ receptor constructs were insensitive to modulation by ethanol, whereas homomeric $\alpha_7$ receptors were significantly inhibited by lower concentrations (25-50mM) of ethanol. Another recent patch-clamp study (Astrup et al., 1999) using cultured rodent cortical neurones has demonstrated that ethanol (3-300mM) reversibly enhanced high affinity neuronal acetylcholine-induced currents which were insensitive to $\alpha$-bungarotoxin (the potentiation ranging from 7.7±5% to 192±52%), whereas ethanol (10-300mM) weakly inhibited low affinity neuronal acetylcholine-induced currents which were sensitive to $\alpha$-bungarotoxin, (the inhibition ranging from 5±5±4% to 29±6%).

In selectivity studies the final concentration of ethanol was 2$\mu$M and therefore less than the concentrations of ethanol required to produce modulation of neuronal GABA$_A$, 5-HT$_3$, nACh, P$_{2x}$ or strychnine-sensitive glycine receptors.

Propofol concentration-dependently and reversibly potentiated GABAA receptor-mediated responses in the rat isolated vagus nerve. The mean maximal potentiation of GABA-evoked responses was 360% and was achieved with 10$\mu$M propofol and the EC$_{50}$ for this potentiating effect was 1.5$\mu$M. These data are in good agreement those of Hara et al., (1994) who report a concentration-dependent potentiation of submaximal GABA-evoked currents in rat hippocampal neurones by propofol with an EC$_{50}$ of 1$\mu$M (interpolated) and a 3-fold potentiation of the GABA-evoked current by 10$\mu$M propofol.

Hales and Lambert (1991) have reported a concentration-dependent, reversible potentiation of GABA-evoked currents by propofol (1.7-16.6$\mu$M) with a maximal potentiation of >850% of control with 8.4$\mu$M propofol in both voltage-clamped bovine chromaffin cells and rat cortical neurones. Additionally, propofol potentiated GABA-evoked currents in clonal murine hypothalamic GT1-7 neurones with an EC$_{50}$ of 5$\mu$M and levels of potentiation with 10$\mu$M propofol were $\approx$ 700% of control (Adodra and Hales, 1995). In contrast, Orser et al., (1994) report potentiation of submaximal GABA-evoked currents in voltage-clamped murine hippocampal neurones with higher concentrations of propofol (2-100$\mu$M) and, for example, a potentiation of 269% of control with 50$\mu$M.
propofol. The variation in potency and efficacy of propofol may be due to the use of different preparations and/or different vehicles and also due to different concentrations of GABA employed. For example, Hara et al., (1994) demonstrated that propofol (1μM) produced a 3-fold potentiation of currents elicited by 1μM GABA, but only a 1.1 fold potentiation of currents elicited by 100μM GABA.

The concentration-dependent potentiation of GABA-evoked responses in the vagus nerve resulted in a bell-shaped curve where potentiations evoked with higher concentrations of propofol (> 10μM) were reduced in magnitude. These data are in agreement with Hara et al., (1994) and Hales and Lambert (1991) who also report that higher concentrations of propofol (~10μM) caused a reduction in the level of potentiation. Similar observations were made by Orser et al., (1994) with higher propofol concentrations (50μM). This reduced level of potentiation may be due to desensitization, since propofol, at these high concentrations can also directly activate the GABA<sub>A</sub> receptor (Hara et al., 1993, Orser et al., 1994; Adodra and Hales, 1995).

Low concentrations of propofol (1-10μM) had little effect on 5-HT-evoked responses of the vagus nerve, but higher concentrations (≥30μM) inhibited these responses. These data are in good agreement with the work of Machu and Harris (1994) who report that propofol (1.1-22μM) did not modulate the function of homomeric murine 5-HT<sub>3</sub> receptors expressed in Xenopus oocytes. Barann et al., (1993) have reported a non-competitive inhibition of maximal 5-HT-induced <sup>14</sup>C-guanidinium flux in N1E-115 mouse neuroblastoma cells by propofol (1-30μM). In a more recent voltage-clamp study using N1E-115 cells, Barann et al., (1998) have reported that propofol inhibited maximally-evoked 5-HT currents with an IC<sub>50</sub> of 56μM; these data are in agreement with the inhibitory effect observed on 5-HT-evoked responses of the vagus nerve with higher concentrations of propofol.

Propofol (1-10μM) had little effect on α,β-meATP-evoked responses of the vagus nerve, but higher (≥30μM) concentrations of propofol inhibited these

*Chapter Three: Results, section 1, 86*
responses. In contrast, a recent voltage-clamp study by Furuya et al., (1999) has demonstrated that propofol (30-100\(\mu\)M) did not affect ATP-evoked responses on neuronal P\(_{2x}\) purinoceptors in a rat pheochromocytoma cell line. No other study has investigated the action of propofol on P\(_{2x}\) receptors in native neurones.

Propofol (1-10\(\mu\)M) had little effect on DMPP-evoked responses of the vagus nerve, but higher (\(\geq\)30\(\mu\)M) concentrations of propofol inhibited these responses. Watchtel and Wegrzynowicz (1992) and Dilger et al., (1994) have demonstrated, using voltage-clamped muscle-like clonal BC3H-1 cells expressing nACh receptors, that propofol (81\(\mu\)M and 25-250\(\mu\)M, respectively) inhibited these receptors by decreasing channel open time. In agreement, a recent voltage-clamp study by Furuya et al., (1999) also demonstrated that higher concentrations of propofol (30-100\(\mu\)M) inhibited neuronal nACh-receptor mediated responses recorded in a rat pheochromoctoma cell line (PC12). The data presented in this study, therefore, are in agreement with the data of Watchtel and Wegrzynowicz (1992), Dilger et al., (1994) and Furuya et al., (1999) who also report inhibition neuronal nACh-receptor mediated responses by propofol (>30\(\mu\)M).

However, two recent voltage-clamp studies of \(\alpha4\beta2\)-containing neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes revealed a concentration-dependent inhibition of acetylcholine-evoked currents by propofol with IC\(_{50}\) values of 4.5\(\mu\)M (Violet et al., 1997) and 19\(\mu\)M, (Flood et al., 1997). Moreover, Flood et al., (1997) also report that this propofol-induced inhibition did not occur in homomeric \(\alpha7\)-containing nicotinic acetylcholine receptors, suggesting that the inhibitory effect of propofol is subunit-dependent. The higher potency of propofol reported by Violet et al., (1997) and Flood et al., (1997) may be attributed to the use of recombinant neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes compared to native neuronal receptors, as in this study, and cell line preparations containing muscle type nicotinic acetylcholine receptors (Watchtel and Wegrzynowicz, 1992; Dilger et al., 1994) or neuronal nicotinic acetylcholine receptors (Furuya
et al., 1999). Additionally, the higher potency of propofol (Violet et al., 1997 and Flood et al., 1997) and may also be due to the reported subunit dependency of propofol (Flood et al., 1997).

Concentrations of propofol (10µM) which caused a maximal potentiation of GABA-evoked responses of the vagus nerve, evoked a marked potentiation of GABA-mediated responses (to 307% of control) and a modest potentiation (to 124% of control) of glycine-mediated responses of the optic nerve. Hales and Lambert (1991) also report a modest potentiation of glycine-evoked responses in cultured murine spinal neurones by propofol (8.4-16.8µM). However, in contrast Hara et al., (1994) report that propofol (1-5µM) had no effect on glycine-mediated responses of voltage-clamped, cultured hippocampal neurones. A possible explanation for this discrepancy may be attributed to the lower concentration of propofol employed by Hara et al., (1994) and/or the different preparations employed.

5.iv. Mefenamic acid potentiates the GABA-mediated response in the rat isolated vagus nerve.

The NSAID, mefenamic acid, also concentration-dependently potentiated submaximal GABA-evoked responses of the vagus nerve. These data are in agreement with Woodward et al., (1994) and Halliwell et al., (1994) who demonstrated that mefenamic acid concentration-dependently potentiated submaximal GABA-evoked currents in Xenopus oocytes and expressing rat brain mRNA and in voltage-clamped rat hippocampal neurones, respectively. However, both Woodward et al., (1994) and Halliwell et al., (1994) have reported higher levels of potentiation by mefenamic acid than those observed in the vagus nerve. Such differences in the potency and efficacy of mefenamic acid may be attributed to the use of different preparations. To further investigate the actions of mefenamic acid on native GABA<sub>A</sub> receptors its effects were determined on rat hippocampal neurones, using the whole-cell patch-clamp technique to record from single neurones maintained in culture.
CHAPTER THREE: RESULTS

Section 3.2

Electrophysiological and neuropharmacological properties of cultured rat embryonic rat hippocampal neurones

1. Introduction

The vagus and optic nerves have proved to be useful preparations for determining drug action at certain neuronal ligand-gated ion channels. However, in order to determine the precise mechanism/s of drug action at these receptor sites, the patch-clamp technique (Hamill et al., 1981) was employed. This technique allows the experimenter to make high fidelity recordings of agonist-evoked ion channel activity, whilst maintaining precise control over the neuronal membrane potential and the internal and external ionic environments of the cell. A directional perfusion system, used in conjunction with this technique, enables the experimenter to rapidly perfuse known concentrations of drugs in close proximity to the cell under investigation. Thus, further experiments investigating the action of fenamate NSAIDs on neuronal ligand-gated ion channels were performed utilising cultured rat hippocampal neurones, maintained under voltage-clamp conditions. This chapter details the physiological and pharmacological properties of whole-cell voltage-clamped hippocampal neurones maintained in culture (see methods).

2. Electrophysiological Characteristics of Hippocampal Neurones

Hippocampal neurones, maintained in culture and initially identified by their morphological characteristics, exhibited spontaneous synaptic activity when held under voltage- or current-clamp in normal bathing solution. This spontaneous activity was more pronounced when cells were bathed in Mg\(^{2+}\)-free bathing solution (see figure 4.1a). In addition, cells grown in Neurobasal media alone often exhibited marked spontaneous activity compared to cells.
Figure 4.1: Hippocampal neurones exhibit spontaneous activity which is inhibited by tetrodotoxin. The figure shows chart recorder traces of agonist-evoked currents in the presence and absence of TTX (0.3 μM). Trace a: shows NMDA-evoked currents recorded in Mg²⁺-free Bath solution. Note the high level of spontaneous activity at the beginning of the trace which is inhibited by TTX-containing bath solution (downward arrow); also note the reduction in response amplitude with decreasing NMDA exposure (agonist duration is indicated below arrows). Trace b: shows GABA-evoked currents recorded in Mg²⁺-containing Bath solution. Note the spontaneous activity at the beginning of the trace which is inhibited by the addition TTX-containing bath solution (downward arrows indicate the onset of perfusion of TTX-containing bath solution).
maintained in serum based media, perhaps due to the clumped distribution of neurones observed when using Neurobasal media (see Methods: figure 2.5). Routine addition of tetrodotoxin (TTX; 0.3μM) to the bathing solution either diminished or abolished this activity (figure 4.1a,b). Thus all recordings, unless otherwise stated, were made in the presence of TTX. From a random sample of hippocampal neurones investigated, the average resting membrane potential (Em) was found to be -59.5± 4mV (n=25). The average hippocampal cell membrane capacitance, series resistance, electrode resistance and membrane resistances, under the recording conditions described in Methods, were calculated from a random sample of 24 hippocampal neurones voltage-clamped at -60mV and are presented in the table below (table 4.1). An example of mean action current amplitude and duration from one cell is also given in this table whereby the amplitude and duration of 20 fast events were measured and averaged.

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean cell capacitance (pF)</td>
<td>26.7±5.6</td>
</tr>
<tr>
<td>Mean access resistance (MΩ)</td>
<td>10.5±0.6</td>
</tr>
<tr>
<td>Mean electrode resistance (MΩ)</td>
<td>2.1±0.06</td>
</tr>
<tr>
<td>Mean membrane resistance (MΩ)</td>
<td>8.4±0.54</td>
</tr>
<tr>
<td>Mean action current amplitude (pA)</td>
<td>3185</td>
</tr>
<tr>
<td>Mean action current rise time (ms)</td>
<td>0.024</td>
</tr>
</tbody>
</table>

**Table 4.1**: table shows mean cell membrane capacitance, series resistance, electrode resistance and membrane resistances calculated from a random sample of 24 cells. Mean action current amplitude and rise time from 20 fast events recorded from one cell is also given.

3. Procedures

Hippocampal neurones held under voltage-clamp at -60mV, unless otherwise stated, displayed rapid inward currents in response to pressure-
applied (10-100 millisecond pulses) GABA, glycine, NMDA (N-methyl-D-aspartate), AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate) and kainic acid. Agonist-evoked responses increased in amplitude with longer duration pulses of agonist exposure. At the beginning of each experiment, an agonist pulse duration was selected which was at most 10% of the maximum response obtainable. All drug effects were determined against submaximal agonist-evoked control responses and were perfused onto the cell until a maximal inhibitory or potentiating effect was observed. Upon removal of the drug, a series of control responses were obtained before further drug applications. The experimental protocol and data analysis were carried out as previously described (see Methods).

4. Results - Ligand-gated Anion Channels

4.i. Physiological and pharmacological properties of GABA-evoked currents

(a) I-V Relationship

GABA (10μM) pressure-applied (1.4kPa, at a rate of 0.02-0.03Hz and between 20-100ms in duration) to voltage-clamped hippocampal neurones (Vh=-60mV) evoked rapidly activating currents of 150-2400pA in amplitude in all cells tested (n=302 neurones; e.g. cell 2.16). The GABA whole-cell current-voltage relationship (I-V) for hippocampal neurones voltage-clamped between -100mV and +60mV was determined (using a CsCl-based internal and a normal external bathing solution as described in Methods). The GABA I-V (all responses were normalised to a holding potential of -60mV) showed outward rectification and reversed at 1.5 mV (n=4-20) (interpolated from the intercept of the curve on the x-axis using Graph Pad Prism Version 2.0a™); this value is consistent with the E_{(Cl)} predicted from the Nernst equation of 0mV with equal chloride across the membrane (figure 4.2).

(b) Pharmacology of the GABA_A receptor

Bicuculline (0.1-3μM), a competitive GABA_A receptor antagonist (e.g. Simmonds, 1982) concentration-dependently and reversibly inhibited
Figure 4.2: The GABA-evoked whole-cell current-voltage relationship for voltage-clamped hippocampal neurones. Left: shows actual chart recorder traces of single GABA (10 μM)-evoked currents recorded over a range of holding potentials given to the right of the currents (cell 3.75). Right: the graph shows the GABA-evoked current amplitude (normalized to a holding potential of -60mV; I, on the ordinate, in pA) plotted against the holding potential (Vh, on the abscissa, in mV). The GABA current reversed direction at 1.5 mV and displayed outward rectification. Each data point represents the mean±s.e.m (represented by the vertical bars) of 4-20 experiments.
submaximal GABA (10μM)-evoked whole-cell currents. From a series of concentration-effect studies, an IC\(_{50}\) of 0.5μM was determined for bicuculline (figure 4.3).

Alphaxalone (0.1-3μM), propofol (1-10μM), loreclezole (3-30μM), diazepam (0.1-1μM), and sodium pentobarbitone (10-300μM) concentration-dependently potentiated submaximal GABA (10μM)-evoked currents with EC\(_{50}\) values of 4μM (2μM-7μM, n=2-4), 6μM (3μM-12μM, n=6-10), 4μM (1μM-16μM, n=4-11), 0.6μM (0.3μM-1.2μM, n=2-7) and 64μM (33μM-121μM, n=3-14), respectively (see figure 4.5).

The potency sequence for these modulators, in descending order is as follows: diazepam> alphaxalone = loreclezole > propofol > sodium pentobarbitone. Mean maximal potentiations ± s.e.m evoked by alphaxalone (10μM), propofol (10μM), loreclezole (10μM), diazepam (1μM), and sodium pentobarbitone (300μM) were 975% (n=2), 421±35% (n=10), 204±11% (n=6), 231±25% (n=11) and 393±30% (n=3), respectively. Additionally, alphaxalone (≥1μM), propofol (≥1μM), loreclezole (≥10μM) and sodium pentobarbitone (≥10μM), but not diazepam, activated an inward transmembrane current (see figure 4.4).

These data are in agreement with those of other investigators, although alphaxalone is usually reported to be more potent than determined here (e.g. Peters et al., 1988). Collectively these data are consistent with activation of a neuronal GABA\(_{A}\) receptor gated chloride ion channel.

4.ii. Physiological and pharmacological properties of glycine-evoked currents

Glycine (100μM) pressure-applied (1.4kPa, at a rate of 0.02-0.03Hz and between 20-130ms in duration) to voltage-clamped hippocampal neurones (Vh=-60mV) evoked rapidly activating currents of 100-1800pA in amplitude in all cells tested (n=14 neurones; e.g. cell 2.92).
Figure 4.3: Bicuculline antagonises GABA-evoked responses in whole-cell voltage-clamped hippocampal neurones. **Top:** Chart recorder trace of GABA (10µM)-evoked whole-cell currents recorded before, in the presence of and following removal of bicuculline (3µM). Drug contact time is indicated by the solid line above the trace. **Bottom:** Graph shows the log_{10} concentration of bicuculline (on the abscissa) plotted against GABA-evoked current, as percent of control on the ordinate. Each data point represents the mean ± s.e.m of 3-6 experiments (represented by the vertical lines).
Figure 4.4: Positive allosteric modulation of GABA-evoked whole-cell currents in voltage-clamped rat hippocampal neurones. Chart recorder traces of submaximal GABA-evoked responses (Vh=-60mV) potentiated by alphaxalone (1µM), diazepam (0.1µM), propofol (1µM), loreclezole (10µM) and sodium pentobarbitone (30µM). All of the modulators shown, except diazepam, evoke a small transmembrane current. Drug contact time is represented by the solid line above each trace. Each chart recorder trace is recorded from a different neuron.
Figure 4.5: Positive allosteric modulation of GABA-evoked responses in whole-cell voltage-clamped hippocampal neurones. Graph shows the log_{10} concentration of modulator (on the abscissa) plotted against GABA-evoked current, as percent of control on the ordinate. Each data point represents the mean ± s.e.m (represented by the vertical lines) of 2-14 experiments.
(a) Pharmacology of the glycine receptor

Strychnine (0.1 and 0.3μM), a potent glycine receptor antagonist (e.g. Simmonds, 1983) concentration-dependently and reversibly inhibited submaximal glycine-evoked (100μM) whole-cell currents. Strychnine (0.1μM) reversibly inhibited submaximal glycine-evoked (100μM) whole-cell currents to 17±5% (n=4). Strychnine (0.3μM) reversibly inhibited submaximal glycine-evoked (100μM) whole-cell currents to 5±4% (n=3) of control. (figure 4.6).

5. Results- Ligand-gated Cation Channels

Ionotropic Glutamate Receptors

5.i. Physiological and pharmacological properties of NMDA-evoked currents

(a) I-V Relationship

NMDA (100μM) pressure-applied (1.4kPa, at a rate of 0.02-0.03Hz and between 15-120ms in duration) to voltage-clamped hippocampal neurones (Vh=-60mV) evoked rapidly activating currents of 180-1280pA in amplitude in all cells tested (n=21 neurones; e.g. cell 9.2). The whole-cell NMDA current-voltage relationship for hippocampal neurones voltage-clamped between -100mV and +40mV was determined in the absence (n=6) and presence (n=4) of Mg²⁺ (2mM). In the absence of Mg²⁺, NMDA-evoked currents varied in an approximately linear fashion over a range of holding potentials. Mg²⁺ blocked the NMDA-gated channel in a voltage-dependent manner with current flow being reduced at negative holding potentials, and a region of negative slope conductance occurring between -40 and -80mV (figure 4.7).

(b) Pharmacology of the NMDA-gated receptor

In agreement with Johnston and Ascher (1987), NMDA-evoked currents were potentiated by glycine (1μM) to 228±20% of control (n=8). Glycine is thought to act as a co-agonist for the NMDA receptor, thus glycine (1μM) was routinely added to the external bathing solution when recording NMDA-evoked currents (see Methods). The competitive NMDA receptor antagonist D-APV
Figure 4.6: Strychnine inhibits glycine-evoked responses in voltage-clamped hippocampal neurones. Top: shows chart recorder traces of glycine (100μM)-evoked whole-cell currents (Vh=-60mV) before (left), in the presence of (middle) and following removal of (right) strychnine (0.1μM). Bottom: histogram summarising the inhibitory effect of strychnine (0.1, 0.3μM) on submaximal (100μM) glycine-evoked responses. Each data point represents the mean ± s.e.m of 3-4 experiments (represented by the vertical lines).
Figure 4.7: The NMDA-evoked whole-cell current-voltage relationship for voltage-clamped hippocampal neurones. Left: shows actual chart recorder traces of single NMDA (100μM)-evoked currents recorded over a range of holding potentials (given to the right of the currents) in the absence and presence of Mg²⁺ (2mM). Right: the graph shows the NMDA-evoked current amplitude (I; on the ordinate, in pA), in the absence (■) and presence (▲) of Mg²⁺(2mM), plotted against the holding potential (Vh; on the abscissa, in mV). Each data point represents the mean ± s.e.m (represented by the vertical bars) of 4-6 experiments.
(0.1-10μM), (Evans et al., 1982) concentration-dependently and reversibly inhibited submaximal NMDA-evoked (100μM) whole-cell currents.

From a series of concentration-effect studies, D-APV (0.1-10μM) reversibly inhibited submaximal NMDA-evoked (100μM) currents with an IC$_{50}$ of 0.15μM (figure 4.8).

5.ii Physiological and pharmacological properties of AMPA-evoked currents

(a) I-V Relationship

AMPA (100μM), pressure-applied (1.4kPa, at a rate of 0.02-0.03Hz and between 15-85ms in duration) to voltage-clamped hippocampal neurones (Vh=-60mV) evoked rapidly activating currents of 220-860pA in amplitude all cells tested (n=4 neurones; e.g. cell 3.31). The AMPA current-voltage relationship for hippocampal neurones whole-cell voltage-clamped between -100mV and +100mV revealed an approximately linear relationship (figure 4.9).

(b) Pharmacology of the AMPA-gated receptor

The competitive AMPA/kainate receptor antagonist CNQX (3 and 10μM), (Stein et al., 1992) concentration-dependently and reversibly inhibited submaximal AMPA-evoked (100μM) whole-cell currents to 31±3% (n=5) and 6±3% (n=5) of control, respectively (figure 4.10).

5.iii. Physiological and pharmacological properties of kainic acid-evoked currents

(a) I-V Relationship

Kainate (100μM), pressure-applied (1.4kPa, at a rate of 0.02-0.03Hz and between 20-150ms in duration) to voltage-clamped hippocampal neurones (Vh=-60mV) evoked rapidly activating currents of 180-960pA in amplitude all cells tested (n=9 neurones; e.g. cell 2.130). The kainate current-voltage
Figure 4.8: (D)-APV antagonises NMDA-evoked responses in voltage-clamped hippocampal neurones. Top: shows actual chart recorder traces of single NMDA (100 μM)-evoked whole-cell currents (Vh= -60mV) before (left), in the presence of (middle) and following removal of (right) (D)-APV (1 μM). Bottom: the graph shows the log₁₀ concentration of (D)-APV (on the abscissa) plotted against the NMDA-evoked current, as percent of control on the ordinate. Each data point represents the mean ± s.e.m of 3-4 experiments (represented by the vertical lines).
Figure 4.9: The AMPA-evoked whole-cell current-voltage relationship for voltage-clamped hippocampal neurones. **Left:** shows actual chart recorder traces of AMPA (100μM)-evoked currents recorded over a range of holding potentials (given to the right of the currents). **Right:** Graph shows the AMPA-evoked current amplitude (normalized to a holding potential of -60mV; I, on the ordinate, in pA) plotted against holding potential (Vh, on the abscissa, in mV). The AMPA current reversed direction at 0.75 mV and was approximately linear between -100mV and +100mV. Each data point represents the mean of 2 experiments.
Figure 4.10: CNQX inhibits AMPA-evoked responses in whole-cell voltage-clamped hippocampal neurones. Top: shows actual chart recorder traces of AMPA (100\(\mu\)M)-evoked whole-cell currents (Vh= -60mV) before (left), in the presence of (middle) and following removal of (right) CNQX (3\(\mu\)M). Bottom: histogram summarising the inhibitory effect of CNQX (3,10\(\mu\)M) on submaximal (100\(\mu\)M) AMPA-evoked responses. Each data point represents the mean ± s.e.m of 4-5 experiments (represented by the vertical lines).
relationship for hippocampal neurones whole-cell voltage-clamped between -100mV and +60mV revealed an approximately linear relationship (figure 4.11).

(b) Pharmacology of the kainate-gated receptor

The competitive AMPA/kainate receptor antagonist CNQX (1-10μM), (Stein et al., 1992) concentration-dependently and reversibly inhibited submaximal kainic acid-evoked (100μM) whole-cell currents. From a series of concentration-effect studies CNQX (1-10μM) reversibly inhibited submaximal kainic acid-evoked (100μM) whole-cell currents. CNQX (1μM) inhibited kainic acid-evoked currents to 47% (n=1). CNQX (3μM) inhibited kainic acid-evoked currents to 33% (n=2) and CNQX (10μM) inhibited kainic acid-evoked currents to 9% (n=2) of control, respectively (figure 4.12).

6. Discussion

Those rat hippocampal neurones which were successfully maintained in culture were viewed under phase-contrast microscopy and visualized as phase-bright cells with pyramidal shaped cell-bodies. These cells were spontaneously active, in the absence of any external chemical or electrical stimuli, and responded to extracellularly applied agonists. These morphological and physiological characteristics are similar to those described by other investigators (Segal, 1983; Segal and Barker, 1984; Ozawa and Yuzaki, 1984; Valeyev et al., 1993, 1995).

GABA-evoked whole-cell responses from voltage-clamped rat hippocampal neurones were pharmacologically and physiologically consistent with the activation of a neuronal GABA\(_A\) receptor. For example, the GABA-evoked current was antagonized by bicuculline and potentiated by known positive allosteric modulators of the GABA\(_A\) receptor, such as pentobarbitone, alphaxalone, propofol and loreclezole. Similar observations have been made by other investigators recording GABA-evoked currents in voltage-clamped rat hippocampal neurones (e.g. Segal and Barker, 1984; Hara et al., 1994; Valeyev et al., 1995) and in other whole-cell voltage-clamp studies using neuronal

Chapter Three: Results: section 2, 95
Figure 4.11: The kainic acid-evoked whole-cell current-voltage relationship for voltage-clamped hippocampal neurones. Left: shows actual chart recorder traces of single kainic acid (100µM)-evoked currents recorded over a range of holding potentials, shown to the right of each current. Right: the graph shows the kainic acid-evoked current amplitude (normalized to a holding potential of -60mV; I, on the ordinate, in pA) plotted against holding potential (Vh, on the abscissa, in mV). The kainic acid current reversed direction at -6.2 mV and was approximately linear between -100mV and +100mV. Each data point represents 1 experiment.
Figure 4.12: CNQX antagonises kainic acid-evoked responses in whole-cell voltage-clamped hippocampal neurones. Top: shows actual chart recorder traces of kainic acid (100μM)-evoked whole-cell currents (Vh= -60mV) before (left), in the presence of (middle) and following removal of (right) CNQX (1μM). Bottom: the graph shows the log₁₀ concentration of CNQX (on the abscissa) plotted against the kainic acid-evoked current, as percent of control, on the ordinate. Each data point represents the mean of 1-2 experiments.
preparations (e.g. Peters et al., 1988; Wafford et al., 1994). The potency sequence in descending order of potency for these modulators was: diazepam > alphaxalone > loreclezole ≈ propofol > pentobarbitone. These data are in good agreement with the observations made in the rat vagus nerve.

Additionally, the GABA-evoked current reversed direction at 2.3mV; this value is consistent with the reversal potential of 0mV for the chloride ion, when chloride is equally distributed across the cell membrane. These data are in agreement with those of Segal and Barker, 1984; Ozawa and Yuzaki, 1984 and Valeyev et al., 1993.

Glycine-evoked whole-cell responses from voltage-clamped rat hippocampal neurones were pharmacologically and physiologically consistent with activation of a neuronal strychnine-sensitive glycine-gated chloride ion channel. For example, the glycine-evoked current was antagonized by strychnine. Similar observations have been made by other investigators recording glycine-evoked currents in voltage-clamped rat hippocampal neurones (e.g. Segal and Barker, 1984; Ito and Cherubini, 1991, Hara et al., 1994).

NMDA-evoked whole-cell responses from voltage-clamped rat hippocampal neurones were pharmacologically and physiologically consistent with activation of a neuronal ionotropic glutamate receptor. The NMDA-evoked current was antagonized by (D)-APV and potentiated by glycine in agreement with Evans et al., (1982) and Johnston and Ascher, (1987), respectively. The NMDA-IV plot was essentially linear between the holding potentials of -100mV and +40mV, but in the presence of Mg²⁺, a voltage-dependent inhibition of the NMDA-evoked current was observed at holding potentials more negative than -20 mV. These data are consistent with those of Nowak et al., (1984) and Mayer and Westbrook, (1985).

AMPA-evoked whole-cell responses from voltage-clamped rat hippocampal neurones were pharmacologically and physiologically consistent with activation of a neuronal ionotropic glutamate receptor. The AMPA-evoked current was antagonized by CNQX and produced an approximately linear I-V plot. These data are commensurate with the work of Stein et al., (1992) and Jonas et al., (1992).
Kainic acid-evoked whole-cell responses from voltage-clamped rat hippocampal neurones were pharmacologically and physiologically consistent with activation of a neuronal ionotropic glutamate receptor. In agreement with Stein et al., (1992) and Jonas et al., (1992), respectively, the kainic acid-evoked current was antagonized by CNQX and produced an approximately linear I-V plot.

These data support the use of hippocampal neurones and the whole-cell voltage-clamp recording technique for examining the mechanism and selectivity of action of drugs on neuronal ligand-gated ion channels.
CHAPTER THREE: RESULTS

Section 3.3: Determination on the effect, site and molecular mechanism of action of fenamates at neuronal GABA receptors

1. Introduction

Woodward et al., (1994) have reported a bi-directional modulation of GABA-evoked responses recorded from Xenopus oocytes injected with rat brain mRNA. Moreover, preliminary studies in native neurones, outlined in the previous chapter, revealed that mefenamic acid evoked a modest potentiation of GABA-evoked responses recorded from rat vagus nerves. In order to further investigate the site and mechanism underlying the effect of mefenamic acid on neuronal GABA receptors, experiments were conducted using whole-cell voltage-clamped hippocampal neurones.

2. Procedures

All hippocampal neurones in these experiments were voltage-clamped at -60mV, unless otherwise stated. Brief pressure application (20-100ms) of GABA to cells resulted in rapidly activating inward currents in all hippocampal neurones, with the amplitude increasing with longer pulses of GABA. All drug effects were determined against submaximal GABA-evoked responses and all responses were measured at their peak. All recordings were made in the presence of TTX (see Methods). Drugs were directionally perfused onto the cell until a maximal effect was observed. Upon removal of the drug, a further series of control responses were obtained before additional drug applications. The experimental protocol and data analysis were carried out as previously described (see Methods).
3. Results

3.1. Mefenamic acid potentiates GABA-evoked whole cell currents recorded in voltage-clamped hippocampal neurones

Mefenamic acid, sodium pentobarbitone and propofol (sodium pentobarbitone and propofol are shown for comparison) positively modulated GABA-evoked whole cell currents recorded from voltage-clamped hippocampal neurones. Mefenamic acid (3-100μM) concentration-dependently potentiated GABA-evoked response amplitude and duration. Similar observations were made for pentobarbitone (10-300μM) and propofol (1-10μM), although mefenamic acid was a more potent modulator than sodium pentobarbitone. The increase in response duration in the presence of mefenamic acid, sodium pentobarbitone and propofol was reflected in the percentage increase in the total charge passed during GABA-evoked responses. Mefenamic acid (3-100μM), sodium pentobarbitone (10-300μM) and propofol (1-10μM) also evoked a concentration-dependent transmembrane current. High concentrations of these drugs caused a rapid desensitisation of GABA-evoked currents, such that the response amplitude was often diminished in the continued presence of the drug (see figure 5.1).

Mefenamic acid (3-100μM) concentration-dependently and reversibly potentiated submaximal GABA-evoked whole-cell current amplitude with EC\textsubscript{50} value of 9μM (5-15μM, n=7-25) and a mean maximal potentiation of 337±44%, (n=19) with 30μM mefenamic acid. In contrast to experiments conducted in the vagus nerve, mefenamic acid was more potent than the general anaesthetic pentobarbitone (EC\textsubscript{50}=64μM), but consistent with the vagus nerve data, was less potent than the general anaesthetic propofol (EC\textsubscript{50}=6μM). However, also consistent with experiments conducted in the vagus nerve, pentobarbitone (300μM) evoked a higher mean maximal potentiation of GABA-activated currents (393±30 %, n=3) than mefenamic acid. (see figure 5.2).

These data demonstrate that mefenamic acid, with greater potency than pentobarbitone, concentration-dependently potentiated submaximal GABA-evoked responses in hippocampal neurones. The characteristics of this potentiation were similar to those observed for sodium pentobarbitone and

Chapter Three: Results: section 3, 99
Figure 5.1: Concentration-dependent potentiation of GABA-evoked responses by mefenamic acid. Chart recorder traces of submaximal GABA-evoked whole-cell currents concentration-dependently and reversibly potentiated by mefenamic acid (3-100\(\text{\textmu M}\)), the effects of propofol (10\(\text{\textmu M}\)) and sodium pentobarbitone (100\(\text{\textmu M}\)) are shown for comparison. 

a and b: Low concentrations of mefenamic acid (3-10\(\text{\textmu M}\)) evoked a marked and well maintained potentiation of submaximal GABA-evoked current amplitude and duration.

c: Peak potentiations of GABA-evoked currents were achieved with 30\(\text{\textmu M}\) mefenamic acid.

d: Higher concentrations of mefenamic acid (>100\(\text{\textmu M}\)) evoked a biphasic effect on submaximal GABA-evoked currents with a transient potentiation, followed by a reduction of the GABA response amplitude with the duration of the response remaining prolonged; this is reversible upon continued wash.

e and f: Propofol (10\(\text{\textmu M}\)) and sodium pentobarbitone (100\(\text{\textmu M}\)) also potentiated the GABA-evoked current amplitude and duration and evoked a transmembrane current. All cells were voltage-clamped at -60mV. Drug contact time is represented by the solid line above each trace. Recordings are taken from different cells.
Figure 5.2: Concentration-dependent potentiation of GABA-evoked responses by mefenamic acid, sodium pentobarbitone and propofol. Mean log concentration-effect curves for potentiation of GABA-evoked whole-cell current amplitude (a: filled symbols) and charge movement (b: open symbols) by mefenamic acid (3-100μM), sodium pentobarbitone (10-300μM) and propofol (1-10μM). The log_{10} concentration of modulator is plotted on the abscissa and the response, as a percentage of the control GABA response, is plotted on the ordinate. Each data point represents the mean±s.e.m (indicated by the vertical lines) of 7-25, 3-14 and 6-10, experiments for mefenamic acid, sodium pentobarbitone and propofol, respectively.
propofol. Experiments were therefore conducted to further investigate the site and mechanism of action of mefenamic acid on the GABA<sub>A</sub> receptor.

3.ii. Determination of the effects of non-fenamate NSAIDs on GABA-gated chloride channels in voltage-clamped hippocampal neurones.

Since mefenamic acid modulated GABA-evoked responses in voltage-clamped hippocampal neurones, the effects of other, non-fenamate, NSAIDs on these responses were determined to investigate the hypothesis that this modulation was a common property of all NSAIDs, perhaps related to their ability to inhibit cyclo-oxygenase activity and prostaglandin synthesis in the cell.

Submaximal GABA-evoked responses in the presence of the non-fenamate NSAIDs, ibuprofen (100|μM) and BPAA (100|μM) were 103±5% (n=3) and 92±6% (n=5) of control, respectively. However, indomethacin (100|μM), also a non-fenamate NSAID, did evoke a modest potentiation of GABA-mediated responses to 124±15% (n=3) of control (see figure 5.3).

3.iii. Modulation of GABA-evoked whole cell currents recorded in voltage-clamped hippocampal neurones by fenamate NSAIDs

Since mefenamic acid caused a significant modulation of GABA-evoked responses in voltage-clamped hippocampal neurones, the effects of other fenamate NSAIDs on these responses were determined to investigate the possibility that this modulation was a common property of fenamates.

The fenamate NSAIDs, mefenamic acid, (3-100|μM), flufenamic (3-1000|μM), meclofenamic (3-100|μM) and tolfenamic (3-100|μM), concentration-dependently potentiated submaximal GABA-evoked currents with EC<sub>50</sub> values of 9|μM (6-15|μM, n=7-25), 112|μM (90 - 220 |μM, n=1-5), 8|μM (2-21|μM, n=1-3) and 14|μM (5-38|μM, n=2-3), respectively. In addition, mefenamic acid, flufenamic, meclofenamic and tolfenamic (all at ≥3|μM) were associated with a concurrent baseline shift (20-720pA) similar to that observed for mefenamic

Chapter Three: Results: section 3, 100
Figure 5.3: The effect of 3 non-fenamate NSAIDs on GABA-evoked whole-cell currents. Top: shows chart recorder traces of submaximal (10μM) GABA-evoked responses in the absence (left), presence (middle) and following wash (right) of: a: ibuprofen (IBUP; 100μM), b: indomethacin (INDO; 100μM) and c: BPAA (100μM). Bottom: the histogram shows control (10μM) GABA-evoked responses in absence and then presence of indomethacin (100μM), ibuprofen (100μM) and BPAA (100μM). Each data point is the mean±s.e.m. (represented by the vertical bars) of 3, 3 and 5 experiments for ibuprofen, indomethacin and BPAA, respectively.
acid. Mean maximal potentiations induced by mefenamic acid (30\(\mu\)M), flufenamic (1000\(\mu\)M), meclofenamic (30\(\mu\)M) and tolfenamic (100\(\mu\)M) were 337 ±44% (n=19), 829±119% (n=2), 321 ±83% (n=2), and 524±153% (n=2), of control, respectively. In contrast, niflumic acid (10-100\(\mu\)M), concentration-dependently inhibited GABA-evoked currents with an IC_{50} of 16\(\mu\)M and was not associated with a baseline holding current shift (see figures 5.4 and 5.5).

The above experiments determined the effects of a series of NSAIDs on GABA-evoked responses of voltage-clamped hippocampal neurones and demonstrated that modulation of GABA-evoked responses is not a general property of NSAIDs, but is particular to fenamate NSAIDs. Thus, the following series of experiments were conducted to determine the site and molecular mechanism of action of one fenamate NSAID in particular, mefenamic acid. The inhibitory effects of niflumic acid were also investigated and will be discussed later.

3.iv. The potentiating effects of mefenamic acid are not mediated via the benzodiazepine site of the GABA_A receptor.

Potentiation of the GABA-evoked response by mefenamic acid may be mediated through the benzodiazepine site of the GABA_A receptor. To address this hypothesis, the potentiating effects of mefenamic acid and diazepam were determined in the presence of the benzodiazepine antagonist, flumazenil.

Flumazenil alone (1\(\mu\)M) was without effect on the GABA-evoked current (106% of control, n=1), but reversed the potentiation of GABA-evoked currents by diazepam (1\(\mu\)M) from 208.5±8.5% (n=2) to 100% (n=2) of control. In contrast, the presence of flumazenil (1\(\mu\)M) did not inhibit the potentiating effects of mefenamic acid (10\(\mu\)M, n=2), but rather increased the potentiation evoked by mefenamic acid (10\(\mu\)M) from 173±2% (n=2) to 236.5±96.5% (n=2) of control (see figure 5.6). All drug effects were reversible upon wash.

These data may indicate that the potentiation of GABA-evoked responses by mefenamic acid is probably not mediated via the benzodiazepine site of the GABA_A receptor. However, given the variable sensitivity of

*Chapter Three: Results: section 3, 101*
Figure 5.4: Fenamate NSAIDs modulate GABA-evoked whole-cell currents in voltage-clamped hippocampal neurons. Chart recorder traces of submaximal GABA (10μM)-evoked currents are shown in the absence, presence and following wash of, for example, tolfenamic acid (a: 3μM; b: 10μM and c: 30μM) and niflumic acid (d: 10μM). Drug contact time is represented by the solid bar above each trace. Tolfenamic acid concentration-dependently and reversibly potentiates submaximal GABA-evoked currents. Note the transmembrane current evoked by tolfenamic acid in traces b and c. Trace d: Niflumic acid does not evoke a transmembrane current and irreversibly inhibits the GABA-evoked current. Traces a and b are taken from one cell, traces c and d are from different cells.
Figure 5.5: Modulation of GABA-evoked responses by fenamate NSAIDs. Graph shows mean log concentration-effect curves for submaximal GABA (10μM)-evoked whole cell responses in voltage-clamped hippocampal neurones by mefenamic acid (1-100μM), flufenamic acid (3-1000μM), meclofenamic acid (3-100μM), tolfenamic acid (3-100μM) and niflumic acid (10-100μM). The log_{10} concentration of fenamate is shown on the abscissa and the GABA response, as a percentage of control, is shown on the ordinate. Each data point represents the mean±s.e.m (represented by the vertical lines) of 7-25, 1-5, 1-3, 1-4 and 1-5 experiments for mefenamic, flufenamic, meclofenamic acid, tolfenamic and niflumic acid, respectively.
Figure 5.6: Mefenamic acid-induced potentiation of GABA-evoked currents is not reversed by the benzodiazepine antagonist, flumazenil. **Top:** Chart recorder traces of submaximal GABA-evoked whole-cell currents (voltage clamped at, $V_h=-60mV$) potentiated by mefenamic acid (10μM) are shown in the absence (left half) and presence of flumazenil (1μM; right half); traces are from the same cell. **Bottom:** Histogram shows control GABA (10μM)-evoked whole-cell currents potentiated by diazepam (1μM) and mefenamic acid (10μM) are shown in the absence (control) and presence of flumazenil (1μM) as indicated in the key. Each data point represents the mean ± s.e.m (represented by the vertical lines) of 3 experiments for mefenamic acid, and the mean of 2 experiments for diazepam.
hippocampal neurones to the potentiating effects of mefenamic acid, these data do not disprove an involvement of the benzodiazepine site over the potentiating effects of mefenamic acid on the GABA<sub>A</sub> receptor.

3.v. The potentiating effects of mefenamic acid are not due to GABA uptake inhibition

GABA-uptake inhibitors have been shown to have anti-convulsant properties (e.g. Suzdak et al., 1992). They are thought to exert these effects by prolonging the duration of inhibitory post-synaptic potentials in neurones by elevating GABA levels at nerve terminals. In order to determine if the potentiating effects of mefenamic acid on GABA-evoked currents were due to inhibition of GABA uptake by mefenamic acid, the effects of two GABA uptake inhibitors, namely nipecotic acid and NNC-711, were examined on GABA-evoked currents. NNC-711, is a lipophilic derivative of nipecotic acid which is a selective and potent inhibitor of the GAT-1 transporter (Borden et al., 1994). The classical GABA-uptake inhibitor, nipecotic acid, is a hydrophilic compound which is less potent and less selective than NNC-711 (nipecotic acid can interact with L-proline and pipecolic acid, Krogsgaard-Larsen et al., 1975) and in addition, can act as substrate for the GABA-transporter potentially complicating the interpretation of pharmacological data (Krogsgaard-Larsen et al., 1994).

Application of nipecotic acid (100μM) or NNC-7111 (3nM), at concentrations 3 fold greater than their IC<sub>50</sub> values in binding experiments (33μM and 1.2μM, respectively, Suzdak et al., 1992), did not mimic the potentiating effects of mefenamic acid on GABA-evoked responses. In the presence of nipecotic acid and NNC-711, GABA currents were 111% (n=2) and 105% (n=2) of control, respectively. However, both compounds did produce a small background current (both between 30-40pA, n=2) and a concurrent increase in baseline noise levels (see figure 5.7). All drug effects were reversible upon wash.

These data suggest that the potentiating effects of mefenamic acid are not due to inhibition of GABA uptake.

Chapter Three: Results: section 3, 102
Figure 5.7: Mefenamic acid-induced potentiation of GABA-evoked currents is not via GABA-uptake inhibition. Left: Chart recorder traces of submaximal (10µM) GABA-evoked responses in the absence and presence of NNC-711 (3µM; top) and nipecotic acid (100 µM; bottom) are shown. Drug contact time is represented by the solid line above each trace. Traces were recorded from one cell. Right: histogram shows control (10µM) GABA-evoked responses in the presence of nipecotic acid (100µM) and NNC-711 (3µM). Each data point is the mean± s.e.m. (represented by the vertical bars) of 3 and 4 experiments for nipecotic acid and NNC-711, respectively.
3.vi. The potentiating effects of mefenamic acid are not due to membrane perturbation

Potentiation of the GABA-evoked response by mefenamic acid may be due to general membrane perturbation (i.e. changes in membrane fluidity), a hypothesis investigated for the action of neuroactive steroids of the GABA<sub>A</sub> receptor (Lambert, 1990). To address this hypothesis, a high concentration of mefenamic acid (1mM) was applied, via the patch electrode, to the inside of the cell membrane. Thus, mefenamic acid at (1mM) was added to the internal solution (see Methods) and the pH of this solution was adjusted to 7.2 by addition of concentrated hydrochloric acid. The effects of intracellularly applied mefenamic acid were investigated on the GABA-activated current after the whole-cell configuration of the voltage-clamp had been obtained for a period of 71 seconds, when diffusional exchange between the recording pipette solution and the cell interior had occurred (see Methods).

The intracellular application of mefenamic acid (1mM) did not inhibit activation of a GABA-evoked response; this response was characteristic of a control GABA-evoked response in the absence of intracellularly applied mefenamic acid. For example, in cells containing mefenamic acid, 30ms pulses of GABA produced whole-cell currents of 400pA in amplitude (n=2), comparable with those GABA-evoked responses observed under normal recording conditions (see Results, section 2, page 88). Moreover, application of mefenamic acid (10µM) to the external membrane surface of these cells evoked potentiations of GABA currents to 203% (n=2) of control. (see figure 5.8). The enhancement of the GABA-evoked response was in keeping with those previously observed when mefenamic acid (10µM) was applied only externally (225±18%, of control, n=25).

The finding that mefenamic acid applied intracellularly had little or no effect on the GABA-activated current, or its ability to enhance GABA responses when applied extracellularly, may be indicative of the existence of an extracellular recognition site existing for mefenamic acid. However, since mefenamic acid is lipid soluble, the final concentration of mefenamic acid achieved intracellularly may be considerably less than 1mM, if mefenamic acid

Chapter Three: Results: section 3, 103
Figure 5.8: The potentiating effects of mefenamic acid are not due to membrane perturbation. Top: shows an actual chart recorder trace of GABA-evoked currents in the presence of mefenamic acid (1mM) applied intracellularly. Control GABA-evoked currents were obtained for a period of time, EQ (EQ=263 seconds), which was approximately 4 times in excess of the calculated period for diffusional exchange to occur (71 seconds, see Methods). Subsequent extracellular application of mefenamic acid (10μM; indicated by the middle arrow above the trace) potentiated the GABA-evoked response. Bottom: Histogram shows the relative potentiations of the GABA response evoked by mefenamic acid (10μM) in the presence (n=2) and absence (n=25) of intracellular mefenamic acid (1mM).
escapes across the cell membrane down its concentration gradient. These experiments cannot therefore convincingly discount a mefenamic acid-mediated membrane perturbation effect.

3.vii. The modulatory effects of niflumic acid and mefenamic acid are not use-dependent

A number of drugs which modulate neuronal ligand-gated ion channels are use-dependent. Such drugs require an agonist-evoked activation of the receptor-gated channel to occur before these drugs can exert their effects. For example, at the GABA\textsubscript{A} receptor, GABA must bind to its site on the receptor to open the ion channel before picrotoxin can bind and produce its blocking effects (Akaike et al., 1985). Similarly, for the most part, the NMDA-gated ionotropic glutamate receptor channel must be activated by NMDA before for MK-801 can produce its channel-blocking effects, although a small component of NMDA receptor blockade by MK-801 is by a non-use-dependent mechanism (Halliwell et al., 1989). It is generally thought that such “use-dependent” drugs may have their binding sites located within the ion channel itself.

Thus, the following experiments were conducted in order to investigate the hypothesis that mefenamic acid and niflumic acid may be exerting their modulatory effects at the GABA\textsubscript{A} receptor-gated chloride channel via a use-dependent mechanism.

3.vii. i. Procedures

Repeated pressure application of GABA (at a rate of 0.03Hz and pulse duration of 10-100ms) was suspended during niflumic acid or mefenamic acid perfusion onto the cell, held under voltage-clamp (V\textsubscript{h}=-60mV) for a predetermined period of time. This time was determined by the time taken for the same or another fenamate drug (control), to achieved its maximum effect in the same cell. GABA application was then recommenced after this interval, whilst in the continued presence of the drug.

Chapter Three: Results: section 3, 104
Figure 5.9: Inhibition of GABA-evoked currents by niflumic acid is not use-dependent. Top: chart recorder trace showing submaximal GABA (10μM)-evoked currents in the presence of niflumic acid (100μM). The line above the trace indicates the drug contact time. The red arrows indicate the period during which GABA application was suspended whilst niflumic acid was perfused into the bath, following a pre-determined equilibrium period (the time required for another fenamate, flufenamic acid to exert its maximum effect). Bottom: graph shows GABA (10μM) response (in pA) plotted on the ordinate plotted against time (secs) on the abscissa. The red arrows indicate the time during which GABA application was suspended. The black arrows indicate the times at which a control drug, flufenamic acid (■) and niflumic acid (□) were applied and removed (wash).
Figure 5.10: Potentiation of GABA-evoked currents by mfenamic acid is not use-dependent. Top: chart recorder traces, a and b, showing submaximal GABA (10μM)-evoked currents in the presence of mfenamic acid (10μM). The line above each trace indicates the drug contact time. Trace b: the red arrows indicate the period during which GABA application was suspended whilst mfenamic acid was perfused into the bath, following a pre-determined equilibrium period (the time required for a previous application of mfenamic acid, trace a, to exert its maximum effect). Bottom: graph shows GABA (10μM) response (in pA) plotted on the ordinate plotted against time (secs) on the abscissa. The red arrows indicate the time during which GABA application was suspended. The black arrows indicate the times at which mfenamic acid (10μM) were applied and removed (wash), during continuous GABA application (●) and during interrupted GABA application (○). Each data point represents the mean of 2 experiments.
3.vii. ii. Results

Niflumic acid (10-100μM) concentration-dependently inhibited the GABA-evoked current. At higher concentrations (100μM) niflumic acid caused immediate inhibition of the GABA-evoked response, when GABA application was resumed (see figure 5.9).

Mefenamic acid concentration-dependently (3-10μM) potentiated the GABA-evoked responses. The potentiation of the GABA-evoked current by mefenamic acid occurred at the same time point as a previous application of mefenamic acid had produced a maximal potentiation. The potentiation of GABA-evoked responses from voltage-clamped rat hippocampal neurones was, therefore, not use-dependent (see figure 5.10).

3.viii. The potentiating effects of mefenamic acid are voltage-dependent

Mefenamic acid may exert its modulatory effects upon the GABA<sub>A</sub> receptor by a number of mechanisms, one of which could be to open other ion channels which may add to, or take away from, the GABA-evoked current. However, in these experiments, currents were measured only from the baseline and were therefore, GABA-evoked currents. Another mechanism for the potentiating effects of mefenamic acid, if they are mediated at a binding site within the chloride channel, is that mefenamic acid could change the membrane electric field and, thereby, change the GABA<sub>A</sub> receptor chloride channel permeability. If mefenamic acid does act at a site within the channel, it may exhibit some voltage-sensitivity or may change the Cl⁻ reversal potential.

3.viii. i. Procedures

Experiments were conducted to determine if the potentiating effects of mefenamic acid and propofol (for comparative purposes) on GABA-evoked currents altered the reversal potential of the GABA-evoked current and/or were voltage-sensitive. GABA-evoked whole-cell currents were recorded over a
range of holding potentials (-100 to +40mV) in the absence and presence of mefenamic acid (3\mu M) and propofol (1\mu M).

3.viii. ii. Results

Mefenamic acid potentiated the GABA-evoked currents throughout the range of holding potentials (-100 to +40mV) investigated. The $E_{Cl}$ was not significantly different in the presence of mefenamic acid when compared to control. However, the potentiating effects of mefenamic acid did exhibit voltage-sensitivity, with those GABA responses recorded at more negative holding potentials being potentiated to a larger degree than those recorded at more positive holding potentials (see figure 5.11 and 5.12).

3.ix. Mefenamic acid directly activates the GABA$_A$ receptor

In studies investigating the potentiating effects of mefenamic acid on GABA-evoked currents, perfusion of mefenamic acid (3-300\mu M) also resulted in the development of an inward current associated with application of the drug and also proportional to its concentration.

Previous studies have shown that the positive allosteric modulators of the GABA$_A$ receptor, including pentobarbitone, propofol, alphaxalone and loreclezole are also able to directly activate the GABA$_A$ receptor in the absence of GABA. The hypothesis that mefenamic acid also directly activated the GABA$_A$ receptor in voltage-clamped rat hippocampal neurones was therefore addressed.

3.ix. i. Procedures

Mefenamic acid (100\mu M), in the absence of GABA, was spritzer-applied to the cell at a duration of 20ms, once per minute. Higher concentrations of mefenamic acid (1mM), applied at this rate and duration, evoked currents which diminished in amplitude over time. The concentration of mefenamic acid and

*Chapter Three: Results: section 3, 106*
Figure 5.11: Potentiation of the GABA response by mefenamic acid shows voltage-sensitivity. Chart recorder traces of submaximal GABA (10μM)-evoked responses in the absence and presence of (left) mefenamic acid (3μM) and (right) propofol (1μM), recorded over a range of holding potentials (given to the right of the individual currents).
Figure 5.12: Potentiation of the GABA response by mefenamic acid, but not propofol, shows voltage-sensitivity. Histograms show the potentiation of submaximal GABA (10μM)-evoked responses by propofol (1μM; top) and mefenamic acid (3μM; bottom). Responses in the presence of drugs are expressed as the percentage of the control GABA-evoked response, normalized to a holding potential of -60mV. Each data point represents the mean±s.e.m (represented by the vertical lines) of 2-4 and 2-3 experiments for propofol and mefenamic acid, respectively.
rate of application were, therefore, predetermined to minimize this current "rundown". The current-voltage relationship for mefenamic acid-activated whole-cell currents in hippocampal neurones, voltage-clamped between -100mV and +40mV was determined (using a CsCl-based internal and a normal external bathing solution as described in Methods).

3.ix. ii. Results - **Mefenamic acid alone activates an inward current**

Repeated pressure application of mefenamic acid (1mM), in the absence of exogenously applied GABA, evoked inward currents which "ran down" over time. Repeated pressure application of mefenamic acid (100μM), in the absence of exogenously applied GABA, evoked inward currents which were stable over time. These currents were inhibited by bicuculline (3μM, n=1) to 12% of control and potentiated by sodium pentobarbitone at 30μM to 210±8% (n=3). Mefenamic acid-induced currents were also potentiated by propofol (10μM) to 200% of control (n=2), by loreclezole (10μM) to 196% of control (n=2), by diazepam (1μM) to 160% of control (n=1), and by alphaxalone (0.3μM) to 225% of control (n=1) (figure 5.13). All drug effects on mefenamic acid-induced currents were reversible upon wash.

3.ix. iii. **Current-voltage relationship of mefenamic acid-activated currents**

Mefenamic acid (100μM) activated a whole-cell current in hippocampal neurones voltage-clamped between -100 to +40mV. Mefenamic acid-induced currents had a reversal potential of 1.9mV (interpolated from the intercept of the curve on the x-axis). This value which was similar to the reversal potential calculated for GABA (2.3mV) with equal chloride across the membrane. The I-V plot for mefenamic acid exhibited outward rectification, also similar to that observed for GABA (see figure 5.14).
Figure 5.13: Mefenamic acid evokes an inward current in the absence of GABA which is modulated by drugs which modulate the GABA_A receptor. Left: chart recorder traces showing mefenamic acid (100μM)-evoked currents in the absence (left) and presence (middle) and following wash (right) of bicuculline (trace a: 10μM) sodium pentobarbitone (trace b: PB; 30μM) and loreclezole (trace c: 10μM). Right: histogram shows control mefenamic acid (100μM)-evoked currents in the presence of bicuculline (10μM), sodium pentobarbitone (30μM), propofol (10μM), loreclezole (10μM), diazepam (1μM) and alphaxalone (0.3μM). Each bar represents 1 data point for bicuculline, diazepam and alphaxalone, 2 data points for propofol and loreclezole and 3 data points for sodium pentobarbitone (mean±s.e.m, represented by the vertical line).
Figure 5.14: The mefenamic acid-evoked whole-cell current for voltage-clamped hippocampal neurones. Left: chart recorder traces of mefenamic acid (100 μM)-evoked currents recorded over a range of holding potentials (given to the right of the current). Right: graph shows the mefenamic acid-evoked current (I in pA, on the ordinate), plotted against the holding potential (Vh, in mV on the abscissa). The mefenamic acid-evoked current reversed at +1.9mV and showed outward rectification. Data points represent the mean of 2 experiments.
3.x. Sensitivity to the modulatory effects of mefenamic acid varies across hippocampal neurones.

Neuronal sensitivity to mefenamic acid (30μM) varied with peak potentiations ranging between 125% and 909%; these data may indicate a subunit selective property of mefenamic acid, which would be concomitant with the observations of Halliwell et al., (in press). Loreclezole has been also been reported to be subunit selective, (Wafford et al., 1994).

In addition, a small number of all cells tested were relatively insensitive to potentiation by mefenamic acid and loreclezole (n=2) but were potentiated, for example, by diazepam (1μM) to 194 % of control (n=1) or sodium pentobarbitone (30μM) to 238% of control (n=1). Mefenamic acid and loreclezole, therefore, have similar characteristic modulatory effects on GABA-evoked responses in hippocampal neurones (see figure 5.15).

3.xi. Mefenamic acid acts at or shares a recognition site with loreclezole

The similarities between the modulatory effects of mefenamic acid and loreclezole in hippocampal neurones may suggest that these drugs are acting at a single or shared recognition site on the GABA_A receptor. To address this hypothesis, the following series of experiments were carried out.

Concentrations of mefenamic acid and loreclezole which evoked maximal potentiations of (submaximal) GABA-evoked responses were previously determined in each cell. The peak potentiations evoked by mefenamic acid (10μM), followed by loreclezole (10μM) were thus determined individually and when co-applied. Peak potentiations evoked by mefenamic acid (10μM) and loreclezole (10μM) were determined individually and found to be 205% (n=2) and 277% (n=2) of control, respectively. When co applied, the peak potentiation evoked by both mefenamic acid and loreclezole, was 237% of control (n=2).

In addition, the peak potentiations evoked by mefenamic acid (10μM), followed by propofol (10μM) were determined individually and when co-applied. Peak potentiations evoked by mefenamic acid (10μM) and propofol (10μM)
Figure 5.15: Some cells are relatively insensitive to modulation by mefenamic acid and loreclezole. Left: shows actual chart recorder traces of submaximal GABA (10μM)-evoked currents taken from one voltage-clamped hippocampal neurone (cell 1), in the absence (left-hand responses), presence (middle responses) and following wash (right-hand responses) of loreclezole (3μM; trace a), diazepam (1μM; trace b) and mefenamic acid (3μM; trace c). Note potentiation of the GABA-evoked response by diazepam, but not mefenamic acid or loreclezole. Top Right: histogram shows the modulation of submaximal GABA (10μM)-evoked currents in cell 1 by diazepam (1μM), but little modulation by mefenamic acid (3μM) or loreclezole (3μM). Bottom Right: histogram shows the modulation of submaximal GABA (10μM)-evoked currents by sodium pentobarbitone (30μM), but little modulation by mefenamic acid (30μM) or loreclezole (30μM) in cell 2. Data are taken from two different cells as shown in the key.
were determined individually and found to be 312% (n=1) and 420% (n=1) of control, respectively. When co applied, the peak potentiation evoked by both mefenamic acid and propofol, was 375% of control (n=1).

Similarly, the peak potentiations evoked by mefenamic acid (10μM), followed by sodium pentobarbitone (100μM) were determined individually and when co-applied. Peak potentiations evoked by mefenamic acid (10μM) and sodium pentobarbitone (100μM) were determined individually and found to be 259% (n=2) and 387% (n=2) of control, respectively. When co applied, the peak potentiation evoked by both mefenamic acid and sodium pentobarbitone, was 277% of control (n=2). (see figure 5.16)

The potentiating effects of mefenamic acid together with loreclezole, at concentrations which evoked maximal potentiations, were not additive when applied together. Under similar recording conditions, the potentiations evoked by mefenamic acid together with propofol or pentobarbitone, at concentrations which evoked maximal potentiations, were also not additive when co-applied. Although all drug effects were determined against submaximal GABA-evoked responses in hippocampal neurones, these data suggest that the non-additive potentiations of loreclezole, propofol and pentobarbitone together with mefenamic acid, are most likely reaching the ceiling of the available potentiation of the GABA-evoked responses in this recording system.

4. Summary - modulation of GABA-evoked responses in hippocampal neurones by mefenamic acid.

Mefenamic acid evoked a complex change in the characteristics of the GABA-evoked response recorded from rat hippocampal neurones. Submaximal GABA-evoked responses were concentration-dependently and reversibly potentiated in both amplitude and duration by mefenamic acid. The maximal potentiations evoked by mefenamic acid (30μM) and loreclezole (10μM) ranged from 125% to 909% and 149 to 349 % of control, respectively.

In addition to its potentiating effects, at concentrations ≥10μM, mefenamic acid evoked a concentration-dependent inward transmembrane
Figure 5.16: The potentiating effects of mefenamic acid together with loreclezole or propofol or pentobarbitone, at concentrations which evoked maximal potentiations, were not additive when applied together. Histograms show the potentiation of submaximal GABA (10µM)-evoked responses by mefenamic acid (10µM), propofol (10µM), sodium pentobarbitone (100µM) and loreclezole (10µM) alone, and the additive potentiations of mefenamic acid (10µM) when co-applied with propofol (A. 10µM, n=1), sodium pentobarbitone (B. 100µM, n=2) and loreclezole (C. 10µM, n=2). An explanatory key is shown above each histogram. Actual chart recorder of GABA-evoked responses potentiated by loreclezole (trace a: 10µM) and mefenamic acid (trace b: 10µM) applied alone and in combination (trace c), are shown above histogram C.
current. The mefenamic acid-activated current, evoked in the absence of GABA, showed a similar current-voltage relationship and reversed at a value similar to that of GABA.

The effects of mefenamic acid were not mimicked by other non-fenamate NSAIDs, such as BPAA, indomethacin or ibuprofen, although indomethacin (100μM) did evoke a small potentiation of the GABA-evoked response.

GABA-evoked responses recorded from hippocampal neurones were modulated not only by mefenamic acid, but also by other fenamates. In descending order of potency, mefenamic> meclofenamic> flufenamic and tolfenamic acid, concentration-dependently and reversibly potentiated submaximal GABA-evoked currents. The potentiation of GABA-evoked responses recorded from rat hippocampal neurones by mefenamic acid was not delayed by the interruption of GABA application, suggesting that the potentiating effects of mefenamic acid are not use-dependent.

In contrast, niflumic acid concentration-dependently inhibited submaximal GABA-evoked responses. This inhibition could not be surmounted by increasing agonist exposure. Inhibition of the GABA-evoked responses by niflumic acid (100μM) was not delayed by the interruption of GABA application, suggesting that the inhibitory effects of niflumic acid are not use-dependent.

The potentiating effects of mefenamic acid were insensitive to the benzodiazepine antagonist, flumazenil.

The potentiating effects of mefenamic acid, loreclezole, propofol and pentobarbitone, at concentrations which evoked maximal potentions, were not additive when co-applied.

The GABA-uptake inhibitors, nipecotic acid and NNC-711 did not mimic the effects of mefenamic acid either qualitatively or quantitatively.

Intracellular application of mefenamic acid did not cause modulation of GABA-evoked responses recorded from voltage-clamped rat hippocampal neurones.

Mefenamic acid potentiated GABA-evoked responses recorded from rat hippocampal neurones in a voltage-sensitive manner without altering the reversal potential of the GABA-evoked current.

Chapter Three: Results: section 3,110
CHAPTER 4:

Determination of the effects of mefenamic acid on other neuronal ligand-gated ion channels

1. Introduction

NSAIDs exert a diverse range of effects within the CNS which include analgesic effects, anti-inflammatory effects, pro- and anti-convulsant effects and neuroprotective effects. It would therefore appear unlikely that such diverse effects are mediated entirely via inhibition of prostaglandin synthesis. Although many studies have examined the effects fenamates on a variety of non-neuronal preparations (see introduction), there is a paucity of data describing the effects of such drugs in neuronal preparations. Recently, Lerma and Del Rio (1992) report inhibition of NMDA-mediated currents in mouse spinal neurones and Chen et al., (1998) report neuroprotective effects of fenamates against the neurotoxic effects of glutamate and ischaemia.

In light of these observations and, furthermore, having determined that fenamates positively modulated GABA-mediated responses recorded from voltage-clamped rat hippocampal neurones, the action of mefenamic acid on a number of other neuronal ligand-gated ion channels was determined. Thus, the effects of mefenamic acid were investigated at another inhibitory ligand-gated ion channel, the strychnine-sensitive glycine receptor and also at the excitatory ligand-gated ion channels gated by NMDA, AMPA and kainic acid.

Additionally, the effects of propofol were also determined on glycine-evoked response in hippocampal neurones given the conflicting reports in the literature (Lambert et al., 1991; Hara et al., 1993; results chapter 1).

2. Methods

Hippocampal neurones held under voltage-clamp at -60mV, produced rapid inward currents in response to pressure-applied (10-100 millisecond pulses) agonists, namely, glycine, NMDA (N-methyl-D-aspartate), AMPA (α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionate) and kainic acid. Agonist-evoked responses increased in amplitude with increased duration of agonist exposure. Glycine-, NMDA-, AMPA- and kainic acid-evoked responses were antagonised by their respective antagonists, strychnine, (D)-AP5, CNQX and CNQX (see Results chapter 2). All drug effects were determined against submaximal agonist-evoked control responses. All responses were measured at their peak.

3. Results
3.i. Glycine

In voltage-clamped rat hippocampal neurones, mefenamic acid (10-30μM), had little effect on submaximal glycine-evoked responses (105±6%, n=3 and 101±10 %, n=3 of control, respectively). However, at these concentrations, mefenamic acid did evoke a large transmembrane current (80-1600pA). A higher concentration of mefenamic acid (100μM) evoked a large transmembrane current and inhibited the glycine-evoked current to 71% of control (n=1; see figures 6.1 and 6.2). Additionally, propofol (3,10μM), also had little effect on submaximal glycine-evoked responses (105±6%, n=3 and 101±10 %, n=3 of control, respectively). Propofol (3-10μM) also evoked a transmembrane current ranging between 160-960pA (see figure 6.3).

3.ii. NMDA

In voltage-clamped rat hippocampal neurones, mefenamic acid (30, 100 and 300μM) had little effect on submaximal NMDA-evoked responses (101±7%, n=4, 101±4 %, n=4 and 98±5 %, n=3 of control, respectively). However, at these concentrations, mefenamic acid did evoke a transmembrane current. Mefenamic acid (1000μM) inhibited the NMDA-evoked response to 26±2% of control, (n=3). The activation of the mefenamic acid-evoked transmembrane current could be inhibited by the competitive GABA<sub>A</sub> receptor antagonist, bicuculline (3-20μM). In some instances the mefenamic acid-evoked current
Figure 6.1: The effect of mefenamic acid on submaximal glycine-evoked currents in whole-cell voltage-clamped hippocampal neurones. The figure shows actual chart recorder traces of glycine (100µM)-evoked whole-cell currents recorded from hippocampal neurones in the absence, presence of (a: 10µM, b: 30µM and c: 100µM) mefenamic acid, and following washout. Note that perfusion of mefenamic acid is associated with a shift in baseline (holding current), which is concentration-dependent. Mefenamic acid at 10µM and 30µM, had little effect on the glycine current, but at 100µM, mefenamic acid causes an apparent inhibition of the glycine response which reverses upon wash. Recording (a) is from one neurone and recordings (b) and (c) are from a second neurone. The drug contact time is represented by the horizontal line above each recording.
Figure 6.2: The effect of mefenamic acid on glycine-evoked whole-cell currents recorded in voltage-clamped hippocampal neurones. Graph shows mean log concentration-effect curves for the action of mefenamic acid (10-100μM) on glycine (100μM)-evoked whole-cell currents. The log_{10} concentration of mefenamic acid is plotted on the abscissa and the response, as percentage of control agonist-evoked response, is plotted on the ordinate. Each data point represents the mean ± s.e.m (represented by the vertical bars) of 1-3 experiments.
Figure 6.3: The effect of propofol on submaximal glycine-evoked whole-cell currents. The figure shows actual chart recorder traces of glycine (100μM)-evoked whole-cell currents recorded from hippocampal neurones in the presence of 3μM (a) and 10μM (b) propofol. Note that the perfusion of propofol is associated with a shift in the baseline (holding) current, but has little or no effect on the glycine currents. Recordings a and b are taken from different neurones. Drug contact time is represented by the horizontal line above each trace.
could not be inhibited by low concentrations of bicuculline (3μM), in these cases higher concentrations of bicuculline (10-20μM) were employed to block/inhibit the mefenamic acid-evoked transmembrane current. In the presence of bicuculline (3-20μM), mefenamic acid (100μM) inhibited the NMDA-evoked response to 82±19% of control (n=3), compared to 101±4 (n=4), in the absence of bicuculline. In the presence of bicuculline (3-20μM), mefenamic acid (300μM) inhibited the NMDA-evoked response to 43±11% of control (n=3), compared to 98±5 (n=3), in the absence of bicuculline. The NMDA-evoked current was also inhibited by bicuculline (20μM) alone to 49% of control (n=1). (Figures 6.4 and 6.5).

3.iii. AMPA

In voltage-clamped rat hippocampal neurones, mefenamic acid (10-30μM) had little effect on submaximal (100μM) AMPA-evoked responses although at these concentrations (84±5%, n=4, and 90±15%, n=3 of control, respectively). However, at these concentrations mefenamic acid did evoke a transmembrane current (200 to 1800pA). Higher concentrations of mefenamic acid (100, 300 and 1000μM) evoked large transmembrane currents. At these concentrations, mefenamic acid caused an inhibition of these AMPA-evoked responses to 66±5%, n=4; 75%, n=2 and 57±3%, n=3 of control, respectively (figures 6.6 and 6.7).

3.iv. Kainate

In voltage-clamped rat hippocampal neurones, mefenamic acid (10, 30μM) had little effect on submaximal kainic acid-evoked responses (93%, n=2 and 75±15%, n=4 of control, respectively). At 100μM mefenamic acid inhibited the kainic acid-evoked response to 21±10% of control, n=3. However, mefenamic acid (10-100μM) did evoke a transmembrane current (190pA-3487pA) This transmembrane current could be inhibited by the competitive GABA<sub>A</sub> receptor antagonist, bicuculline (3-10μM). In the presence of bicuculline
Figure 6.4: The effects of mefenamic acid on submaximal NMDA-evoked currents in whole-cell voltage-clamped hippocampal neurones: chart recorder traces of NMDA (100μM)-evoked currents in the presence of mefenamic acid. Drug contact time is represented by the solid line above the trace. Traces a and b: mefenamic acid (30-100μM) evokes a concentration-dependent transmembrane current and a modest inhibition of NMDA-evoked currents. Trace c: A transmembrane current is evoked in the presence of mefenamic acid (100μM) and bicuculline (20μM) and an inhibition of the NMDA-evoked current is also seen. Trace d: The NMDA-evoked current is inhibited by bicuculline (20μM) alone. Recordings a and b are taken from one neurone; recordings c and d are taken from a second neurone.
Figure 6.5: The effect of mefenamic acid on NMDA-evoked whole-cell currents recorded in voltage-clamped hippocampal neurones. Graph shows: mean log concentration-effect curves for action of mefenamic acid (30-1000μM) on NMDA (100μM)-evoked whole-cell currents in the absence (▲) and presence of bicuculline (■; 3-20μM). The logₖ concentration of mefenamic acid is plotted on the abscissa and the response, as percentage of control agonist-evoked response, is plotted on the ordinate. Each data point represents the mean ± s.e.m. (represented by the vertical lines) of 2-4 experiments.
Figure 6.6: The effect of mefenamic acid on submaximal AMPA-evoked currents in whole-cell voltage-clamped hippocampal neurones. The figure shows actual chart recorder traces of AMPA (100μM)-evoked whole-cell currents recorded from hippocampal neurones in the absence, presence of (a: 10μM, b: 30μM and c: 100μM) mefenamic acid and following washout. Note that perfusion of mefenamic acid is associated with a shift in the baseline (holding) current. Mefenamic acid at 10μM has little effect on the AMPA-evoked current, but with 30μM and 100μM, there is an apparent inhibition of the AMPA response which reverses upon wash. Drug contact time is represented by the solid line above each trace. Recordings are taken from the same cell.
Figure 6.7: The effect of mefenamic acid on AMPA-evoked whole-cell currents recorded in voltage-clamped hippocampal neurones. Graph shows: mean log concentration-effect curves for action of mefenamic acid (10-1000μM) on AMPA (100μM)-evoked whole-cell currents. The log₁₀ concentration of mefenamic acid is plotted on the abscissa and the response, as percentage of control agonist-evoked response, is plotted on the ordinate. Each data point represents the mean ± s.e.m. (represented by the vertical lines) of 2-4 experiments.
and mefenamic acid (30μM), the kainic acid-evoked current was 101% (n=2). In the presence of bicuculline and mefenamic acid (100μM), the kainic acid-evoked current was 78% (n=2) (Figures 6.8 and 6.9).

4. Summary- Specificity of action of mefenamic acid

No previous study has examined the selectivity of action of mefenamic acid on the major inhibitory and excitatory neuronal ligand gated ion channels. In this study, concentrations of mefenamic acid which evoked maximal potentiations of GABA-evoked currents had little or no effect on glycine-, NMDA-, AMPA- or kainic acid-evoked currents in voltage-clamped rat hippocampal neurones.

However, higher concentrations of mefenamic acid (≥100-1000μM) evoked a large transmembrane current and concentration-dependent inhibition of all these receptor-mediated response. Co-application of bicuculline (3-10μM), with higher concentrations of mefenamic acid, reduced or abolished this transmembrane current. In the presence of concentrations of bicuculline which blocked the mefenamic acid-induced transmembrane current, kainic acid-evoked currents were not inhibited by mefenamic acid. In contrast, in the presence of bicuculline, inhibition of the NMDA-evoked currents by mefenamic acid was greater.
Figure 6.8: The effects of mefenamic acid on submaximal kainic acid-evoked currents in whole-cell voltage-clamped hippocampal neurones. Chart recorder traces of kainic acid (100μM)-evoked currents in the presence of mefenamic acid. Drug contact time is represented by the solid line above each trace. Trace a: mefenamic acid (10μM) evokes a transmembrane current and has little effect on the amplitude of the kainic acid-evoked current. Traces b and c: mefenamic acid (30-100μM) evokes a transmembrane current and inhibits the amplitude of the kainic acid-evoked current. Trace d: in the presence of 100μM mefenamic acid and 3μM bicuculline, no transmembrane current is evoked and there is little effect on kainic acid-evoked current. Recordings a and b are taken from the same cell, recordings c and d are taken from different cells.
Figure 6.9: The effect of mefenamic acid on kainic acid-evoked whole-cell currents recorded in voltage-clamped hippocampal neurones. Graph shows: mean log concentration-effect curves for action of mefenamic acid (10-100μM) on kainic acid (100μM)-evoked whole-cell currents, in the absence (△) and presence of bicuculline (3-10μM, ■). The log₁₀ concentration of mefenamic acid is plotted on the abscissa and the response, as percentage of control agonist-evoked response, is plotted on the ordinate. Each data point represents the mean ± s.e.m. (represented by the vertical lines) of 2-4 experiments for mefenamic acid alone and the mean of 2 experiments for mefenamic acid in the presence of bicuculline.
General Discussion

The experiments described in this thesis set out to investigate the hypothesis that NSAIDs could affect neuronal function by directly modulating ligand-gated ion channel function. The rationale behind this hypothesis was based upon a number of observations. Briefly these were, firstly, that NSAIDs can produce analgesic effects even when administered directly into the CNS of rodents. Secondly, in humans, NSAIDs induce complex behavioral effects especially when taken in overdose and this appeared to be particularly true for the fenamate NSAID, mefenamic acid. Thirdly, two studies had demonstrated that the fenamate, mefenamic acid could modulate the function of GABA\textsubscript{A} receptors.

Initial investigations were therefore undertaken using a simple extracellular recording technique to record agonist-evoked responses from rat isolated vagus and optic nerves. To validate the use of the vagus nerve as a suitable preparation to investigate the possible effects of NSAIDs, the modulatory effects of several well characterized drugs were first investigated. Propofol, in particular, produced a marked potentiation of GABA-evoked responses of the vagus nerve. Since the selectivity of propofol on neuronal ligand-gated ion channels was unknown at the time of this study, it was investigated using the vagus and optic nerves.

1. The selectivity of action of propofol

The data presented in this thesis indicate that, at clinically relevant concentrations, propofol markedly potentiates GABA\textsubscript{A}-mediated responses, and in contrast, has little or no effect on 5-HT\textsubscript{3}, nACh- or P\textsubscript{2x} -mediated responses of the rat vagus nerve. At these concentrations, propofol also produced marked potentiations of GABA\textsubscript{A}-mediated responses and modest potentiations of glycine-mediated responses of the rat optic nerve. However, higher concentrations of propofol (up to 100\textmu M) inhibited 5-HT\textsubscript{3}, nACh- or P\textsubscript{2x} -mediated responses of the rat vagus nerve.
These data suggest that, at low concentrations, the actions of propofol in the vagus and optic nerves are most likely to be mediated at the GABA<sub>A</sub> receptor. If propofol is able to potentiate GABA-mediated responses in human brain at these low concentrations (which are probably close to those achieved during the induction and maintenance of anaesthesia), then the actions of propofol at human GABA<sub>A</sub> receptors in the CNS might be a significant contributing factor for the sedative and anaesthetic properties of propofol.

Although inhibition of the 5-HT<sub>3</sub> and nACh receptor channel may contribute towards the anaesthetic properties of propofol, the concentrations of propofol which have inhibitory effects at these receptors in native neurones are probably outside the therapeutic dose range (Machu and Harris, 1994; Barann et al., 1993, 1998; Watchtel and Wegrzynowicz, 1992; Dilger et al., 1994, 1995 and Furuya et al., 1999). Nonetheless, the small inhibitory actions of propofol (at higher concentrations) at 5-HT<sub>3</sub> and nACh receptors cannot be dismissed and may contribute to the anaesthetic actions and/or side effects observed with propofol-induced anaesthesia. Notably, Violet et al., (1997) have recently reported using *Xenopus* oocytes, that propofol inhibits neuronal-type recombinant nicotinic acetylcholine receptors with a greater potency than it does muscle-type recombinant nicotinic acetylcholine receptors. Further studies investigating the inhibitory actions of propofol on neuronal-type nicotinic acetylcholine receptors may elucidate contribution of these receptors to propofol-induced sedation or anaesthesia.

Administration of 5-HT<sub>3</sub> receptor antagonists do not produce drowsiness, motor impairment or cognitive deficits (Costall et al., 1990). Additionally, a scarcity of 5-HT<sub>3</sub> receptors in higher brain structures (Tyers, 1991; Tecott et al., 1993) has also been reported. These observations, together with the lack of modulation of homomeric murine 5-HT<sub>3</sub> receptors expressed in *Xenopus* oocytes by propofol, led Machu and Harris (1994) to the conclusion that the 5-HT<sub>3</sub> receptor does not play a major role in anesthesia. Antagonists of the 5-HT<sub>3</sub> receptor, such as ondansetron, are however known to produce anti-emetic effects (Leeser and Lip, 1991). The anti-emetic properties of propofol reported

*Chapter Five: General Discussion*, 116
by Borgeat et al., (1992, 1994a) might be attributed to inhibition of 5-HT$_3$ receptors, although other investigators have suggested that this is not the case since the inhibitory effects of propofol on 5-HT$_3$ receptors occurs at concentrations outside the therapeutic range (Appadu and Lambert, 1996). At present, the clinical relevance of the inhibitory effects of propofol at neuronal 5-HT$_3$ receptors remains unclear.

Similarly, concentrations of propofol which inhibit P$_{2x}$ receptor-mediated responses of the vagus nerve are also outside the therapeutic range. Furuya et al., (1999) have demonstrated that propofol, even at concentrations outside the therapeutic range, did not affect ATP-evoked responses on neuronal P$_{2x}$ purinoceptors in a rat pheochromocytoma cell line.

Propofol produced a marked potentiation of GABA-evoked responses and a modest potentiation of glycine-evoked responses in the rat optic nerve. At the time of this study there were 2 conflicting electrophysiological reports in the literature. Hales and Lambert, (1991) demonstrated that propofol produced a modest potentiation of glycine currents in murine spinal neurones. In contrast, Hara et al., (1994) demonstrated that propofol did not modulate glycine-evoked currents in primary dissociated hippocampal neurones. The actions of propofol were therefore examined on single cultured rat hippocampal neurones, maintained in culture, using the patch-clamp recording technique.

Notably, although propofol has been shown to potentiate glycine-evoked responses in murine spinal neurones (Hales and Lambert, 1991), in the present study propofol activated a transmembrane current, but did not modulate the glycine-evoked response in voltage-clamped rat hippocampal neurones maintained in culture. Similar observations were made by Hara et al., (1994) also using voltage-clamped acutely dissociated rat hippocampal neurones. The lack of potentiation of native glycine receptors in hippocampal neurons compared to the modest poteniations observed in native murine spinal neurones (Hales and Lambert, 1991), suggests that differences may exist.
between central and spinal glycine receptors. Consistent with this observation, the α and β subunits comprising glycine receptors exhibit distinctive expression patterns within the central nervous system (Malosio et al., 1991). Additionally, and similar to the GABA_A receptor, a number of receptor isoforms for the glycine receptor have been identified (α1-4) and shown to impart different biophysical and pharmacological properties upon the receptor (for review see Kuhse et al., 1995).

Notwithstanding, recent electrophysiological studies using recombinant glycine receptors expressed in Xenopus oocytes have shown that glycine receptor subunit composition had little effect on the modulatory effects of propofol (Pistis et al., 1997). In this study propofol potentiated homomeric glycine receptors composed of human α1 subunits with an EC_50 of 16μM and also potentiated hetero-oligomeric glycine receptors composed of human α1 and rat β subunits with an EC_50 of 27μM. Similar studies by Mascia et al., (1996a,b) have demonstrated that propofol potentiated human homomeric α1, α2 and mutant α(A52S; mutation that alters the ability of glycine to activate the receptor) receptors expressed in Xenopus oocytes to an equal extent.

Behavioural evidence for the action of propofol at the strychnine-sensitive glycine receptor is conflicting. Some studies have demonstrated anticonvulsant effects of propofol (Al-Muhandis et al., 1991) and others have demonstrated pro-convulsant effects (Dolin et al., 1992, Bansinath et al., 1995) in mice challenged with i.v. strychnine.

The modulatory effects of propofol on glycine receptors in spinal preparations and on recombinant glycine receptors are modest compared to its effects at the native and recombinant GABA_A receptor receptors (Hales and Lambert, 1991; Mascia et al., 1996ab; Pistis et al., 1997). Nonetheless, a role for the strychnine-sensitive glycine receptor in the anaesthetic/anticonvulsant actions of propofol cannot be discounted and warrants further investigation in native neurones. Future electrophysiological studies examining the modulatory effects of propofol on glycine-evoked responses in spinal neuronal preparations.
versus brain neurone preparations might indicate the relative importance of the effects of propofol on native glycine receptors within the CNS.

Similar to, though less potent than propofol, the NSAID, mefenamic acid also induced a modest and concentration-dependent potentiation of GABA-evoked responses of the rat vagus nerve. However, this modulation was less than that reported by Woodward et al., (1994) using Xenopus oocytes and Halliwell et al., (1994) recording from cultured rat hippocampal neurones. In order to investigate the site and molecular mechanism of the interaction between mefenamic acid and the GABA\textsubscript{A} receptor, further investigations were therefore carried out on single cultured rat hippocampal neurones using the more powerful patch-clamp recording technique.

2. Mefenamic acid potentiates GABA-evoked responses in voltage-clamped rat hippocampal neurones

Mefenamic acid potentiated GABA-evoked responses in voltage-clamped rat hippocampal neurones in a complex manner. The degree of potentiation observed in this study was similar to the levels of potentiation reported by Halliwell et al., (1994; 218\% with 10\textmu M mefenamic acid) and Woodward et al., (1994; \approx300\% with 30\textmu M mefenamic acid). More recent patch-clamp studies using human recombinant \(\alpha1\beta2\gamma2s\) GABA\textsubscript{A} receptors expressed in Xenopus oocytes report potentiations of 355\% with 30\textmu M mefenamic acid (Halliwell et al., in press) and 350\% with 3\textmu M mefenamic acid (Whittemore et al., 1996).

Moreover, the data presented in this thesis demonstrates several characteristic features of the modulatory effects of mefenamic acid. These are:

1. Mefenamic acid potentiated GABA-evoked responses in both amplitude and duration.
2. Mefenamic acid evoked a transmembrane current in addition to its potentiating effects on GABA-evoked responses.
3. The modulatory effects of mefenamic acid were biphasic with low concentrations potentiating GABA-evoked responses, and higher concentrations, evoking a transient potentiation, followed by an inhibition of the GABA-evoked response.

4. The modulatory effects of high concentrations of mefenamic acid on GABA-evoked responses required long periods of washing to return to control.

5. Hippocampal neurones varied in their sensitivity to the potentiating effects of mefenamic acid.

In this study, mefenamic acid (and propofol and sodium pentobarbitone) potentiated GABA-evoked responses in both amplitude and duration. Single-channel studies have revealed that propofol (Hales and Lambert, 1991; Orser et al., 1994) potentiated GABA-evoked responses by increasing the probability of the channel being in the open state, whereas pentobarbitone increased the duration of the mean open channel state (Study and Barker, 1981). The similarities between the GABA response characteristics for the potentiating effects of propofol, pentobarbitone and mefenamic acid suggest a similar mechanism of action for these drugs. Future single channel studies will allow this hypothesis to be tested.

The observation that high concentrations of mefenamic acid required long periods of washing may be attributed to a number of factors. It is possible that the prolonged effect of mefenamic acid may be due to slow removal of the drug by the perfusion system. However, the rapid reversal of the modulatory effects of high concentrations of other drugs, such as diazepam or bicuculline, suggest that this is not the case. Another possibility is that mefenamic acid is highly lipophilic and having dissolved in the cell membrane, dissociates into aqueous solutions relatively slowly. Alternatively, mefenamic acid may bind to a site on the GABA_A receptor, for example within the ionophore, from which its subsequent removal is difficult. These hypotheses will be addressed later.
3. Inhibition of GABA-evoked responses by niflumic acid in hippocampal neurones

Submaximal GABA-evoked responses recorded from voltage-clamped rat hippocampal neurones were concentration-dependently inhibited by niflumic acid. High concentrations of niflumic acid (100μM) caused inhibition of the GABA-evoked response which could not be reversed even with extended washout of the drug (up to 4 times normal washout period) and could not be surmounted by increasing the agonist exposure time. Interestingly, in a binding study using whole rat brain homogenates, Evonuik & Skolnick, (1988) demonstrated that niflumate inhibited anion-enhanced [35S]TPBS binding (IC$_{50}$ ≈ 100μM for 100mM Cl$^-$), but not GABA-modulated radio-ligand binding to benzodiazepine receptors, and suggested that niflumate binds within or close to an anion binding site within the channel pore of neuronal GABA$_A$ receptors.

In contrast to the data presented here, Woodward et al., (1994) demonstrated that niflumic acid evoked a modest potentiation of submaximal GABA-evoked responses recorded from Xenopus oocytes injected with rat poly*A RNA. Although the effects of fenamates on maximal GABA-evoked responses were not determined in this study, Woodward et al., (1994) demonstrated that, in descending order of potency, niflumic acid (with an IC$_{50}$ value of 7μM), meclofenamic acid, flufenamic acid and mefenamic acid (IC$_{50}$=33μM) acid all caused a non-competitive inhibition of maximal GABA-evoked responses. Shirasaki et al, (1991) have also reported that mefenamic acid (100μM) inhibited EC$_{60/70}$ GABA-evoked responses in acutely dissociated rat hippocampal neurones by ~ 40%. Most recently, Halliwell et al., (in press) report that mefenamic acid (100μM) inhibited submaximal GABA-evoked currents in human α,β, receptor constructs, expressed in Xenopus oocytes and in HEK-293 cells. Woodward and colleagues (1994) suggest that in Xenopus oocytes injected with rat poly*A RNA, agonist concentration determines the development of a potentiating or inhibitory effect by fenamates, whereby low concentrations of GABA (10-100μM; EC$_{10}$-EC$_{50}$) are potentiated by mefenamic acid (0.3-30μM) and higher concentrations of GABA (>100-3000μM; approximating EC$_{50}$-EC$_{100}$) are inhibited by higher concentrations of mefenamic acid.

In the present study, high concentrations (100μM) of mefenamic acid evoked a transient potentiation, followed by an inhibition of the GABA-evoked current. One explanation for this observation may be attributed to the directional perfusion system employed in these experiments. Given the volume of solution in the culture dish (=2mls), the initial concentration of mefenamic acid which bathes the cell will be lower than 100μM, which may explain the transient potentiation of the GABA-evoked response. With continued perfusion, the concentration of mefenamic acid which surrounds the cell approaches 100μM, and at this point the inhibitory effects of mefenamic acid are observed. The biphasic modulatory effects of mefenamic acid are similar to those reported for high concentrations of pentobarbitone (e.g. Akaike et al., 1987, Peters et al., 1988).

In this study, the reduction in the GABA response amplitude observed with higher concentrations of mefenamic acid may be attributed to receptor desensitization (partly mediated by the direct activation of the GABA_A receptor by mefenamic acid) and/or via the inhibitory site for mefenamic acid on the β1-subunit reported by Halliwell et al., (in press). Experiments investigating the effects of mefenamic acid (and other fenamates) on maximally-evoked GABA currents in voltage-clamped hippocampal neurones may further characterize the inhibitory effects of high concentrations of mefenamic acid observed in native neurones.

4. Fenamate Structure-activity relationships at native GABA_A receptors

The data in this study show that GABA-evoked currents recorded from hippocampal neurones were modulated by a range of fenamates. Similar observations were made by Woodward et al., (1994) who examined the effects of fenamates on GABA-evoked responses in Xenopus oocytes. In the present study, the descending order of potency for the potentiating effects of fenamates was: mefenamic acid > meclofenamic acid > tolfenamic acid > flufenamic acid.
Woodward et al., (1994) report a similar potency sequence for potentiation of GABA-evoked responses in Xenopus oocytes: mefenamic acid > meclofenamic acid > flufenamic acid > niflumic acid.

Fenamates, most commonly mefenamic acid, flufenamic acid, meclofenamic acid, tolfenamic acid and niflumic acid all belong to a group of compounds derived from the synthetic compound N-phenylanthranilic acid (PPA). Crystallographic and theoretical studies performed by Dhanaraj and Vijayan, (1988) demonstrated that fenamates are comprised of two, 6-membered rings which are linked by an imino bridge. For most fenamates, the A-ring (see Introduction, figure 1.1) carboxyl group is coplanar with the imino bridge and is stabilized by an internal hydrogen bond. Rotation of the B-ring is possible, but is limited by the steric hindrance occurring between the A-ring hydrogen ortho to the imino linkage and the substituted R1 and R2 groups on the B-ring, such that the 2 rings have non-planar orientations. This appears to be especially true for mefenamic acid (R1 and R2=CH3) and meclofenamic acid (R1=Cl; R2=CH3) which have relatively bulky R1 and R2 groups compared to flufenamic acid (R1=H; R2=CF3). In the case of niflumic acid, replacement of a carbon atom with a nitrogen on the B-ring, results in a loss of steric hindrance enabling the molecule to adopt an almost planar conformation. This difference in structural conformation might account for the difference in activity of niflumic acid, compared to the other fenamates examined in this thesis.

The ability of fenamates to potentiate or inhibit GABA-mediated responses being dependent upon the conformation of the molecule was also suggested by Woodward et al., (1994). Planar conformations, such as niflumic acid, were effective inhibitors and non-planar conformations, such as mefenamic acid, meclofenamic acid, flufenamic acid and tolfenamic acid, were found to be effective modulators; the degree of this modulation depended on phenyl-ring substitutions at the R2 group on the B-ring.

These data suggest that modulation of GABA-evoked responses is a feature common to fenamate NSAIDs. Moreover, the differences in potency and efficacy of the fenamates examined in this study, which may be governed by the phenyl-ring substitutions at the R2 group, are also commensurate with the existence of a specific binding site for fenamates on native GABA_A receptors.
These data may also provide a template for the design and development of new subunit selective modulators of the GABA\textsubscript{A} receptor.

5. Possible sites and molecular mechanism(s) of action of mefenamic acid at native GABA\textsubscript{A} receptors

5.i. The role of the "Benzodiazepine site" for the modulation of GABA currents by mefenamic acid.

In native GABA\textsubscript{A} receptors, the potentiating effects of MFA were insensitive to the benzodiazepine antagonist, flumazenil. The potentiation of GABA responses by mefenamic acid recorded in \textit{Xenopus} oocytes expressing rat cortex mRNA was also not affected by flumazenil (Woodward \textit{et al.}, 1994). Additionally, mefenamic acid evoked similar levels of potentiation in human recombinant receptors expressing either $\alpha 1\beta 2$ (benzodiazepine insensitive) or $\alpha 1\beta 2\gamma 2s$ subunit combinations in \textit{Xenopus} oocytes (Halliwell \textit{et al.}, in press).

These data therefore suggest that fenamates do not exert their primary effect through benzodiazepine binding sites although, an involvement of this site cannot be completely discounted since mefenamic acid induced-potentiations in native neurones was greater in the presence of flumazenil. Consistent with this possibility, maximal enhancement of GABA responses by mefenamic acid in $\alpha 1\beta 2$ receptors expressed in \textit{Xenopus} oocytes was greater than the enhancement recorded from $\alpha 1\beta 2\gamma 2$ receptors in oocytes (Halliwell \textit{et al.}, in press). Similar to mefenamic acid, a number of allosteric modulators of the GABA\textsubscript{A} receptor such as propofol, sodium pentobarbitone, alphaxalone, loreclezole and etomidate have also been shown to mediate their GABA-potentiating effects at sites distinct from the benzodiazepine site (e.g. Hales and Lambert, 1991; Prince and Simmonds, 1992; Cottrell \textit{et al.}, 1987; Wafford \textit{et al.}, 1994; Uchida \textit{et al.}, 1995).
5.ii. Possible mechanisms of action of mefenamic acid on neuronal GABA\textsubscript{A} receptors

There are a number of possible mechanism by which the potentiating effects of mefenamic acid (and by inference, the other fenamates which produce potentiating effects) at the GABA\textsubscript{A} receptor could be mediated. For example, increased availability of GABA either due to a decrease in GABA uptake or an increase in GABA release from cells in and around the neuron under voltage-clamp: an enhancement of GABA receptor function mediated at the chloride channel: an allosteric modulatory site or possibly via changes in receptor phosphorylation. Other mechanisms also include the possibility that mefenamic acid may exert its effects by disrupting neuronal membranes or through mechanisms related to prostaglandin synthesis inhibition.

5.iii. Potentiation of GABA currents by fenamates and GABA-re-uptake inhibition.

GABA uptake inhibitors are thought to prolong the duration of inhibitory post-synaptic potentials in neurones by elevating GABA levels at nerve terminals (Krogsgaard-Larsen et al., 1984). The GABA-uptake inhibitors, nipecotic acid and NNC-711 did not mimic the effects of mefenamic acid either qualitatively or quantitatively. These data suggest that mefenamic acid does not mediate its GABA-potentiating effects by altering GABA-uptake mechanisms in this system. Similar to mefenamic acid, the potentiating actions of propofol, alphaxalone and sodium pentobarbitone are not due to inhibition of GABA-uptake (Lambert et al., 1991; Cottrell et al., 1987; Jessel and Richards, 1977).

5.v. Mefenamic acid-induced modulation of GABA currents and inhibition of prostaglandin synthesis.

Even at high concentrations (relative to those of mefenamic acid for modulation of the GABA current), the non-fenamate NSAIDs, ibuprofen and BPAA did not modulate GABA-evoked responses in voltage-clamped rat hippocampal neurones, although, indomethacin did produce a small

*Chapter Five: General Discussion*, 125
potentiation of the GABA-evoked response. Shirasaki et al., (1991) also examined the actions of different classes of NSAIDs (up to 100μM) on GABA-evoked responses in voltage-clamped acutely dissociated rat hippocampal neurones and found that only mefenamic acid inhibited the GABA-evoked response. In contrast, Halliwell et al., (1994) reported that mefenamic acid potentiated GABA-evoked responses in voltage-clamped hippocampal neurones in culture, and that another NSAID, BPAA, did not mimic the effects of mefenamic acid. Most recently, Halliwell et al., (in press) have also shown that indomethacin (100μM) and ibuprofen (100μM) had little effect on GABA-evoked responses recorded from Xenopus oocytes expressing human α1β2γ2s subunits.

Inhibition of prostaglandin synthesis is thought to be a property of all NSAIDs, but there appears to be no direct relationship between the GABA-potentiating effects of the NSAIDs examined here and their ability to inhibit prostaglandin synthesis. For example, indomethacin is a more potent prostaglandin synthesis inhibitor than mefenamic acid, but has only modest GABA-potentiating ability in rat hippocampal neurones. Moreover, the other prostaglandin synthesis inhibitors tested, i.e. BPAA and ibuprofen, did not potentiate that GABA-evoked response at all. Nonetheless, the modest potentiation of GABA currents by indomethacin observed in this study and the similar modest potentiations of GABA responses by diflusinal, indomethacin, ibuprofen, naproxen and piroxicam in Xenopus oocytes (Woodward et al., 1994) suggest that NSAIDs might indirectly modulate GABA-mediated responses by a number of other mechanisms which do not involve inhibition of prostaglandin synthesis. These are discussed below.

5.v. Modulation of GABA currents by membrane perturbation

In this study, only extracellular application of mefenamic acid resulted in modulation of GABA-mediated responses. Intracellular application, via the patch electrode, had no appreciable effects on the GABA currents or on their potentiation by extracellular application of mefenamic acid. Since only
extracellular application of fenamates causes any appreciable potentiation of GABA-evoked responses, it is probable that such an action is not due to changes in membrane fluidity, but rather that a membrane-bound recognition site exists for mefenamic acid (and, by inference, other fenamates) on the GABA_A receptor. Furthermore, the short latency of action and rapid reversibility of action upon washout of mefenamic acid (3-30μM) are consistent with a specific interaction at a recognition site. Consistent with the data presented in this thesis, Woodward et al., (1994) reported that intracellular application of mefenamic acid in Xenopus oocytes did not modulate GABA currents.

5.vi. Modulation of GABA currents by changes in receptor protein phosphorylation

GABA_A receptor subunits are known to contain several potential sites for protein phosphorylation by protein kinases and compounds which increase protein phosphorylation can modulate GABA_A receptor function (for review see Moss and Smart, 1996). Tyrosine kinases are of particular interest here since tyrosine phosphorylation is known to increase GABA_A receptor function in native neurones by increasing the probability of channel opening and mean channel open time (Moss et al., 1995). A recent study has demonstrated that native GABA_A receptors of cultured spinal dorsal horn neurones are phosphorylated and modulated in situ by endogenous protein tyrosine kinase (PTK; Wan et al., 1997). These authors also report that in these cells, exogenously applied PTK increased control GABA currents by almost 2-fold, but that the time course for this was 10 minutes. In HEK cells expressing combinations of rat α1β2γ2 GABA_A receptor subunits, the presence of the β2 subunit imparted sensitivity of functional GABA_A receptors to phosphorylation (Wan et al., 1997). The importance of the β-subunit for phosphorylation is intriguing given the β-dependence for modulatory effects by mefenamic acid. However, the slow latency of action of PTK for potentiating GABA, compared to the rapid potentiating effects of mefenamic acid applied extracellularly and, moreover, the lack of modulation by intracellular application of mefenamic acid,
suggests that the potentiating effects of mefenamic acid are not mediated by changes in phosphorylation of the GABA_A receptor. Similar conclusions were made by Woodward et al., (1994) using Xenopus oocytes expressing rat GABA_A receptors.

The effects of mefenamic acid are therefore similar to those of certain positive allosteric modulators of the GABA_A receptor, such as propofol, alphaxalone and etomidate, which are also only effective when applied extracellularly (Hales and Lambert, 1991; Lambert et al., 1990, Belleli et al., 1997).

5.vii. Use- and Voltage-dependence of the effects of mefenamic acid and niflumic acid on GABA_A receptors.

The effects of niflumic acid were examined and it was found that at 100μM, niflumic acid caused rapid inhibition of the GABA-evoked response which could not be reversed even with extended washout of the drug and could not be surmounted by increasing agonist exposure time. The inhibitory effects of niflumic acid were, therefore, not use-dependent but were consistent with niflumic acid producing a non-competitive inhibition of GABA-mediated responses. The non-competitive inhibition of the GABA-mediated current might occur, possibly via a channel-blocking mechanism. Consistent with these data, Evonuik & Skolnick, (1988) have suggested that niflumate binds with high affinity at or near an anion binding site within the channel pore of neuronal GABA_A receptors.

There are no known positive modulators of the GABA_A receptor which exhibit use-dependent potentiation. The potentiation of GABA-evoked responses recorded from rat hippocampal neurones by mefenamic acid was not use-dependent.

It is generally thought that "use-dependent" drugs, such as picrotoxin (Akaike et al., 1985) and MK-801(Halliwell et al., 1989), have their binding sites located within the ion channel itself. The lack of use-dependency of niflumic
acid and mefenamic acid, therefore, provide no support of a fenamate binding site located within the chloride channel of the GABA\(_A\) receptor.

Mefenamic acid potentiated GABA-evoked responses recorded from rat hippocampal neurons in a voltage-sensitive manner without altering the reversal potential of the GABA-evoked current. The relative potentiation at -100mV was approximately three-fold greater than at +20 mV. Consistent with these data, Halliwell et al., (in press) revealed a marked voltage-dependence of the potentiating effects of mefenamic acid on GABA currents, with no associated change in reversal potential, in \(\alpha_1\beta_2\)-containing GABA\(_A\) receptors expressed in *Xenopus* oocytes and in \(\alpha_1\beta_3\gamma_2\) and \(\alpha_1\beta_3\)-containing GABA\(_A\) receptors expressed in HEK-293 cells; a similar degree of voltage-sensitivity was also observed for loreclezole in HEK-293 cells in this study. Woodward et al., (1994) showed the potentiating effects of mefenamic acid were voltage-independent in rat brain GABA\(_A\) receptors expressed in *Xenopus* oocytes, with no changes in the GABA reversal potential. Additionally, although Woodward et al., (1994) report that there was no change in the levels of rectification, close inspection of Woodward's data reveals that potentiations evoked by mefenamic acid (5\(\mu\)M) were 1.4 fold greater at -120mV (\(\approx\)233\%) than at +10mV (\(\approx\)167\%).

For comparative purposes, the potentiating effects of propofol were investigated and found to be voltage-independent and there was no change in GABA reversal potential. These findings are in agreement with Hales and Lambert, (1991) using bovine chromaffin cells, Hara et al., (1994) using rat hippocampal neurones and Orser et al., (1994) utilizing murine hippocampal neurones.

Peters et al., (1988) and Cottrell et al., (1987) have reported voltage-independent potentiation of GABA currents by sodium pentobarbitone and alphaxalone, respectively. Inspection of these data also reveals that potentiation of the GABA current by sodium pentobarbitone and alphaxalone was not associated with a change in reversal potential. However, the magnitude of those potentiations evoked by sodium pentobarbitone (Peters et al., 1988), but not alphaxalone (Cottrell et al., 1987), at hyperpolarising potentials is

*Chapter Five: General Discussion,* 129
approximately 1.7 times greater than that induced at depolarising potentials. Recently, Leidenheimer et al., (1998), using Xenopus oocytes expressing human $\alpha_1\beta_2\gamma_2$ GABA$_A$ receptor subunit cDNAs, have demonstrated that potentiation of GABA-evoked responses by diazepam, pentobarbital and THDOC is not associated with a change in reversal potential, but is at least 2 fold greater at negative holding potentials compared to positive holding potentials. Notably, potentiation of the GABA response by THDOC was ~ 5 times greater at a holding potential of -60mV compared to +60mV. In conclusion, with the possible exceptions of propofol and alphaxalone, potentiation of GABA-mediated responses by a number of chemically diverse compounds, including mefenamic acid, may be dependent on membrane holding potential.

One possible explanation may be attributed to the outward rectification of the GABA current at positive holding potentials (Leidenheimer et al., 1998). At negative holding potentials, there is a greater scope for potentiation of the GABA-evoked current which may explain the larger mefenamic acid-induced potentiations at negative versus positive holding potentials. However, in the present study the concentrations of GABA, mefenamic acid (and propofol) were submaximal and the voltage-dependence of mefenamic acid may not be explained by this hypothesis. Moreover, this hypothesis does not explain the different degrees of voltage-sensitivity between different modulators or the absence of voltage-sensitivity observed in this study for propofol, and in other studies for alphaxalone (Peters et al., 1989).

Additionally, the differences in hydrophobicity between propofol, alphaxalone, sodium pentobarbitone, loreclezole and mefenamic acid might contribute to their different voltage-sensitivities. However at pH 7.2, there is little correlation between the relative hydrophobicity of these compounds and the level of voltage-sensitivity For example, at pH 7.2, mefenamic acid is 99.94% in anionic form and loreclezole is uncharged (Halliwell et al., in press), sodium pentobarbitone is 25% in anionic form (Robertson et al., 1989) and diazepam (pKa=3.4; Merck Index, 1998) is 99.99% in anionic form (calculated using the Henderson-Hasselbalch equation). However, propofol differs from the other
modulators in that it is a liquid compound with high lipophilicity (the octane/water partition coefficient is 5000, Merck Index, 1998). This lack of voltage-sensitivity of propofol may be attributed to its marked hydrophobicity.

Mefenamic acid, loreclezole and etomidate exhibit β2/3-subunit dependency for potentiation which is dependent upon the presence of the N290 residue. This residue resides in the TM2 region of the β2/3 subunit, which forms part of channel wall and it is conceivable that this site may contribute to the binding site and/or transductional mechanism, including the voltage-dependent potentiating effects of these drugs (Halliwell et al., in press; Wafford et al., 1994; Belleli et al., 1997). On the basis of crystallographic and theoretical studies, Dhanaraj and Vijayan (1988) hypothesise that a potential binding site for fenamates may contain hydrophobic and hydrophilic regions. This molecular structure might be consistent with a binding site located in a channel ionophore. Although, it is presently unknown if N290 in the β2/3 subunit of the GABA_A receptor is luminal facing, Xu and Akabas, (1996) have demonstrated that an equivalent N290 residue in α1 subunits of the GABA_A receptor is not luminal facing.

With regard to propofol, Krasowski et al., (1998) have reported that a point-mutation in the TM3 region of the β1-subunit (M286W) of human recombinant GABA_A receptors expressed in HEK cells together with α1 and α1γ2s subunits, abolished the potentiation of GABA responses by propofol, without affecting the ability of propofol to directly activate the GABA_A receptor. Conversely, a mutation in the TM2 region of the β1 subunit (S265I) produced normal potentiation, but reduced direct activation by propofol. Birnir et al., (1997) have also reported the existence of a residue in TM2 in the β1 subunit which determines GABA-modulatory effects and GABA-mimetic effects of sodium pentobarbitone. The β-subunit is therefore critically important for the modulatory and GABA-mimetic effects of a range of modulators. The β1 subunit is important for the modulation and direct activation of the GABA_A receptor by propofol, whereas the β2/3 subunit mediate the potentiating and direct activation effects of mefenamic acid, loreclezole and etomidate. However, since diazepam, a drug which is not β-subunit dependent, also exhibits a degree of...
voltage-sensitivity (Leidenheimer et al., 1998), the importance of the β-subunit in mediating the voltage-sensitivity of these modulators remains unclear.

Potentiation of GABA currents by mefenamic acid might arise from changes in the chloride channel gating characteristics, such as increases in single channel conductance, probability of channel opening or increases in mean channel open time. An investigation of the modulation of GABA single channel properties by mefenamic acid would further elucidate the mechanism of action of mefenamic acid.

5.viii. Neuronal sensitivity to mefenamic acid varies across cultured hippocampal neurones - similarities to loreclezole?

In native neurones, a small number of cells were insensitive to modulation by mefenamic acid and loreclezole, but were modulated by other allosteric modulators such as diazepam, or sodium pentobarbitone. Additionally, the maximal potentiations evoked by mefenamic acid (30μM) and loreclezole (10μM) ranged from 125% to 909% and 149 to 349 % of control, respectively. This variation in sensitivity may reflect some degree of subunit selectivity.

In support of this suggestion, mefenamic acid differentially modulated human recombinant GABA_A receptors expressed in Xenopus oocytes and HEK cells, depending on the presence of specific β-subunits (Halliwell et al., in press). Similar observations have been made for loreclezole in Xenopus oocytes expressing recombinant GABA_A receptors (Wafford et al., 1994). Mefenamic acid potentiated GABA-evoked currents and directly activated GABA_A receptors composed of α_1β_2γ_2s receptor constructs, but did not potentiate or directly activate α_1β_1γ_2s receptor constructs. Moreover, inhibition of GABA-currents by mefenamic acid was observed for α_1β_1 receptor constructs (Halliwell, op. cit.). Mutation studies also showed that the modulatory effects of mefenamic acid were dependent on the asparagine residue (N290) in the predicted second transmembrane domain of β2 or β3 subunits (Halliwell et al.,

Chapter Five: General Discussion, 132
in press); similar observations have been made for loreclezole (Wingrove et al., 1994) and etomidate (Belleli et al., 1997).

Additionally, Whittemore et al., (1996) have demonstrated that mefenamic acid (and loreclezole) induced a strong modulation of $\beta_2\gamma_2L$ receptors expressed in *Xenopus* oocytes, but that there was little difference between modulation of $\alpha 1\beta 2\gamma 2L$ and $\alpha 4\beta 2\gamma 2L$ receptors, indicating that the presence of the $\alpha$-subunit was not critical for mefenamic acid-induced potentiation of GABA-evoked currents in these receptors.

In light of these observations, the overall potentiating effects of mefenamic acid on native GABA$_A$ receptors of rat hippocampal neurones suggests that these receptors were predominantly $\beta_{23}$-containing receptors.

Interestingly, Zwart et al., (1995) have reported an inhibition of acetylcholine-evoked currents on $\alpha 3\beta 2$ nicotinic receptor constructs, but a potentiation with $\alpha 3\beta 4$ receptor constructs by mefenamic acid. However, little sequence homology exists between nicotinic acetylcholine $\beta_2$ and $\beta_4$ receptor subunits compared to GABA$_A$ $\beta_1$ and $\beta_{23}$ receptor subunits, suggesting that mefenamic acid-evoked effects at nicotinic receptor constructs probably occur by different mechanisms or site(s) to those at GABA$_A$ receptor constructs (Halliwell et al., in press).

No other study has demonstrated the effects of mefenamic acid on GABA$_A$ receptors in native neurones, although similar observations have been made for loreclezole. Indeed, Kapur and Macdonald (1996) have demonstrated that only 50% of whole-cell voltage-clamped dentate granule cells (acutely dissociated from neonatal rats) were insensitive to modulation by loreclezole and suggested that these were $\beta_1$-containing receptors. In agreement, Xue et al., (1996) in a binding study have demonstrated a greater potency of loreclezole and a higher GABA sensitivity in the cerebellum and thalamus, where there is a relatively higher expression of $\beta_2$ and $\beta_3$ subunits compared to other areas of the CNS.

The variation in sensitivity of native neuronal GABA$_A$ receptors to modulation by mefenamic acid and loreclezole might be, in part, explained by
the reported β-subunit dependency for mefenamic acid and loreclezole observed in recombinant GABA_\text{A} receptors (Halliwell et al., in press; Wafford et al., 1994). Similar to loreclezole (Kapur and Macdonald, 1996), the ability of mefenamic acid to discriminate between β1 and β2/3 containing GABA_\text{A} receptors might be exploited to identify the presence of specific β-subunits in native receptors.

In conclusion, the β2/3-subunit-dependency for potentiation of the GABA_\text{A} receptor is a common feature of mefenamic acid, loreclezole and etomidate which distinguishes the actions of these modulators from those of propofol, pentobarbitone and alphaxalone. These observations also lend credence to the hypothesis that a distinct site exists for these modulators on the GABA_\text{A} receptor.

5.ix. Overlapping sites and/or transduction mechanisms for mefenamic acid and loreclezole?

The potentiating effects of mefenamic acid and loreclezole, at concentrations which evoked maximal potentions, were not additive when applied together. Maximal potentions of mefenamic acid together with loreclezole were also recently found to be non-additive in HEK cells expressing α1β3γ2s GABA_\text{A} receptor subunits (Halliwell et al., in press). These authors suggest that mefenamic acid and loreclezole, may act at the same or partly overlapping sites, or share the same allosteric mechanism for potentiation.

However, experiments reported in this thesis showed that the potentiating effects of mefenamic acid together with propofol or pentobarbitone, at concentrations which evoked maximal potentions, were also not additive when applied together. Although all drug effects were determined against submaximal GABA-evoked responses in hippocampal neurones, these data suggest that the non-additive potentions with loreclezole, propofol and pentobarbitone together with mefenamic acid, are simply a ceiling effect in this recording system. Further experiments are therefore required to determine if
mefenamic acid shares a binding site with other known modulators on the GABA<sub>A</sub> receptor.

Woodward et al., (1994) have demonstrated that the modulatory effects of mefenamic acid together with pentobarbitone or 5-hexachlorohexane on GABA responses in oocytes expressing rat cortex mRNA, were additive, suggesting different sites of action for these drugs. Similarly, Wafford et al., (1994) demonstrated that loreclezole-induced potentiation of GABA responses was additive to sodium pentobarbitone- and 3α-OH-DHP-induced potentiation, again suggesting different sites of action for these drugs.

Woodward et al., (1994) reported that the steroid antagonist, 5β-pregnan-3β-ol-20-one (3β-OH-DHP) accelerated the response decay rate of the GABA current in the presence of mefenamic acid, but had little effect on the response amplitude. No study to-date has demonstrated a synergistic effect of fenamates and steroids on GABA response decay rate in native neurones. Woodward et al., (1994) have suggested that the modulatory effects of fenamates on GABA<sub>A</sub> receptor may be further modulated by endogenous steroids in vivo.

Further combination experiments with mefenamic acid and other modulators using a "fast step" perfusion system, would allow a range of agonists and modulator concentrations to be applied to the same cell. The results of such experiments may provide additional information regarding the site and mechanism of action of mefenamic acid.

5.x. Evidence for direct activation of the GABA<sub>A</sub> receptor by mefenamic acid.

Mefenamic acid, like pentobarbitone, alphaxalone and propofol, evoked a transmembrane current, at concentrations higher than those required for potentiation of GABA-evoked responses. The mefenamic acid current was modulated by propofol, pentobarbitone, alphaxalone, diazepam and loreclezole and was inhibited by bicuculline, suggesting that the current was mediated by activation of the GABA<sub>A</sub> receptor-gated chloride channel. Additionally, the I-V characteristics of the mefenamic acid-induced current were similar to those.
observed for GABA in voltage-clamped rat hippocampal neurones. These data indicate that mefenamic acid, in common with other positive allosteric modulators of the GABA<sub>A</sub> receptor, can directly activate the GABA<sub>A</sub> chloride channel and are consistent with the observations of Halliwell et al., (1994 and in press, 1999).

Recently, Halliwell and colleagues (in press) demonstrated that spontaneously gated chloride channels formed by homomeric β<sub>3</sub> or β<sub>1</sub> receptors expressed in HEK cells, were directly activated or inhibited by MFA, respectively. The authors suggest that the binding sites for the direct activation and inhibition effects must be largely contained within the β<sub>3</sub> and β<sub>1</sub> subunits, respectively. In addition, in the β<sub>3</sub> homomers, pentobarbitone (1mM)-induced currents were inhibited by mefenamic acid (100μM), suggesting that these drugs may share an overlapping site or the same allosteric mechanism for direct activation or alternatively, that binding of one drug to its site hinders access of the other drug to its respective binding site (Halliwell et al., op. cit.). These data are however consistent with direct activation/ modulation of the GABA-gated chloride channel by mefenamic acid.

6. Effects of mefenamic acid on other ligand-gated ion channels.

No previous study has examined the selectivity of action of mefenamic acid on the major inhibitory and excitatory neuronal ligand gated ion channels. In this study, lower concentrations (≤100μM) of mefenamic acid, which evoked maximal potentiations of GABA-evoked currents, had little effect on glycine-, NMDA-, AMPA- or kainic acid-evoked responses in voltage-clamped rat hippocampal neurones.

Higher concentrations of mefenamic acid (≥100-1000μM), however, evoked a large transmembrane current and concentration-dependent inhibition of all the ligand-gated ion channels examined in this thesis.

In the presence of concentrations of bicuculline which blocked the mefenamic acid-induced transmembrane current, kainic acid-evoked currents were not greatly inhibited by mefenamic acid. These data suggest that the
inhibitory effects of mefenamic acid at kainate receptors, at least, may be mediated through changes in chloride permeability. In contrast, the experiments reported in this thesis indicate that the inhibition of NMDA-evoked currents in hippocampal neurones by mefenamic acid greater in the presence of bicuculline.

Recently, Chen et al., (1998) have reported inhibition of NMDA-gated ionotropic glutamate receptors of salamander retinal neurones with high concentrations mefenamic acid (1mM). In contrast to the data presented here, however, Chen et al., (1998) do not observe inhibition of kainate-mediated responses by mefenamic acid and do not report activation of a transmembrane current by mefenamic acid. The absence of the development of a transmembrane current may be due to the use of the salamander retinal ganglion since retinal GABA_A receptor have distinct pharmacology governed by the presence of p-subunits. In light of the observations made in this study that the inhibition of kainic acid-evoked currents by mefenamic acid is reduced when the mefenamic acid-evoked transmembrane current is abolished or reduced, the absence of a mefenamic acid-evoked transmembrane current in salamander retinal neurones may explain the lack of inhibition of kainate-mediated currents in this preparation. However, the inhibition of NMDA-gated currents by mefenamic acid in salamander retinal neurones suggests that a distinct mechanism exists for inhibition of NMDA-mediated currents.

Lerma and Del Rio (1991) also report inhibition of NMDA-gated currents in rat spinal cord neurones by flufenamic acid with IC_{50} values of ≈350μM. In contrast to this study, but in agreement with Chen et al., (1998), these authors report that flufenamic acid and niflumic acid (1mM) had no effect on baseline holding currents. Notably, chloride ion substitution experiments by Lerma and Del Rio (1991) indicated that the antagonism of the NMDA-currents was not mediated via an interaction with chloride permeation or a change of the chloride equilibrium potential. Moreover, these authors report that spermine was not required for inhibition of the NMDA-evoked current and suggest that flufenamic acid and niflumic acid act as inverse agonists at the polyamine site of the NMDA receptors.
The data reported in this thesis also support different mechanisms of inhibition for kainic acid and NMDA-evoked currents by mefenamic acid. However, further experiments are required to characterise the inhibitory effects of mefenamic acid on NMDA-gated glutamate receptors. The effects of blockade of the mefenamic acid-induced transmembrane currents by bicuculline on the inhibition of glycine- or AMPA-evoked currents evoked by mefenamic acid was not determined. These experiments would indicate if the inhibitory effects of mefenamic acid at strychnine-sensitive glycine receptors, and AMPA- and NMDA-gated ionotropic glutamate receptors is attributable to changes in chloride permeation or due to a direct effect of mefenamic acid at these receptor sites. Additionally, the absence of direct effects on fenamates on spinal neurones and salamander ganglion neurones warrants further investigation given the large transmembrane currents observed in voltage-clamped rat hippocampal neurones with such high concentrations of mefenamic acid.

7. Pharmacological Implications—a mefenamic acid binding site exists on the GABA<sub>A</sub> receptor?

The experiments described in this thesis add to the understanding of the pharmacology of native GABA<sub>A</sub> receptors and to the understanding of NSAID pharmacology. They are supportive of a central role of action for NSAID s, in particular fenamates and more specifically, the experiments reported in this thesis support a selective allosteric interaction of mefenamic acid with native GABA<sub>A</sub> receptors, which is not related to cyclo-oxygenase inhibition. Additionally, these data indicate that the interaction of mefenamic acid with the GABA<sub>A</sub> receptor is not unlike that observed for a number of other positive allosteric modulators of the GABA<sub>A</sub> receptor.
8. Neurophysiological and Clinical relevance of the action of mefenamic acid at the GABA<sub>A</sub> receptor.

Although it is clear from the data reported in this thesis that mefenamic acid selectively modulates the GABA<sub>A</sub> receptor, other mechanisms may contribute to the clinically observed effects of mefenamic acid overdose. These will be addressed first.

NSAID inhibition of prostaglandin synthesis may lead to accumulation of arachidonic acid, which in turn induces a prolonged inhibition of glutamate uptake in glial cells (Barbour et al., 1989; Volterra et al., 1992) which may subsequently lead to neuronal excitation. This may be a mechanism by which mefenamic acid and other NSAIDs produce excitatory effects, however it does not explain CNS depression (e.g. coma) also observed with mefenamic acid overdose.

Leukotrienes and their metabolites may also accumulate following NSAID inhibition of prostaglandin synthesis. Leukotrienes are thought to be involved in the function of leukocytes and endothelial cells (Cronstein and Weismann, 1995). Although, Baran et al., (1994) have reported that a lipoxigenase inhibitor, ebselen, had no effect on kainic acid-induced seizures in rats, at present there is no data reported on the effects of leukotrienes on GABA<sub>A</sub> receptor function. Voltage-clamp studies investigating the action of leukotrienes on GABA-evoked responses (and other agonist-evoked responses) in rat hippocampal neurones would determine if leukotrienes can modulate neuronal ion channels function.

A direct relationship between the analgesic effects of certain NSAIDs and central serotonergic pathways has been reported (e.g. Shyu et al., 1984), with NSAIDs reducing brain stem levels of serotonin and 5-hydroxyindoleacetic acid (5-HIAA) (reviewed by Cashman, 1996). However, no study to-date has reported the effects of mefenamic acid on 5-HT turnover. Since decreased levels of 5-HT are associated with convulsant effects (e.g. Dailey et al., 1994), it is conceivable that the convulsant effects of mefenamic acid in overdose might, in part, be attributed to reduced serotonin levels. Although this mechanism may contribute to the pro-convulsant properties of mefenamic acid in overdose, it
does not explain the complex behavioral effects of mefenamic acid overdose observed in humans or the anti-convulsant effects of mefenamic acid in rodents.

Interestingly, a study by Dailey et al., (1994) who demonstrated that loreclezole, like certain other anticonvulsant drugs, caused elevations in serotonin release in CNS. Loreclezole has, however, been proposed to mediate its anti-convulsant effects by potentiating the inhibitory actions of GABA in the CNS (Wafford et al., 1994). Given the pharmacological similarities reported in this thesis and by Halliwell et al., (in press) of mefenamic acid and loreclezole, it will be of interest to investigate the effects of mefenamic acid on serotonergic function in the CNS to further characterise the mechanism of action of mefenamic acid in the CNS.

At therapeutic doses of mefenamic acid, peak plasma concentrations have been reported to be within the range of 4-40μM, with 50% bound to plasma proteins (Flower, 1974; Glazco, 1966; Court and Volans, 1984). Such concentrations of mefenamic acid are sufficient to modulate GABA_A receptor function in periphery. However, no study to date has determined the concentrations of mefenamic acid which can access the CNS. Indeed, given the ability of mefenamic acid to modulate GABA_A receptors at lower concentrations than those reported in overdose, it would be of interest to determine the concentrations of mefenamic acid capable of penetrating the blood-brain-barrier. In light of this information, it would be of further interest to examine the behavioral effects of mefenamic acid at concentrations within the therapeutic range, since it conceivable that at such concentrations, mefenamic acid may modulate synaptic inhibition to produce anxiolytic and/or sedative effects.

The complex modulation of GABA-gated chloride channels by mefenamic acid observed in rat neurones and in human recombinant GABA_A receptors (Halliwel et al., in press) might contribute to the complex behavioral effects seen in humans following mefenamic acid overdose. Mefenamic acid overdose is associated with a high incidence of seizures and coma. Several studies investigating the actions of fenamates on chemically- and electrically-induced seizures in rodents support a bi-directional mechanism of action of
fenamates which is distinct from other NSAIDs whereby low doses of fenamates had anti-convulsant effects and high doses had pro-convulsant effects (Wallenstein, 1985ab, 1987, 1991; Ikonomidou-Turski et al., 1988).

In the main, reported cases of mefenamic acid overdose in humans are associated with convulsive seizures (Shipton and Müller, 1985, Young et al., 1979, Balali-Mood et al., 1981, Gossinger et al., 1982; Turnbull et al., 1988). For example, Balali-Mood et al., (1981) studied 54 patients who had overdosed on mefenamic acid and reported a concentration-dependent relationship between plasma concentrations of mefenamic acid and CNS toxicity. Fewer cases of sedation or coma have been reported. However, in some studies, symptoms of coma or depressed levels of consciousness have also been reported with mefenamic acid plasma concentrations ranging from 21mg/L (Gossinger et al., 1982) to 46mg/L (Turnbull et al., 1988) to 462mg/L (Hendrikse, 1988). Intriguingly, Gossinger et al., (1982) report one case of coma followed by a grand mal convulsion with a mefenamic acid plasma concentration as low as 21mg/L.

NSAIDs, including fenamates have been shown to lower the incidence and delay the onset of Alzheimer's disease (McGeer et al., 1996) and to be neuroprotective against ischaemia (Chen et al., 1998). These effects have previously been attributed to inhibition of prostaglandin synthesis (McGreer et al., 1996; Nogawa et al., 1997). The interactions of mefenamic acid and other fenamates at the GABA_A receptor may shed new light on the neuroprotective effects of these drugs. Speculatively, the chemical structure of fenamates may serve as a template for the design of novel anti-epileptic and/or neuroprotective drugs.

Several studies have shown a lack of correlation between the analgesic properties of NSAIDs and their ability to inhibit prostaglandin synthesis (e.g. McCormack, 1994). The action of fenamates of neuronal GABA_A receptors is supportive of a central role of action for NSAIDs, in addition to their ability to inhibit COX-enzymes. In light of these data, investigation of the actions of NSAIDs on other neuronal ligand and perhaps voltage-gated ion channels may further elucidate the central analgesia actions of NSAIDs.

Chapter Five: General Discussion, 141


References 143


References


References


**References**


Dailey, J.W., Seo, D.O., Yan, Q-S., Ko, K.H., Jo, M. and Jobe, P.C. (1994) The anticonvulsant effect of the broad spectrum anticonvulsant loreclezole may be


References 154


Draguhn, A., Verdoon, T.A., Ewert, M., Seeburg, P.H. and Sakmann, B. (1990), Functional and molecular distinction between recombinant rat GABA\(\alpha\) receptor subtypes by Zn\(^{2+}\). Neuron, 5: 781-188.


Dubourdieu, C. and Dray, F. Central analgesic action of ketoprofen through prostaglandins and substance P inhibition in rats. Proc. 3rd Int. World Conference on inflammation, Antihemutics, analgesics , immunomodulators 15-18th March, 1989 pp262


References


Flood, P., Ramirez-Latorre, J. and Role, L. (1997) α4β2 neuronal nicotinic acetylcholine receptors in the central nervous sytem are inhibited by isoflurane and propofol, but α7-type nicotinic acetylcholine receptors are unaffected. Anaesthesiology, 86: 859-865.


References 157


References 159


Halliwell, R.F. and Davey, P.G. (1994) Modulation of GABA_A receptor-evoked currents recorded from the rat hippocampal neurone by mefenamic acid. [Journal ?]


References


References 164


References 165


References 169


References 170


\textit{References} 171


References 172


References 175


Merck Index, 1998, Merck, Rahway, N. Jersey, U.S.A.


References 178


Orser, B.A., Bertlik, M., Wang, L-Y. and MacDonald, J.F. (1995) Inhibition of propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of


Pollard, S., Thompson, C.L. and Stephenson, A.F. (1995) Quantitative characterisation of $\alpha 6$ and $\alpha 1\alpha 6$ subunit-containing native $\gamma$-aminobutyric acid$_A$

References 180
receptors of adult rat cerebellum demonstrates two $\alpha$ subunits per oligomer. The Journal of Biological Chemistry, 270(36): 21285-21290


References


References


References 183


References 184
Birkhäuser Verlag Basel.41-50.


References 185


References


aminobutyric acid via the loreclezole binding site as well as the benzodiazepine site. Molecular Pharmacology 48: 965-969.


References
Valeyev, AY; Cruciani, RA; Lange, GD; Smallwood, VS; Barker, JL (1993) Cl-channels are randomly activated by continuous GABA secretion in cultured embryonic rat hippocampal neurons. Neuroscience 155, 199-203.


References


Wagstaff, J., Chaillet, J.R. and Lalande, M. (1991) The GABA\textsubscript{A} receptor \(\beta3\) subunit gene: characterization of a human cDNA from chromosome 15q11q13 and mapping to a region of conserved synteny on mouse chromosome 7.


References


References


